data_1cw5_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1cw5 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 -0.105 0 CA-C-O 120.656 0.265 . . . . 0.0 111.619 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.586 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 34.8 t80 -50.02 -34.6 21.8 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 112.84 0.681 . . . . 0.0 112.84 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.598 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 1.8 tt0 -79.71 -32.24 41.28 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.237 -177.01 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -76.24 -31.76 58.52 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.443 0.64 . . . . 0.0 109.295 179.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.1 ttt180 -77.16 -60.58 2.3 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 114.847 -1.07 . . . . 0.0 111.61 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.598 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -63.18 -54.53 36.12 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 113.056 0.761 . . . . 0.0 113.056 -178.03 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.45 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.5 m -58.93 -36.05 74.11 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.514 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -53.4 -49.54 67.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.04 0.448 . . . . 0.0 110.645 178.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 -33.87 28.66 Favored Glycine 0 C--N 1.33 0.229 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.449 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 5.2 mt -74.99 -29.59 22.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.746 0.308 . . . . 0.0 110.773 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.439 ' N ' ' O ' ' A' ' 27' ' ' THR . 37.9 t-20 -71.79 -49.14 41.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.038 0.447 . . . . 0.0 110.353 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.3 m -54.78 -45.17 74.24 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.524 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.461 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -48.43 -35.42 12.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.02 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 38' ' ' ALA . 3.0 t -70.66 -61.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.412 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -48.29 -58.44 4.57 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.49 -58.39 13.38 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.693 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.461 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 53.5 t -59.36 -22.25 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.617 0.246 . . . . 0.0 110.666 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.448 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.334 -0.106 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.276 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 -0.283 0 CA-C-O 121.003 0.43 . . . . 0.0 110.731 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.591 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.2 t80 -54.89 -34.02 62.59 Favored 'General case' 0 C--O 1.22 -0.496 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.644 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -76.94 -39.04 52.1 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.03 0.443 . . . . 0.0 110.537 -177.874 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -68.08 -28.37 67.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.7 ttt-85 -80.61 -55.21 5.0 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.429 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.644 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -76.66 -55.09 5.82 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -177.948 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.0 m -54.8 -32.57 60.41 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.244 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.15 -50.77 62.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.536 179.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.87 -41.38 82.81 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.822 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.463 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 10.4 tp -70.84 -42.99 77.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.93 0.395 . . . . 0.0 111.001 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 -62.6 -43.72 98.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.414 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.4 m -59.3 -37.66 78.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.876 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.502 ' CD2' HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -59.28 -35.29 73.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.883 179.853 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.502 HG23 ' CD2' ' A' ' 33' ' ' PHE . 3.0 t -72.55 -62.04 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.57 -178.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 72.2 m -47.77 -57.65 5.32 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.408 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.21 -51.26 57.07 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.16 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 33' ' ' PHE . 53.3 t -64.24 -25.36 37.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.63 0.252 . . . . 0.0 110.513 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.421 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.11 0 CA-C-O 120.742 0.306 . . . . 0.0 111.617 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.635 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 30.1 t80 -56.48 -28.54 60.03 Favored 'General case' 0 CA--C 1.509 -0.605 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.711 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.5 tt0 -77.23 -43.45 33.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 121.117 0.484 . . . . 0.0 110.068 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -66.99 -29.49 69.33 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.832 178.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.48 -53.23 7.08 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.514 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.711 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.08 -55.75 5.42 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.066 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.8 m -55.34 -27.9 50.21 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.96 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.82 -51.99 23.3 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.892 0.377 . . . . 0.0 111.253 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.91 -44.13 56.49 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.896 -179.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.429 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 2.5 tp -63.28 -44.01 98.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.968 0.414 . . . . 0.0 111.691 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 36.0 t-20 -57.31 -49.21 76.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.858 0.361 . . . . 0.0 110.558 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 39.6 p -59.07 -41.07 87.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.072 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -57.08 -36.57 70.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.97 0.414 . . . . 0.0 110.808 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 t -62.42 -59.55 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.142 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.4 m -49.31 -47.2 47.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.197 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.3 -44.91 93.27 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.421 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.4 m -78.62 -25.88 13.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.818 0.342 . . . . 0.0 110.842 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.809 -179.454 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.086 0 CA-C-O 120.634 0.254 . . . . 0.0 111.551 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -52.68 -41.99 64.36 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.629 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 3.5 tm0? -65.92 -42.09 90.58 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.897 0.379 . . . . 0.0 111.106 -177.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -70.45 -30.07 66.8 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.307 0.575 . . . . 0.0 110.161 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -80.03 -54.05 6.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.513 -0.767 . . . . 0.0 111.504 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.629 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.86 -55.83 6.82 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -178.016 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.523 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.3 m -55.98 -32.28 63.77 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 120.694 -0.402 . . . . 0.0 110.807 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.41 -32.85 68.87 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.705 179.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.84 -42.82 8.0 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.632 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 4.0 tp -68.87 -36.12 72.62 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.598 0.713 . . . . 0.0 110.863 -179.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -77.3 -38.03 51.46 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.082 0.467 . . . . 0.0 109.901 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 47.2 t -66.68 -30.79 71.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -59.47 -40.67 87.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 t -65.98 -61.99 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.472 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -55.37 -34.71 64.55 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.49 -45.86 93.84 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.293 179.214 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 31.3 m -76.8 -27.63 16.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-O 121.119 0.485 . . . . 0.0 110.055 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.199 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.289 -179.951 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 -0.192 0 CA-C-O 120.571 0.224 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.527 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.3 t80 -56.09 -35.26 66.81 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.047 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.674 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 40.0 mt-30 -73.99 -34.09 64.07 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 123.144 0.277 . . . . 0.0 111.099 -177.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -75.74 -30.24 59.15 Favored 'General case' 0 C--N 1.33 -0.264 0 O-C-N 123.732 0.645 . . . . 0.0 109.946 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.2 ttt-85 -80.65 -57.9 3.36 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.114 -0.948 . . . . 0.0 111.096 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.674 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -65.64 -57.74 7.4 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.239 -0.892 . . . . 0.0 113.378 -178.105 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.508 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.3 m -56.84 -44.95 82.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.785 0.326 . . . . 0.0 111.27 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.27 -43.42 64.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.457 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.44 -51.51 8.35 Favored Glycine 0 CA--C 1.52 0.377 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.872 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.435 HG21 ' HA ' ' A' ' 27' ' ' THR . 9.8 tp -65.53 -46.15 90.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.018 0.437 . . . . 0.0 111.714 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.405 ' HB2' ' O ' ' A' ' 27' ' ' THR . 1.1 t30 -63.04 -38.25 90.44 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.956 0.408 . . . . 0.0 110.199 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.5 m -57.14 -37.37 71.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.237 178.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.84 -37.82 77.34 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.106 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.8 t -68.92 -63.08 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.732 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.5 m -47.9 -39.52 19.15 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.013 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.18 -50.31 69.05 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.592 179.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.0 m -72.14 -29.33 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.177 0.513 . . . . 0.0 109.982 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.129 -179.995 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 -0.264 0 CA-C-O 120.706 0.289 . . . . 0.0 111.333 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.727 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 60.3 t80 -51.05 -30.14 14.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.601 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.9 tt0 -81.6 -35.67 29.85 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 111.941 0.349 . . . . 0.0 111.941 -177.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.18 -25.19 54.95 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.673 0.749 . . . . 0.0 109.086 -179.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.51 -59.09 2.89 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.111 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.727 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -68.11 -57.74 5.6 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 113.164 0.801 . . . . 0.0 113.164 -178.789 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.491 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 0.7 OUTLIER -53.79 -36.69 62.71 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.661 -179.756 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.81 -51.51 67.22 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.677 0.275 . . . . 0.0 110.647 178.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.79 -36.68 46.99 Favored Glycine 0 C--N 1.332 0.32 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.178 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 38.1 mm -70.2 -42.03 78.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 110.288 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -62.48 -39.74 94.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.054 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -55.3 -48.7 73.72 Favored 'General case' 0 CA--C 1.519 -0.221 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.332 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.452 ' CD1' ' N ' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -44.68 -38.58 4.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.194 179.217 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.486 ' O ' ' N ' ' A' ' 38' ' ' ALA . 2.7 t -69.25 -64.21 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.34 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.404 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.6 m -45.56 -56.11 5.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.826 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.85 -54.03 35.95 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.499 -0.858 . . . . 0.0 111.835 179.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.401 ' CG2' ' O ' ' A' ' 33' ' ' PHE . 58.8 t -64.62 -19.16 24.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.715 0.293 . . . . 0.0 110.719 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.333 -0.14 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.027 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.711 0.291 . . . . 0.0 111.301 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.667 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 24.1 t80 -53.64 -30.8 44.64 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.721 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 29.5 tt0 -76.95 -39.87 49.1 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.769 -177.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -71.52 -31.7 67.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.908 179.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.92 -54.14 6.96 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.509 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.721 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.21 -58.41 3.57 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -177.884 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.7 m -54.13 -31.66 52.97 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.579 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.68 -45.76 85.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.495 -0.321 . . . . 0.0 111.024 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.27 -43.78 12.54 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.05 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 46.7 mm -62.33 -36.28 73.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.369 0.604 . . . . 0.0 110.442 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -67.67 -44.05 78.76 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -62.49 -37.87 87.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.992 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -55.7 -39.73 71.43 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.016 0.436 . . . . 0.0 109.987 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.0 t -59.81 -59.17 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.893 178.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -57.37 -42.02 81.3 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.25 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.4 -43.17 95.91 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.954 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.0 m -79.72 -27.22 12.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.106 0.479 . . . . 0.0 110.403 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.26 -179.719 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.106 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.65 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.6 t80 -52.54 -32.24 39.79 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 -178.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.687 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.8 tt0 -77.92 -36.4 49.45 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.745 -177.322 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -75.05 -29.82 60.86 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.274 0.559 . . . . 0.0 109.538 179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt85 -78.73 -52.36 8.5 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.12 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.687 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.05 -57.32 3.97 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.205 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.1 m -56.03 -20.48 16.97 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.102 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.49 -48.9 13.12 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.964 0.412 . . . . 0.0 110.075 179.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.83 -45.31 27.95 Favored Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.284 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.401 ' O ' HG23 ' A' ' 34' ' ' VAL . 50.5 mm -60.49 -45.44 96.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.778 0.323 . . . . 0.0 110.72 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -61.26 -37.07 81.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.776 0.322 . . . . 0.0 110.81 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.5 t -69.11 -38.88 79.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.793 0.33 . . . . 0.0 110.755 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.529 ' CD1' HG21 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -59.42 -34.45 72.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.208 0.528 . . . . 0.0 110.457 179.54 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.529 HG21 ' CD1' ' A' ' 33' ' ' PHE . 2.7 t -69.28 -61.81 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.785 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 52.4 m -47.12 -57.49 5.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.28 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.42 -48.69 78.85 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.011 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.424 ' CG2' ' O ' ' A' ' 33' ' ' PHE . 52.5 t -67.43 -21.83 28.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.765 0.317 . . . . 0.0 110.739 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.434 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.502 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 -0.095 0 CA-C-O 120.682 0.277 . . . . 0.0 111.103 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.64 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.4 t80 -51.67 -30.75 23.07 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -178.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.722 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.2 tt0 -76.45 -47.48 22.9 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 117.969 0.35 . . . . 0.0 110.762 -178.109 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -64.8 -27.52 68.94 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.444 0.64 . . . . 0.0 109.521 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.31 -52.73 7.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.86 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.722 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -77.74 -56.6 4.37 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -178.86 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.52 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.8 m -53.37 -23.46 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.857 179.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.52 -52.64 11.33 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.892 0.377 . . . . 0.0 110.484 178.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.05 -42.15 59.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.611 -0.805 . . . . 0.0 112.426 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 48.1 mm -62.11 -46.35 96.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.122 0.486 . . . . 0.0 111.436 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -56.99 -48.0 79.48 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.925 0.393 . . . . 0.0 110.568 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.3 t -60.72 -36.69 79.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -57.66 -38.71 75.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.983 0.421 . . . . 0.0 110.43 179.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.0 t -61.45 -62.49 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.305 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.5 179.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.2 m -54.83 -38.89 67.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -61.93 -41.64 99.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.749 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 29.7 m -80.2 -27.21 11.91 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-O 121.027 0.441 . . . . 0.0 110.221 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.531 -179.747 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 -0.312 0 CA-C-O 120.889 0.375 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.568 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.7 t80 -53.55 -33.12 53.54 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -178.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.698 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 21.5 tt0 -76.38 -43.26 41.47 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.902 0.382 . . . . 0.0 110.81 -178.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.21 -33.23 75.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.439 0.638 . . . . 0.0 109.82 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.0 -54.35 6.11 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.57 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.698 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.37 -57.5 3.97 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -177.957 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.519 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.9 m -52.39 -33.53 43.86 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.98 -0.288 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.39 -47.77 75.2 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.736 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.08 -47.81 57.27 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.27 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.427 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 17.7 tt -64.86 -36.46 77.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.21 0.528 . . . . 0.0 110.344 -179.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 31.7 m-20 -57.71 -40.97 80.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.509 179.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.5 t -66.57 -36.98 83.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.118 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.422 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -58.55 -38.29 77.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.225 0.536 . . . . 0.0 110.328 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.421 ' O ' ' N ' ' A' ' 38' ' ' ALA . 3.2 t -62.59 -61.67 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.235 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 54.5 m -50.25 -56.11 12.54 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.369 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.11 -52.16 54.12 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.296 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.422 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 50.4 t -66.46 -21.19 28.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.706 0.288 . . . . 0.0 110.375 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.454 -0.228 0 CA-C-O 120.919 0.39 . . . . 0.0 110.676 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.173 0 CA-C-O 120.709 0.29 . . . . 0.0 111.574 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.661 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 32.4 t80 -52.1 -33.51 39.91 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -178.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.738 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 14.7 tt0 -79.21 -39.76 32.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.025 0.44 . . . . 0.0 110.38 -178.494 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -65.4 -30.61 71.44 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 178.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.64 -56.93 4.05 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.573 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.738 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.4 OUTLIER -73.89 -58.04 3.57 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -178.184 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.6 m -51.01 -33.67 25.93 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.621 179.808 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.19 -55.2 30.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.118 0.485 . . . . 0.0 110.932 179.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.8 -35.74 61.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.182 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 42.6 mm -70.85 -35.67 61.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.3 0.572 . . . . 0.0 111.181 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.2 t-20 -61.51 -50.34 73.08 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.085 0.469 . . . . 0.0 109.821 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 86.2 p -57.28 -43.74 83.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.928 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -52.83 -39.34 62.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 110.681 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.6 t -58.66 -60.3 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.593 179.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -52.73 -42.29 64.74 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.735 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.06 -44.25 97.47 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.142 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.3 m -79.82 -24.95 12.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.913 0.387 . . . . 0.0 110.809 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.693 -179.397 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.946 0.403 . . . . 0.0 111.485 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.643 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 26.3 t80 -54.19 -29.06 44.54 Favored 'General case' 0 C--O 1.219 -0.522 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -178.292 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.641 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.6 tt0 -78.81 -36.94 41.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 118.196 0.453 . . . . 0.0 111.341 -177.568 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -74.75 -33.1 62.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.299 0.571 . . . . 0.0 109.743 179.537 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.4 -57.44 3.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.862 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.643 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -66.18 -58.74 4.75 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -177.8 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 3.2 m -54.08 -36.68 63.42 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.669 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.4 -41.66 89.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.846 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.29 -47.27 6.16 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.387 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.402 ' O ' ' CG2' ' A' ' 34' ' ' VAL . 9.2 mt -63.67 -26.04 39.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 121.008 0.432 . . . . 0.0 110.759 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -76.15 -53.8 7.76 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.917 0.389 . . . . 0.0 110.547 179.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.0 t -62.3 -35.71 79.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.203 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.432 ' CD2' HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -57.38 -35.72 70.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.913 0.387 . . . . 0.0 110.849 -179.878 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.432 HG23 ' CD2' ' A' ' 33' ' ' PHE . 2.9 t -70.18 -62.84 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.086 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.7 m -52.15 -37.91 55.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.863 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.91 -43.91 98.76 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.621 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.5 -26.79 11.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.933 0.397 . . . . 0.0 110.772 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.231 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.676 -179.407 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.836 0.35 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.711 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 44.4 t80 -54.58 -27.14 36.86 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -179.492 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.517 ' HA ' ' CD1' ' A' ' 26' ' ' TYR . 29.9 mm-40 -75.17 -38.8 60.73 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.849 -178.274 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -78.16 -44.47 25.85 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.2 0.524 . . . . 0.0 109.926 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -56.22 23.92 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.61 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.711 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -63.44 -37.39 87.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.891 -1.049 . . . . 0.0 113.639 -177.094 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 31' ' ' ASN . 4.3 p -65.68 -45.1 84.16 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.448 -0.501 . . . . 0.0 109.706 177.656 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -43.34 64.79 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.847 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.37 -43.95 11.98 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.497 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 35.7 mm -72.84 -54.0 17.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 121.007 0.432 . . . . 0.0 111.176 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.506 ' N ' ' O ' ' A' ' 27' ' ' THR . 3.3 t-20 -56.36 -50.19 72.25 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.771 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.6 m -54.23 -40.3 67.58 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.688 0.28 . . . . 0.0 111.089 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.11 -35.7 67.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 -179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 t -74.8 -60.36 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.93 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.9 m -57.05 -38.09 72.73 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.081 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.54 -43.06 97.9 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.674 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 20.3 m -80.79 -29.51 11.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.044 0.45 . . . . 0.0 110.318 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.227 -179.824 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.124 0 N-CA-C 111.543 0.201 . . . . 0.0 111.543 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -53.31 -42.35 66.59 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 -178.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.67 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.8 tt0 -68.38 -36.86 79.77 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.991 -177.321 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -72.93 -28.88 62.71 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -80.45 -53.94 6.14 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.506 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.67 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.58 -54.25 8.62 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.273 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.503 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.8 m -57.66 -25.39 60.14 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.731 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.36 -33.36 49.07 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.438 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.94 -42.72 7.99 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.682 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.411 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 9.0 tp -67.37 -41.32 86.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.641 0.734 . . . . 0.0 111.339 -179.228 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -72.48 -41.72 65.71 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 58.4 m -65.24 -31.1 72.09 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -59.49 -40.58 87.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.984 0.421 . . . . 0.0 110.006 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.9 t -66.81 -63.38 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.221 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.1 m -56.44 -34.79 67.16 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.355 179.568 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.15 -43.3 98.87 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.322 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.9 m -80.23 -27.38 11.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.972 0.415 . . . . 0.0 110.268 179.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.141 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.844 -179.463 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 -0.267 0 CA-C-O 120.764 0.316 . . . . 0.0 110.547 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.529 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.4 t80 -57.22 -33.35 67.44 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -179.143 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.704 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.1 tt0 -75.37 -37.24 60.72 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 121.121 -0.232 . . . . 0.0 111.035 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -70.64 -30.8 67.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.526 0.679 . . . . 0.0 109.627 179.776 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -79.82 -58.31 3.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.144 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.704 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -68.48 -58.53 4.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.132 -0.94 . . . . 0.0 113.3 -177.93 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.526 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.4 m -54.38 -37.45 65.02 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.893 -0.323 . . . . 0.0 110.912 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.99 -48.9 75.02 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.176 179.267 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.42 -53.66 8.52 Favored Glycine 0 CA--C 1.52 0.369 0 C-N-CA 120.595 -0.812 . . . . 0.0 113.097 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.407 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 2.5 tt -61.41 -29.45 45.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.138 0.494 . . . . 0.0 111.915 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -69.51 -48.92 59.0 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 122.035 -0.415 . . . . 0.0 110.169 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 16.6 m -54.04 -38.85 65.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.241 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -59.11 -37.73 77.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.195 0.522 . . . . 0.0 110.49 179.59 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.589 ' O ' HG11 ' A' ' 37' ' ' VAL . 4.2 t -67.49 -59.87 3.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.892 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 73.1 m -45.32 -55.65 5.74 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.471 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.93 -47.49 85.39 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.349 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.589 HG11 ' O ' ' A' ' 34' ' ' VAL . 5.0 p -65.95 -24.98 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.849 0.357 . . . . 0.0 110.439 -179.887 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.446 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--O 1.231 0.113 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.549 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 -0.122 0 CA-C-O 120.79 0.329 . . . . 0.0 111.198 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.875 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 28.4 t80 -55.33 -17.92 5.6 Favored 'General case' 0 CA--C 1.508 -0.644 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.26 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.692 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 49.0 tt0 -84.38 -45.26 12.93 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.334 -178.004 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -69.28 -33.68 73.58 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -67.89 -55.46 12.78 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.125 179.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.875 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.3 OUTLIER -68.21 -36.93 80.29 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.543 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.603 ' HA ' HG23 ' A' ' 30' ' ' ILE . 1.1 p -59.79 -46.19 89.96 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 120.198 -0.601 . . . . 0.0 109.575 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -41.38 63.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.229 179.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.06 -52.01 7.18 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.54 179.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.603 HG23 ' HA ' ' A' ' 27' ' ' THR . 1.2 tt -70.91 -50.33 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 120.78 0.324 . . . . 0.0 111.836 -179.165 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.514 ' N ' ' O ' ' A' ' 27' ' ' THR . 2.1 t-20 -55.34 -50.97 68.27 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 120.805 0.336 . . . . 0.0 110.417 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 44.0 m -49.66 -44.33 47.68 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.631 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -53.38 -34.73 58.77 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.089 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.2 t -72.2 -61.65 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.345 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.3 m -51.49 -39.17 57.06 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.763 179.619 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.15 98.73 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.818 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.9 m -80.95 -29.52 11.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.073 0.463 . . . . 0.0 110.432 179.237 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.448 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.626 179.768 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 -0.238 0 CA-C-O 120.752 0.311 . . . . 0.0 111.113 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.574 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 56.9 t80 -51.53 -31.31 23.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.573 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.2 mt-30 -80.15 -47.49 14.64 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.999 0.428 . . . . 0.0 111.27 -177.834 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.445 ' O ' ' CB ' ' A' ' 28' ' ' ALA . 45.8 tt0 -60.61 -27.06 67.46 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.461 0.648 . . . . 0.0 109.403 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.1 ttm-85 -81.09 -57.01 3.71 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.058 -0.974 . . . . 0.0 111.084 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.574 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -76.44 -45.1 32.86 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.679 -178.624 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.469 ' HA ' ' CG2' ' A' ' 30' ' ' ILE . 1.4 m -63.35 -39.09 93.59 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.307 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.445 ' CB ' ' O ' ' A' ' 24' ' ' GLU . . . -58.48 -49.62 76.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.751 0.31 . . . . 0.0 111.356 179.047 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.18 -43.04 82.05 Favored Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.533 -0.842 . . . . 0.0 113.019 -179.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.469 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 1.0 OUTLIER -72.17 -47.36 54.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.782 0.325 . . . . 0.0 111.152 -179.348 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -59.28 -41.22 88.42 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.757 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 24.0 p -57.33 -47.97 80.18 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.981 0.42 . . . . 0.0 109.918 179.661 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.475 ' CD1' ' N ' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -46.83 -39.2 11.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.268 179.031 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.475 ' N ' ' CD1' ' A' ' 33' ' ' PHE . 2.7 t -70.71 -66.01 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.423 -178.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 50.6 m -46.71 -53.75 11.09 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.866 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.79 -45.62 90.96 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.035 179.213 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.465 ' CG2' ' O ' ' A' ' 33' ' ' PHE . 47.3 t -71.96 -23.27 21.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.821 0.343 . . . . 0.0 110.509 179.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.457 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.332 -0.182 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.527 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.145 0 CA-C-O 120.643 0.258 . . . . 0.0 110.978 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.682 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 22.2 t80 -55.12 -31.28 61.13 Favored 'General case' 0 CA--C 1.509 -0.606 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 -179.366 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.704 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 9.2 tt0 -78.74 -34.58 45.66 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.419 -177.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -73.56 -29.46 62.45 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.024 0.828 . . . . 0.0 109.515 179.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.27 -57.07 3.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.477 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.704 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -69.7 -57.72 4.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -177.884 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.507 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 0.6 OUTLIER -54.88 -41.29 70.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.744 0.307 . . . . 0.0 111.03 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.11 -45.78 83.14 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.347 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.87 -42.88 19.3 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.825 -0.702 . . . . 0.0 113.419 -179.2 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.403 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 10.7 tp -71.05 -31.35 44.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.963 0.411 . . . . 0.0 111.839 -178.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -72.24 -45.03 61.91 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.785 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 65.9 p -62.76 -36.18 82.21 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.072 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.71 -35.72 73.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.934 0.397 . . . . 0.0 110.889 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.7 t -70.93 -63.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.519 -179.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -50.68 -38.17 45.28 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.737 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.37 -44.51 97.51 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.513 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.7 m -80.38 -26.62 11.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.934 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.203 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.821 -179.245 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 -0.115 0 CA-C-O 120.843 0.354 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.721 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 40.0 t80 -57.3 -27.74 62.42 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -179.037 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.486 ' O ' ' HD1' ' A' ' 26' ' ' TYR . 18.1 tt0 -71.46 -46.25 60.47 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.025 -178.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.81 -48.04 49.1 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.014 0.435 . . . . 0.0 110.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -56.13 -58.58 7.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.574 0.702 . . . . 0.0 111.457 179.576 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.721 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.18 -32.82 73.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.867 -1.061 . . . . 0.0 113.182 -177.442 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.577 ' HA ' HG21 ' A' ' 30' ' ' ILE . 1.2 p -66.7 -45.27 79.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.121 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -49.42 -46.3 47.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.47 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.85 -53.85 9.07 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.823 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.577 HG21 ' HA ' ' A' ' 27' ' ' THR . 7.2 tp -66.8 -49.65 72.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.779 0.29 . . . . 0.0 111.63 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.453 ' N ' ' O ' ' A' ' 27' ' ' THR . 8.3 t-20 -52.46 -40.11 61.9 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.826 0.346 . . . . 0.0 110.583 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.4 m -60.75 -43.92 97.36 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 110.522 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.459 ' CD1' HG21 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -56.59 -33.59 66.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.136 0.493 . . . . 0.0 110.981 179.779 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.459 HG21 ' CD1' ' A' ' 33' ' ' PHE . 3.4 t -69.06 -60.94 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.373 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -48.04 -58.0 5.04 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.021 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.73 -50.01 66.38 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.273 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 33' ' ' PHE . 75.2 t -68.53 -16.35 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.546 0.213 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.422 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.333 -0.134 0 CA-C-O 120.831 0.348 . . . . 0.0 111.371 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.179 0 CA-C-O 120.976 0.417 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.834 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 38.1 t80 -57.78 -21.0 39.41 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.209 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.706 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 7.5 tm0? -81.49 -48.01 12.41 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.689 -178.205 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -64.73 -30.74 71.76 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.558 179.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.04 -51.61 11.93 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.563 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.834 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -77.44 -55.55 5.29 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -177.811 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.469 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.2 m -55.94 -21.97 23.65 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.932 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.84 -58.11 3.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.066 0.46 . . . . 0.0 110.495 179.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.88 -43.55 65.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.173 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.44 HG21 HD11 ' A' ' 30' ' ' ILE . 42.0 mm -56.57 -51.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.923 0.392 . . . . 0.0 110.957 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -50.09 -53.16 29.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.904 0.383 . . . . 0.0 110.408 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 p -63.17 -36.15 82.67 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.763 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -55.99 -38.55 70.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.029 0.442 . . . . 0.0 110.703 179.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 t -63.97 -58.98 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.42 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.368 179.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 70.7 m -53.92 -42.81 69.19 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.677 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.14 -47.06 92.65 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.0 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.7 m -76.6 -26.62 16.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.886 0.374 . . . . 0.0 110.703 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.217 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.718 -179.725 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 1.263 ' CG2' ' H ' ' A' ' 2' ' ' ASN . 0.3 OUTLIER . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 1.263 ' H ' ' CG2' ' A' ' 1' ' ' VAL . 27.6 m-80 45.18 42.03 6.5 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.489 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -80.66 106.71 12.88 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.503 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.63 -70.94 0.02 OUTLIER Glycine 0 C--N 1.331 0.275 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.674 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 25.6 m-80 -162.63 29.64 0.1 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.717 0.294 . . . . 0.0 111.023 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -123.16 -15.1 3.88 Favored Glycine 0 CA--C 1.52 0.356 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.75 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.2 m -88.37 -32.06 5.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.769 0.319 . . . . 0.0 110.464 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.2 t -105.15 88.93 2.98 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.56 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.7 t -69.27 128.76 37.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.969 0.414 . . . . 0.0 111.507 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.556 ' O ' ' O ' ' A' ' 11' ' ' LYS . 1.9 p -56.04 154.91 6.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.21 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.556 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.9 mtpm? 45.21 163.45 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.147 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 t -90.05 58.82 4.29 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.116 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -158.25 -90.38 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.261 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 53.2 m 75.27 93.71 0.07 Allowed 'General case' 0 C--O 1.232 0.147 0 CA-C-O 120.67 0.271 . . . . 0.0 110.827 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.1 m -162.2 -47.87 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.78 0.324 . . . . 0.0 111.498 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.5 p -164.69 117.09 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.828 0.347 . . . . 0.0 111.552 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -85.48 157.19 20.51 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.974 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -63.55 -31.82 73.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.121 0.486 . . . . 0.0 109.868 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -45.28 -46.68 11.05 Favored Glycine 0 C--N 1.331 0.304 0 CA-C-N 115.551 -0.749 . . . . 0.0 113.002 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.67 -46.24 91.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.846 0.355 . . . . 0.0 110.821 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.57 -59.36 5.56 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.619 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.586 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 34.8 t80 -50.02 -34.6 21.8 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 112.84 0.681 . . . . 0.0 112.84 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.598 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 1.8 tt0 -79.71 -32.24 41.28 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.237 -177.01 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -76.24 -31.76 58.52 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.443 0.64 . . . . 0.0 109.295 179.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.1 ttt180 -77.16 -60.58 2.3 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 114.847 -1.07 . . . . 0.0 111.61 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.598 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -63.18 -54.53 36.12 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 113.056 0.761 . . . . 0.0 113.056 -178.03 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.45 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.5 m -58.93 -36.05 74.11 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.514 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -53.4 -49.54 67.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.04 0.448 . . . . 0.0 110.645 178.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 -33.87 28.66 Favored Glycine 0 C--N 1.33 0.229 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.449 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 5.2 mt -74.99 -29.59 22.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.746 0.308 . . . . 0.0 110.773 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.439 ' N ' ' O ' ' A' ' 27' ' ' THR . 37.9 t-20 -71.79 -49.14 41.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.038 0.447 . . . . 0.0 110.353 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.3 m -54.78 -45.17 74.24 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.524 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.461 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -48.43 -35.42 12.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.02 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 38' ' ' ALA . 3.0 t -70.66 -61.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.412 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -48.29 -58.44 4.57 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.49 -58.39 13.38 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.693 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.461 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 53.5 t -59.36 -22.25 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.617 0.246 . . . . 0.0 110.666 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.448 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -75.26 -26.65 58.98 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.276 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.9 p -74.1 -45.06 51.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.152 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -72.91 -50.75 12.3 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.646 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 179.04 82.7 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 121.279 0.562 . . . . 0.0 111.144 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.08 26.41 24.02 Favored Glycine 0 C--N 1.317 -0.524 0 CA-C-N 115.144 -0.934 . . . . 0.0 112.66 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 96.9 p -108.45 30.54 6.35 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.671 0.272 . . . . 0.0 111.339 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 6.6 tp -178.21 69.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.96 0.41 . . . . 0.0 111.216 179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -179.72 32.99 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.619 179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 69.5 mtt180 -100.42 54.97 0.89 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.923 0.392 . . . . 0.0 110.689 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -132.9 91.97 27.5 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.694 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo . . . . . 0 C--O 1.249 1.054 0 C-N-CA 122.498 2.132 . . . . 0.0 112.159 179.74 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.65 ' O ' HG12 ' A' ' 1' ' ' VAL . 39.7 t . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.453 ' O ' ' HB2' ' A' ' 3' ' ' TYR . 4.3 p-10 -80.01 -36.53 35.77 Favored 'General case' 0 C--N 1.333 -0.136 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 179.374 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.453 ' HB2' ' O ' ' A' ' 2' ' ' ASN . 46.6 m-85 68.9 86.63 0.13 Allowed 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -177.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -156.16 61.77 0.34 Allowed Glycine 0 C--N 1.333 0.416 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.938 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -162.74 -64.82 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.955 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -167.87 -56.14 0.03 OUTLIER Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.499 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.8 t 62.98 -64.82 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 111.903 0.334 . . . . 0.0 111.903 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.433 ' N ' ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER 48.48 92.1 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 120.866 0.365 . . . . 0.0 110.99 -179.738 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.7 m 54.55 89.05 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.238 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.6 t -81.15 71.34 8.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.383 179.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 55.17 41.86 31.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.569 -179.316 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 41.6 m -88.95 -84.16 0.22 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.959 178.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.8 pttt -158.37 38.63 0.24 Allowed 'General case' 0 C--O 1.233 0.222 0 C-N-CA 120.983 -0.287 . . . . 0.0 111.576 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.7 m -89.42 164.27 14.92 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.749 0.309 . . . . 0.0 111.779 179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 47.5 m -119.49 -11.4 9.49 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.4 p -163.65 99.9 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.757 0.789 . . . . 0.0 110.65 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.423 ' OD1' ' N ' ' A' ' 17' ' ' ASN . 6.4 p-10 -135.39 139.95 44.6 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.135 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -50.09 -28.25 6.91 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.043 0.449 . . . . 0.0 111.136 -179.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.58 -65.21 3.09 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.896 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 20.2 mm-40 -70.76 -33.05 70.39 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -179.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.94 -70.04 0.14 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.003 0.43 . . . . 0.0 110.731 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.591 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.2 t80 -54.89 -34.02 62.59 Favored 'General case' 0 C--O 1.22 -0.496 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.644 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -76.94 -39.04 52.1 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.03 0.443 . . . . 0.0 110.537 -177.874 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -68.08 -28.37 67.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.7 ttt-85 -80.61 -55.21 5.0 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.429 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.644 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -76.66 -55.09 5.82 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -177.948 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.0 m -54.8 -32.57 60.41 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.244 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -66.15 -50.77 62.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.536 179.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.87 -41.38 82.81 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.822 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.463 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 10.4 tp -70.84 -42.99 77.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.93 0.395 . . . . 0.0 111.001 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 -62.6 -43.72 98.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.414 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.4 m -59.3 -37.66 78.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.876 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.502 ' CD2' HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -59.28 -35.29 73.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.883 179.853 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.502 HG23 ' CD2' ' A' ' 33' ' ' PHE . 3.0 t -72.55 -62.04 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.57 -178.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 72.2 m -47.77 -57.65 5.32 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.408 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.21 -51.26 57.07 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.16 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 33' ' ' PHE . 53.3 t -64.24 -25.36 37.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.63 0.252 . . . . 0.0 110.513 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -79.64 -24.07 42.12 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.421 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.43 -48.72 18.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.283 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -90.94 -27.94 17.32 Favored Glycine 0 CA--C 1.518 0.268 0 C-N-CA 120.661 -0.78 . . . . 0.0 113.166 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 65.91 74.89 0.35 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 121.352 0.596 . . . . 0.0 110.948 -179.504 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -113.28 37.99 3.39 Favored Glycine 0 C--N 1.319 -0.373 0 CA-C-N 115.106 -0.952 . . . . 0.0 112.617 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 32.9 p -106.72 9.76 31.08 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 111.599 0.222 . . . . 0.0 111.599 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.4 pt -123.49 -11.02 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 112.022 0.379 . . . . 0.0 112.022 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 89.54 -26.87 8.48 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.184 -179.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 66.13 118.76 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.495 0.188 . . . . 0.0 110.705 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 61.1 mtm180 -151.28 154.66 34.03 Favored Pre-proline 0 N--CA 1.464 0.273 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.446 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 C--O 1.251 1.148 0 C-N-CA 122.372 2.048 . . . . 0.0 112.217 -179.746 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.1 m . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -161.1 -45.12 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.868 0.366 . . . . 0.0 111.413 -179.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 14.9 p90 -80.59 -36.06 33.31 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.076 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 53.65 71.37 0.71 Allowed Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.983 -0.627 . . . . 0.0 113.274 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 62.1 37.65 14.43 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.764 0.316 . . . . 0.0 110.811 179.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -135.99 34.83 2.21 Favored Glycine 0 C--N 1.33 0.233 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.282 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 10.9 p -88.28 110.34 20.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.66 0.267 . . . . 0.0 110.594 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 10.2 t -149.12 106.48 3.63 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.045 0.45 . . . . 0.0 110.662 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 37.7 t -155.49 103.91 2.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.324 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.9 m -163.59 92.28 0.7 Allowed 'General case' 0 N--CA 1.463 0.203 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER 75.34 8.73 3.86 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.255 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.65 158.48 44.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.976 0.417 . . . . 0.0 110.774 -179.467 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 68.6 -69.38 0.15 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.966 -179.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 4.0 m -71.06 91.4 0.89 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.37 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 62.96 176.39 0.15 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.358 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 14.1 p -163.88 111.13 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.362 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.466 ' HB3' ' CE3' ' A' ' 18' ' ' TRP . 13.1 t30 -70.23 152.44 44.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.125 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.51 ' O ' ' CD1' ' A' ' 18' ' ' TRP . 6.6 p90 49.13 27.32 1.73 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.86 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.34 -46.05 4.5 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.568 -0.825 . . . . 0.0 111.505 179.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -68.04 -38.35 82.41 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.683 0.278 . . . . 0.0 111.262 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -73.12 -53.71 10.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.617 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.635 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 30.1 t80 -56.48 -28.54 60.03 Favored 'General case' 0 CA--C 1.509 -0.605 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.711 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.5 tt0 -77.23 -43.45 33.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 121.117 0.484 . . . . 0.0 110.068 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -66.99 -29.49 69.33 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.832 178.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.48 -53.23 7.08 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.514 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.711 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.08 -55.75 5.42 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.066 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.8 m -55.34 -27.9 50.21 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.96 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.82 -51.99 23.3 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.892 0.377 . . . . 0.0 111.253 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.91 -44.13 56.49 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.896 -179.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.429 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 2.5 tp -63.28 -44.01 98.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.968 0.414 . . . . 0.0 111.691 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 36.0 t-20 -57.31 -49.21 76.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.858 0.361 . . . . 0.0 110.558 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 39.6 p -59.07 -41.07 87.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.072 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -57.08 -36.57 70.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.97 0.414 . . . . 0.0 110.808 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.5 t -62.42 -59.55 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.142 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.4 m -49.31 -47.2 47.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.197 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.3 -44.91 93.27 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.421 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.4 m -78.62 -25.88 13.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.818 0.342 . . . . 0.0 110.842 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -71.33 -24.85 62.19 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.809 -179.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -59.61 -27.49 66.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.375 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -121.77 -44.64 0.37 Allowed Glycine 0 C--N 1.33 0.221 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.824 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 178.95 83.63 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.318 0.58 . . . . 0.0 110.891 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.81 -16.18 73.46 Favored Glycine 0 C--N 1.318 -0.459 0 CA-C-N 115.23 -0.895 . . . . 0.0 113.666 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.0 m -67.22 -75.07 0.1 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 117.015 0.407 . . . . 0.0 110.787 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 16.6 mt 66.77 11.75 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.222 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 55.4 14.49 6.62 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.736 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.8 tmm_? -116.28 122.84 46.12 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.861 0.362 . . . . 0.0 111.334 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.66 98.86 2.64 Favored Pre-proline 0 CA--C 1.53 0.178 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.872 179.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 C--O 1.249 1.071 0 C-N-CA 122.412 2.075 . . . . 0.0 112.261 179.744 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 1.232 ' CG1' ' CG1' ' A' ' 7' ' ' VAL . 6.7 p . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 1.087 ' H ' ' CG2' ' A' ' 1' ' ' VAL . 14.0 t30 -160.44 28.09 0.16 Allowed 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.249 0.547 . . . . 0.0 110.047 -178.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.839 ' HD2' HG12 ' A' ' 1' ' ' VAL . 5.3 m-85 -80.78 -52.69 7.23 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.065 -179.283 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 90.49 12.23 61.42 Favored Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.984 -0.626 . . . . 0.0 113.24 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -162.33 39.34 0.12 Allowed 'General case' 0 C--O 1.233 0.205 0 CA-C-O 121.124 0.488 . . . . 0.0 111.163 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 131.19 89.24 0.48 Allowed Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.927 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 1.232 ' CG1' ' CG1' ' A' ' 1' ' ' VAL . 19.9 m -87.34 -26.33 5.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.689 0.281 . . . . 0.0 111.1 -179.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.3 m -96.0 74.09 3.02 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.922 0.391 . . . . 0.0 110.52 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -176.74 131.37 0.19 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.565 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 m -76.9 79.39 3.47 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.131 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 4.0 mmmm 48.08 20.42 0.25 Allowed 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.859 -179.202 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.7 p -92.79 -24.64 18.47 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.3 mttp 80.25 -6.65 1.7 Allowed 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.764 0.426 . . . . 0.0 111.61 -178.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.0 m 69.1 -70.35 0.14 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.939 0.4 . . . . 0.0 111.515 179.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.8 m -57.34 -167.51 0.0 OUTLIER 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.73 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 16.3 t 81.15 -70.61 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.768 179.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.6 p30 173.36 -33.31 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.234 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -39.18 -33.99 0.16 Allowed 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.123 -178.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.09 -44.63 87.19 Favored Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.695 -0.764 . . . . 0.0 113.559 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -62.74 -38.21 89.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.919 0.39 . . . . 0.0 111.242 -179.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -67.64 -51.19 52.92 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.551 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -52.68 -41.99 64.36 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.629 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 3.5 tm0? -65.92 -42.09 90.58 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.897 0.379 . . . . 0.0 111.106 -177.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -70.45 -30.07 66.8 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.307 0.575 . . . . 0.0 110.161 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -80.03 -54.05 6.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.513 -0.767 . . . . 0.0 111.504 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.629 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.86 -55.83 6.82 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -178.016 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.523 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.3 m -55.98 -32.28 63.77 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 120.694 -0.402 . . . . 0.0 110.807 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.41 -32.85 68.87 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.705 179.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.84 -42.82 8.0 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.632 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 4.0 tp -68.87 -36.12 72.62 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.598 0.713 . . . . 0.0 110.863 -179.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -77.3 -38.03 51.46 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.082 0.467 . . . . 0.0 109.901 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 47.2 t -66.68 -30.79 71.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -59.47 -40.67 87.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 t -65.98 -61.99 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.472 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -55.37 -34.71 64.55 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.49 -45.86 93.84 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.293 179.214 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 31.3 m -76.8 -27.63 16.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-O 121.119 0.485 . . . . 0.0 110.055 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -79.09 -23.05 44.39 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.289 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.9 t -79.81 -43.76 21.83 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.355 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.423 ' O ' ' CB ' ' A' ' 41' ' ' ALA . . . -174.53 -43.5 0.05 OUTLIER Glycine 0 CA--C 1.52 0.367 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.587 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.423 ' CB ' ' O ' ' A' ' 40' ' ' GLY . . . 83.37 -9.55 1.04 Allowed 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 179.484 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.13 28.62 53.27 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.384 -0.912 . . . . 0.0 113.047 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 19.1 m -104.03 -65.31 1.03 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.885 0.374 . . . . 0.0 110.816 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.0 tt -155.62 33.56 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.442 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -114.21 28.95 7.97 Favored Glycine 0 C--N 1.331 0.267 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.232 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -173.55 39.36 0.01 OUTLIER 'General case' 0 C--O 1.235 0.316 0 CA-C-O 120.667 0.27 . . . . 0.0 111.007 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 34.0 ptt85 42.24 85.67 0.16 Allowed Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.375 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo . . . . . 0 C--O 1.249 1.065 0 C-N-CA 122.223 1.949 . . . . 0.0 112.182 179.123 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.545 HG12 ' N ' ' A' ' 2' ' ' ASN . 77.4 t . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.545 ' N ' HG12 ' A' ' 1' ' ' VAL . 1.4 t30 71.11 -69.04 0.19 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.394 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 26.5 p90 -80.45 -179.33 7.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.419 -179.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 113.82 63.09 0.42 Allowed Glycine 0 CA--C 1.512 -0.112 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -178.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -162.47 -42.42 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.507 0.194 . . . . 0.0 111.412 -179.05 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -162.22 55.22 0.3 Allowed Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.828 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 m -89.4 22.92 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.9 m 60.81 95.34 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.675 0.274 . . . . 0.0 110.755 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -71.58 137.62 48.15 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.869 0.366 . . . . 0.0 110.411 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.54 17.7 14.24 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.411 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt -162.73 174.97 11.81 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-O 120.883 0.373 . . . . 0.0 110.896 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 49.3 p -89.5 26.0 1.82 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.982 -179.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.544 ' O ' ' HB2' ' A' ' 14' ' ' CYS . 12.6 tttt -158.5 -68.64 0.09 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.682 0.277 . . . . 0.0 110.366 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.544 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 62.9 m 74.31 66.25 0.08 Allowed 'General case' 0 CA--C 1.521 -0.163 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.1 m -121.67 -2.26 9.39 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.404 -0.817 . . . . 0.0 111.56 -179.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.9 t -75.61 -54.01 14.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.716 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 63.36 -63.36 0.13 Allowed 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 178.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 4.7 p90 -67.6 -15.31 63.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -177.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.96 -57.11 13.58 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.89 179.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -64.06 -26.47 68.57 Favored 'General case' 0 C--N 1.33 -0.254 0 O-C-N 122.717 -0.284 . . . . 0.0 111.614 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.5 -69.67 0.19 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.571 0.224 . . . . 0.0 110.817 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.527 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.3 t80 -56.09 -35.26 66.81 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.047 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.674 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 40.0 mt-30 -73.99 -34.09 64.07 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 123.144 0.277 . . . . 0.0 111.099 -177.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -75.74 -30.24 59.15 Favored 'General case' 0 C--N 1.33 -0.264 0 O-C-N 123.732 0.645 . . . . 0.0 109.946 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.2 ttt-85 -80.65 -57.9 3.36 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.114 -0.948 . . . . 0.0 111.096 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.674 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -65.64 -57.74 7.4 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.239 -0.892 . . . . 0.0 113.378 -178.105 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.508 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.3 m -56.84 -44.95 82.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.785 0.326 . . . . 0.0 111.27 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.27 -43.42 64.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.457 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.44 -51.51 8.35 Favored Glycine 0 CA--C 1.52 0.377 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.872 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.435 HG21 ' HA ' ' A' ' 27' ' ' THR . 9.8 tp -65.53 -46.15 90.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.018 0.437 . . . . 0.0 111.714 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.405 ' HB2' ' O ' ' A' ' 27' ' ' THR . 1.1 t30 -63.04 -38.25 90.44 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.956 0.408 . . . . 0.0 110.199 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.5 m -57.14 -37.37 71.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.237 178.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.84 -37.82 77.34 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.106 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.8 t -68.92 -63.08 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.732 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.5 m -47.9 -39.52 19.15 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.013 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.18 -50.31 69.05 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.592 179.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.403 ' O ' ' CB ' ' A' ' 41' ' ' ALA . 35.0 m -72.14 -29.33 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.177 0.513 . . . . 0.0 109.982 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -71.25 -22.58 61.96 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.129 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 54.2 m -55.94 -26.16 46.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.576 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 169.01 34.14 0.02 OUTLIER Glycine 0 CA--C 1.52 0.353 0 C-N-CA 119.637 -1.268 . . . . 0.0 114.358 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 37' ' ' VAL . . . -80.27 -31.95 38.26 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 117.49 0.645 . . . . 0.0 110.74 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 129.94 61.23 0.1 Allowed Glycine 0 C--N 1.331 0.281 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.325 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 58.2 p -173.06 77.05 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.917 0.389 . . . . 0.0 110.706 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -154.58 59.87 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.683 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 179.0 39.8 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.115 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.4 ' O ' ' O ' ' A' ' 47' ' ' ARG . 0.2 OUTLIER 58.76 -173.0 0.1 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.464 0.173 . . . . 0.0 110.574 -179.687 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.4 ' O ' ' O ' ' A' ' 46' ' ' ARG . 22.8 ptt85 44.9 101.17 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.859 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo . . . . . 0 C--O 1.249 1.034 0 C-N-CA 122.345 2.03 . . . . 0.0 112.353 179.767 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.638 ' CG2' ' O ' ' A' ' 1' ' ' VAL . 1.4 p . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 6.4 p-10 -160.78 69.5 0.37 Allowed 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.821 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -80.48 141.87 34.78 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.41 112.29 0.69 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.039 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 79.61 71.6 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.656 0.265 . . . . 0.0 110.45 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.67 83.43 1.0 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.894 -179.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.3 m -88.25 107.63 17.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.223 0.535 . . . . 0.0 111.232 -179.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -178.87 68.67 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.181 -179.517 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.1 76.9 1.39 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.572 -179.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.595 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 25.4 p -98.05 148.22 23.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.971 -179.524 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.595 ' HB2' ' O ' ' A' ' 10' ' ' SER . 0.9 OUTLIER 77.63 129.24 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.491 -179.658 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.3 m 60.0 176.83 0.09 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.457 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -81.08 161.86 23.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.162 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 3.4 t -107.39 115.61 30.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.931 0.396 . . . . 0.0 111.352 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.414 ' O ' HG22 ' A' ' 16' ' ' VAL . 0.9 OUTLIER -85.11 -167.84 1.99 Allowed 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.664 179.669 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.414 HG22 ' O ' ' A' ' 15' ' ' SER . 2.2 t 81.01 90.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.209 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 49.1 m-20 -123.04 31.48 6.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.29 0.567 . . . . 0.0 110.45 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.405 ' O ' ' N ' ' A' ' 22' ' ' PHE . 0.6 OUTLIER -41.5 -29.56 0.17 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.223 -0.898 . . . . 0.0 112.118 -179.796 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.56 -60.69 3.16 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.871 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 mm-40 -71.53 -38.04 71.1 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.719 0.295 . . . . 0.0 111.482 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -65.51 -67.78 0.41 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.333 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.727 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 60.3 t80 -51.05 -30.14 14.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.601 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.9 tt0 -81.6 -35.67 29.85 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 111.941 0.349 . . . . 0.0 111.941 -177.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.18 -25.19 54.95 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.673 0.749 . . . . 0.0 109.086 -179.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.51 -59.09 2.89 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.111 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.727 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -68.11 -57.74 5.6 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 113.164 0.801 . . . . 0.0 113.164 -178.789 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.491 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 0.7 OUTLIER -53.79 -36.69 62.71 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.661 -179.756 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.81 -51.51 67.22 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.677 0.275 . . . . 0.0 110.647 178.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.79 -36.68 46.99 Favored Glycine 0 C--N 1.332 0.32 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.178 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 38.1 mm -70.2 -42.03 78.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 110.288 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -62.48 -39.74 94.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.054 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -55.3 -48.7 73.72 Favored 'General case' 0 CA--C 1.519 -0.221 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.332 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.452 ' CD1' ' N ' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -44.68 -38.58 4.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.194 179.217 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.486 ' O ' ' N ' ' A' ' 38' ' ' ALA . 2.7 t -69.25 -64.21 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.34 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.404 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.6 m -45.56 -56.11 5.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.826 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.85 -54.03 35.95 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.499 -0.858 . . . . 0.0 111.835 179.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.401 ' CG2' ' O ' ' A' ' 33' ' ' PHE . 58.8 t -64.62 -19.16 24.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.715 0.293 . . . . 0.0 110.719 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -78.56 -25.55 45.41 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.027 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.9 t -64.49 -43.61 93.59 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.366 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -80.57 -54.86 3.57 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.764 -0.732 . . . . 0.0 111.908 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 60.81 19.5 9.69 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.811 0.338 . . . . 0.0 111.712 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -158.37 31.41 0.48 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.614 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.45 28.11 3.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.671 0.272 . . . . 0.0 110.929 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.0 mt 72.64 79.87 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.97 0.414 . . . . 0.0 111.048 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -161.64 38.13 0.39 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.287 179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -160.34 98.75 1.29 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.937 0.399 . . . . 0.0 110.8 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -139.84 153.67 70.04 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.646 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo . . . . . 0 C--O 1.248 1.014 0 C-N-CA 122.404 2.069 . . . . 0.0 112.099 -179.801 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.74 ' O ' HG12 ' A' ' 1' ' ' VAL . 71.7 t . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -78.89 164.66 24.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.927 0.394 . . . . 0.0 110.856 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -157.3 38.41 0.29 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.486 0.66 . . . . 0.0 109.27 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -133.9 52.86 0.8 Allowed Glycine 0 C--O 1.228 -0.263 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.039 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -161.55 -49.19 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.48 0.657 . . . . 0.0 109.974 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.04 86.06 0.07 OUTLIER Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.608 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.5 p -149.46 138.16 14.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.0 t -122.17 55.68 1.13 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.441 -178.245 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 52.7 t -153.5 125.98 8.12 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.775 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 t -93.17 -68.84 0.78 Allowed 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.404 ' O ' ' N ' ' A' ' 13' ' ' LYS . 13.6 pttm -162.77 170.81 17.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.227 179.166 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER 64.6 -65.11 0.14 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.507 179.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.404 ' N ' ' O ' ' A' ' 11' ' ' LYS . 8.5 mttp -81.05 86.2 6.17 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -166.56 42.41 0.06 Allowed 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.369 179.029 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.8 m -155.37 131.23 9.97 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.224 0.535 . . . . 0.0 111.481 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.2 p -165.0 130.21 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.651 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -107.36 135.78 48.28 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.732 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 2.5 t-105 54.13 34.97 21.26 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.905 0.383 . . . . 0.0 110.783 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -113.78 -43.5 0.8 Allowed Glycine 0 C--N 1.33 0.237 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.261 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -71.05 -34.72 71.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.891 0.377 . . . . 0.0 110.726 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.73 -59.14 3.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.301 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.667 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 24.1 t80 -53.64 -30.8 44.64 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.721 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 29.5 tt0 -76.95 -39.87 49.1 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.769 -177.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -71.52 -31.7 67.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.908 179.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.92 -54.14 6.96 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.509 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.721 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.21 -58.41 3.57 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -177.884 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.7 m -54.13 -31.66 52.97 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.579 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -64.68 -45.76 85.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.495 -0.321 . . . . 0.0 111.024 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.27 -43.78 12.54 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.05 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 46.7 mm -62.33 -36.28 73.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.369 0.604 . . . . 0.0 110.442 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -67.67 -44.05 78.76 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -62.49 -37.87 87.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.992 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -55.7 -39.73 71.43 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.016 0.436 . . . . 0.0 109.987 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.0 t -59.81 -59.17 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.893 178.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -57.37 -42.02 81.3 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.25 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.4 -43.17 95.91 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.954 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.0 m -79.72 -27.22 12.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.106 0.479 . . . . 0.0 110.403 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -76.2 -24.92 54.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.26 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -75.16 -47.5 28.14 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.087 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.7 39.92 0.23 Allowed Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.929 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 60.4 24.19 13.73 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.884 0.373 . . . . 0.0 111.606 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -54.82 -63.72 5.0 Favored Glycine 0 C--N 1.321 -0.305 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.727 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.3 t 62.83 66.43 0.75 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.893 0.378 . . . . 0.0 110.782 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.6 mt -106.12 43.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.139 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -114.55 31.46 6.37 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.767 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.1 mmp_? -133.22 175.59 9.26 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.533 0.206 . . . . 0.0 110.666 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.2 mtp180 -140.01 55.02 5.98 Favored Pre-proline 0 N--CA 1.463 0.176 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.986 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo . . . . . 0 C--O 1.248 1.012 0 C-N-CA 122.444 2.096 . . . . 0.0 112.346 179.847 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.885 HG23 ' O ' ' A' ' 1' ' ' VAL . 0.3 OUTLIER . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.0 m-80 -80.17 68.46 6.32 Favored 'General case' 0 C--N 1.34 0.155 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.148 178.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.25 70.25 6.85 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.967 -0.293 . . . . 0.0 110.224 -179.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -124.1 43.61 1.39 Allowed Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.695 -0.764 . . . . 0.0 113.257 -179.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 29.5 t30 64.28 47.42 3.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.873 0.368 . . . . 0.0 110.731 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 170.29 55.67 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.76 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.7 p -89.18 -37.06 9.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.702 0.287 . . . . 0.0 110.995 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.3 t 64.4 101.02 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.812 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.3 m -93.11 172.31 8.39 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.839 0.352 . . . . 0.0 111.037 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -129.29 28.13 5.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.181 -0.463 . . . . 0.0 112.075 -179.478 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 5.1 tttm -163.3 -174.8 3.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.966 0.412 . . . . 0.0 111.142 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.2 p -88.98 -42.1 11.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.66 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.7 mtpt -81.24 -63.42 1.4 Allowed 'General case' 0 C--N 1.334 -0.099 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.892 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 55.98 54.54 7.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.028 0.442 . . . . 0.0 110.759 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.3 t -75.26 -149.53 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.023 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.7 p -164.24 108.98 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-O 120.88 0.372 . . . . 0.0 110.597 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 71.4 m-80 -121.68 -43.33 2.38 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.337 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -100.17 35.06 2.16 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.084 0.469 . . . . 0.0 110.569 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.41 -60.98 0.85 Allowed Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.936 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -66.49 -36.98 84.07 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.85 0.357 . . . . 0.0 111.304 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.45 -64.84 0.82 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.151 -0.477 . . . . 0.0 112.018 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.65 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.6 t80 -52.54 -32.24 39.79 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 -178.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.687 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.8 tt0 -77.92 -36.4 49.45 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.745 -177.322 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -75.05 -29.82 60.86 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.274 0.559 . . . . 0.0 109.538 179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt85 -78.73 -52.36 8.5 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.12 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.687 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.05 -57.32 3.97 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.205 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.1 m -56.03 -20.48 16.97 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.102 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.49 -48.9 13.12 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.964 0.412 . . . . 0.0 110.075 179.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.83 -45.31 27.95 Favored Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.284 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.401 ' O ' HG23 ' A' ' 34' ' ' VAL . 50.5 mm -60.49 -45.44 96.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.778 0.323 . . . . 0.0 110.72 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -61.26 -37.07 81.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.776 0.322 . . . . 0.0 110.81 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.5 t -69.11 -38.88 79.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.793 0.33 . . . . 0.0 110.755 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.529 ' CD1' HG21 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -59.42 -34.45 72.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.208 0.528 . . . . 0.0 110.457 179.54 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.529 HG21 ' CD1' ' A' ' 33' ' ' PHE . 2.7 t -69.28 -61.81 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.785 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 52.4 m -47.12 -57.49 5.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.28 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.42 -48.69 78.85 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.011 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.424 ' CG2' ' O ' ' A' ' 33' ' ' PHE . 52.5 t -67.43 -21.83 28.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.765 0.317 . . . . 0.0 110.739 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.434 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -78.18 -25.9 47.37 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.502 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 30.7 t -72.61 -34.72 67.55 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.286 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.83 51.98 0.19 Allowed Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.65 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -91.62 -32.03 15.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.939 0.4 . . . . 0.0 111.159 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -168.87 -61.49 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.0 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.9 p 52.03 58.93 4.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.924 0.392 . . . . 0.0 111.42 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.9 tt -166.83 60.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.131 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -125.89 -38.19 0.48 Allowed Glycine 0 C--N 1.328 0.137 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.944 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 ttm-85 -179.81 99.34 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.78 0.324 . . . . 0.0 110.358 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.446 ' N ' ' CD ' ' A' ' 48' ' ' PRO . 44.6 mtp85 -64.03 -48.39 77.92 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.029 -179.661 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.446 ' CD ' ' N ' ' A' ' 47' ' ' ARG . 63.8 Cg_exo . . . . . 0 C--O 1.249 1.064 0 C-N-CA 122.284 1.989 . . . . 0.0 112.218 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.503 ' CG2' ' O ' ' A' ' 1' ' ' VAL . 2.4 m . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -79.96 67.82 5.88 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 113.405 0.891 . . . . 0.0 113.405 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.575 ' O ' HG22 ' A' ' 7' ' ' VAL . 5.2 m-85 -82.08 -37.19 26.73 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 179.733 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.52 150.09 6.01 Favored Glycine 0 CA--C 1.524 0.636 0 C-N-CA 120.928 -0.653 . . . . 0.0 113.732 -178.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 53.37 67.45 1.0 Allowed 'General case' 0 C--O 1.233 0.221 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 152.66 -24.74 0.84 Allowed Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.105 -1.045 . . . . 0.0 114.038 178.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.575 HG22 ' O ' ' A' ' 3' ' ' TYR . 2.9 m -150.25 98.41 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.4 m -149.05 113.25 5.21 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.229 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 29.9 p -119.74 176.46 5.38 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.476 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.4 m -56.12 -23.81 36.72 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.233 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 81.53 -1.72 1.64 Allowed 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.09 -179.386 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.439 ' CG2' ' H ' ' A' ' 13' ' ' LYS . 8.9 t -88.79 -61.63 1.66 Allowed 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.439 ' H ' ' CG2' ' A' ' 12' ' ' THR . 0.0 OUTLIER -82.85 17.29 1.93 Allowed 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 179.269 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.6 m -102.07 137.16 40.71 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.194 0.521 . . . . 0.0 112.125 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.468 ' O ' ' CG2' ' A' ' 16' ' ' VAL . 0.4 OUTLIER 61.5 -177.56 0.12 Allowed 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.982 -179.426 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.468 ' CG2' ' O ' ' A' ' 15' ' ' SER . 22.0 t -162.32 113.61 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.356 0.598 . . . . 0.0 111.434 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.4 t30 -127.75 -49.27 1.37 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.32 178.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -116.58 32.14 6.31 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.34 178.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -104.05 -43.58 1.75 Allowed Glycine 0 C--N 1.331 0.282 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.735 179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -65.2 -44.1 89.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.944 0.402 . . . . 0.0 110.349 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -65.05 -69.77 0.27 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 178.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.64 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.4 t80 -51.67 -30.75 23.07 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -178.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.722 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.2 tt0 -76.45 -47.48 22.9 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 117.969 0.35 . . . . 0.0 110.762 -178.109 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -64.8 -27.52 68.94 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.444 0.64 . . . . 0.0 109.521 179.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.31 -52.73 7.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.86 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.722 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -77.74 -56.6 4.37 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -178.86 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.52 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.8 m -53.37 -23.46 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.857 179.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -74.52 -52.64 11.33 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.892 0.377 . . . . 0.0 110.484 178.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.05 -42.15 59.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.611 -0.805 . . . . 0.0 112.426 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 48.1 mm -62.11 -46.35 96.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.122 0.486 . . . . 0.0 111.436 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -56.99 -48.0 79.48 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.925 0.393 . . . . 0.0 110.568 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.3 t -60.72 -36.69 79.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -57.66 -38.71 75.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.983 0.421 . . . . 0.0 110.43 179.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.0 t -61.45 -62.49 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.305 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.5 179.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.2 m -54.83 -38.89 67.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -61.93 -41.64 99.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.749 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 29.7 m -80.2 -27.21 11.91 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-O 121.027 0.441 . . . . 0.0 110.221 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -80.15 -20.97 43.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.531 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 47.2 p -75.43 -39.23 59.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.471 -0.332 . . . . 0.0 111.407 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.54 -44.69 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.434 -0.889 . . . . 0.0 112.926 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -145.35 -59.35 0.34 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.612 0.244 . . . . 0.0 111.352 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 67.65 43.9 83.63 Favored Glycine 0 C--N 1.33 0.234 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.831 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.2 p -91.58 -29.51 16.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.652 0.263 . . . . 0.0 111.127 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.441 ' CD1' ' N ' ' A' ' 44' ' ' ILE . 0.2 OUTLIER -152.18 63.77 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.954 0.407 . . . . 0.0 111.102 179.922 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -95.78 -44.11 3.2 Favored Glycine 0 CA--C 1.518 0.275 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.692 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.2 mmt-85 -113.23 -31.62 6.55 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.625 0.25 . . . . 0.0 111.413 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.3 mtt85 -96.57 108.73 44.31 Favored Pre-proline 0 CA--C 1.531 0.241 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.625 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 C--O 1.25 1.076 0 C-N-CA 122.105 1.87 . . . . 0.0 112.137 179.714 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.779 ' O ' HG13 ' A' ' 1' ' ' VAL . 53.9 t . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 32.7 p-10 -79.15 116.21 19.29 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -82.03 173.19 12.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.872 0.368 . . . . 0.0 111.223 178.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 162.65 -158.28 30.43 Favored Glycine 0 C--O 1.227 -0.294 0 C-N-CA 121.007 -0.616 . . . . 0.0 111.812 179.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -77.1 -36.54 55.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.873 0.368 . . . . 0.0 111.294 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -60.62 -28.34 67.65 Favored Glycine 0 CA--C 1.522 0.503 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.418 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 10.9 m -88.21 84.57 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 117.299 0.55 . . . . 0.0 110.952 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 30.6 t -136.61 73.07 1.44 Allowed 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.123 0.487 . . . . 0.0 111.397 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 53.3 t -166.59 82.59 0.26 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.135 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.5 m -72.14 -163.62 0.12 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.795 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 15.7 mmmt -76.85 -49.22 16.25 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 178.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.3 m -89.27 -47.9 7.74 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.436 178.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.62 ' O ' ' HB2' ' A' ' 14' ' ' CYS . 30.6 mtpt -80.85 115.66 20.45 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.241 -179.539 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.62 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 49.9 t 167.28 -46.43 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.719 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.4 p -139.9 128.21 22.62 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-O 121.111 0.482 . . . . 0.0 111.128 179.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.4 p -164.5 86.98 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.117 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 -63.85 -31.92 73.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.833 179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -88.17 27.23 1.24 Allowed 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.54 -0.3 . . . . 0.0 111.789 -179.529 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.54 -81.48 1.46 Allowed Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.97 -179.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.28 -26.52 68.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.726 0.298 . . . . 0.0 111.406 -179.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.29 -71.55 0.13 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.889 0.375 . . . . 0.0 111.101 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.568 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.7 t80 -53.55 -33.12 53.54 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -178.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.698 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 21.5 tt0 -76.38 -43.26 41.47 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.902 0.382 . . . . 0.0 110.81 -178.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.21 -33.23 75.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.439 0.638 . . . . 0.0 109.82 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.0 -54.35 6.11 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.57 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.698 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.37 -57.5 3.97 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -177.957 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.519 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.9 m -52.39 -33.53 43.86 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.98 -0.288 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.39 -47.77 75.2 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.736 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.08 -47.81 57.27 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.27 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.427 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 17.7 tt -64.86 -36.46 77.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.21 0.528 . . . . 0.0 110.344 -179.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 31.7 m-20 -57.71 -40.97 80.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.509 179.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.5 t -66.57 -36.98 83.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.118 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.422 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -58.55 -38.29 77.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.225 0.536 . . . . 0.0 110.328 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.421 ' O ' ' N ' ' A' ' 38' ' ' ALA . 3.2 t -62.59 -61.67 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.235 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 54.5 m -50.25 -56.11 12.54 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.369 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.11 -52.16 54.12 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.296 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.422 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 50.4 t -66.46 -21.19 28.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.706 0.288 . . . . 0.0 110.375 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -70.22 -32.33 70.16 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-O 120.919 0.39 . . . . 0.0 110.676 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 87.9 p -72.52 -31.92 65.72 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.857 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 130.81 -25.09 4.23 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.734 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -178.88 -71.42 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.821 0.343 . . . . 0.0 111.538 -179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -162.86 44.94 0.34 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.687 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.1 m 64.83 71.19 0.46 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.905 0.383 . . . . 0.0 111.06 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.9 mt -83.24 -66.59 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.19 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.01 -14.94 57.51 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.291 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 62.22 95.89 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.811 0.306 . . . . 0.0 110.841 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 20.1 mtm180 -91.79 125.18 58.21 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.771 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--O 1.249 1.042 0 C-N-CA 122.223 1.948 . . . . 0.0 112.12 179.899 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.744 ' O ' HG11 ' A' ' 1' ' ' VAL . 63.7 t . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -79.27 91.87 5.07 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 179.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -80.75 96.75 7.04 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 178.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -104.25 -80.57 1.42 Allowed Glycine 0 CA--C 1.521 0.414 0 C-N-CA 120.805 -0.712 . . . . 0.0 114.205 -178.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -161.23 53.69 0.27 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.228 0.537 . . . . 0.0 109.866 -178.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.413 ' O ' HG12 ' A' ' 7' ' ' VAL . . . -159.31 67.43 0.27 Allowed Glycine 0 CA--C 1.51 -0.257 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.413 HG12 ' O ' ' A' ' 6' ' ' GLY . 8.5 m -150.33 37.4 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.246 0.546 . . . . 0.0 110.096 -179.547 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 11.7 p -176.93 40.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.245 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 15.7 t 55.17 31.8 17.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.128 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 38.6 m -74.67 -73.36 0.24 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.07 0.462 . . . . 0.0 109.865 179.198 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.89 -25.17 48.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.991 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 82.4 p -88.48 135.49 33.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.127 0.489 . . . . 0.0 111.72 -179.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -80.89 124.46 29.12 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.329 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.2 m -93.48 -38.18 11.55 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.934 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -147.29 139.13 24.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.656 0.741 . . . . 0.0 111.825 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.433 ' O ' ' CG1' ' A' ' 16' ' ' VAL . 14.5 p -76.61 103.46 3.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.08 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -141.97 112.25 7.01 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.691 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -58.45 -51.15 71.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.055 0.455 . . . . 0.0 110.263 -179.726 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.07 -50.05 40.68 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.948 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 6.9 mp0 -62.61 -55.39 27.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.594 0.235 . . . . 0.0 111.561 -179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -55.37 -61.63 2.21 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.709 0.29 . . . . 0.0 111.574 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.661 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 32.4 t80 -52.1 -33.51 39.91 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -178.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.738 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 14.7 tt0 -79.21 -39.76 32.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.025 0.44 . . . . 0.0 110.38 -178.494 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -65.4 -30.61 71.44 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 178.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.64 -56.93 4.05 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.573 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.738 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.4 OUTLIER -73.89 -58.04 3.57 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -178.184 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.6 m -51.01 -33.67 25.93 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.621 179.808 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -62.19 -55.2 30.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.118 0.485 . . . . 0.0 110.932 179.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.8 -35.74 61.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.182 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 42.6 mm -70.85 -35.67 61.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.3 0.572 . . . . 0.0 111.181 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.2 t-20 -61.51 -50.34 73.08 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.085 0.469 . . . . 0.0 109.821 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 86.2 p -57.28 -43.74 83.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.928 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -52.83 -39.34 62.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 110.681 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.6 t -58.66 -60.3 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.593 179.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -52.73 -42.29 64.74 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.735 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.06 -44.25 97.47 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.142 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.3 m -79.82 -24.95 12.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.913 0.387 . . . . 0.0 110.809 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -72.03 -25.7 61.91 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.693 -179.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 72.1 p -61.36 -28.03 68.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.247 179.736 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.85 37.02 6.52 Favored Glycine 0 CA--C 1.518 0.258 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.772 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -157.29 -72.08 0.1 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.676 0.274 . . . . 0.0 111.227 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 146.26 89.06 0.08 OUTLIER Glycine 0 N--CA 1.453 -0.188 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.327 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.6 m -61.07 -69.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.663 0.268 . . . . 0.0 111.481 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -58.82 -67.77 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.074 -179.501 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 55.15 25.23 38.7 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.81 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.65 -49.3 5.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.774 0.321 . . . . 0.0 110.804 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -136.7 155.12 76.86 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.664 179.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 C--O 1.249 1.025 0 C-N-CA 122.413 2.075 . . . . 0.0 112.342 -179.904 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.7 m . . . . . 0 N--CA 1.449 -0.522 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -160.87 26.65 0.14 Allowed 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -179.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.402 ' CD2' ' HA ' ' A' ' 7' ' ' VAL . 31.0 m-85 -80.1 174.81 11.22 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-O 120.41 0.148 . . . . 0.0 111.304 -179.101 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.15 -36.34 0.71 Allowed Glycine 0 N--CA 1.465 0.627 0 C-N-CA 120.919 -0.657 . . . . 0.0 113.214 -177.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -162.59 58.3 0.22 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.697 0.761 . . . . 0.0 110.275 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.517 ' O ' HG23 ' A' ' 7' ' ' VAL . . . -161.38 -62.2 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.642 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 6' ' ' GLY . 6.8 m 51.12 88.3 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-O 121.023 0.44 . . . . 0.0 111.002 179.053 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -145.22 87.28 1.8 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.135 -179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.421 ' HB3' ' HB3' ' A' ' 14' ' ' CYS . 4.9 m -62.75 115.36 4.26 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.254 179.131 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.9 p -172.73 -39.2 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.33 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 27.5 ttmt -77.6 -50.87 11.63 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.945 0.402 . . . . 0.0 110.45 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.7 p -88.6 -172.38 3.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.33 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.3 pttm -81.0 124.32 29.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.638 -0.256 . . . . 0.0 111.048 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.421 ' HB3' ' HB3' ' A' ' 9' ' ' CYS . 0.5 OUTLIER -153.91 109.57 3.22 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.685 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 21.5 p -173.61 -174.22 0.96 Allowed 'General case' 0 CA--C 1.519 -0.214 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.884 179.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.421 HG11 ' N ' ' A' ' 17' ' ' ASN . 14.3 p -164.99 -43.29 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.802 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.186 178.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.421 ' N ' HG11 ' A' ' 16' ' ' VAL . 0.3 OUTLIER -64.36 91.93 0.08 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.542 0.687 . . . . 0.0 109.673 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -66.63 -42.87 86.07 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.511 -178.529 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.26 -60.35 8.28 Favored Glycine 0 C--N 1.332 0.337 0 CA-C-N 116.287 -0.415 . . . . 0.0 114.066 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.6 tp60 -53.16 -43.55 67.15 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.708 0.254 . . . . 0.0 111.434 -178.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -67.61 -62.08 1.59 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.946 0.403 . . . . 0.0 111.485 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.643 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 26.3 t80 -54.19 -29.06 44.54 Favored 'General case' 0 C--O 1.219 -0.522 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -178.292 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.641 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.6 tt0 -78.81 -36.94 41.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 118.196 0.453 . . . . 0.0 111.341 -177.568 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -74.75 -33.1 62.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.299 0.571 . . . . 0.0 109.743 179.537 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.4 -57.44 3.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.862 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.643 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -66.18 -58.74 4.75 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -177.8 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 3.2 m -54.08 -36.68 63.42 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.669 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -59.4 -41.66 89.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.846 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.29 -47.27 6.16 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.387 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.402 ' O ' ' CG2' ' A' ' 34' ' ' VAL . 9.2 mt -63.67 -26.04 39.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 121.008 0.432 . . . . 0.0 110.759 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -76.15 -53.8 7.76 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.917 0.389 . . . . 0.0 110.547 179.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.0 t -62.3 -35.71 79.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.203 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.432 ' CD2' HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -57.38 -35.72 70.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.913 0.387 . . . . 0.0 110.849 -179.878 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.432 HG23 ' CD2' ' A' ' 33' ' ' PHE . 2.9 t -70.18 -62.84 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.086 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.7 m -52.15 -37.91 55.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.863 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.91 -43.91 98.76 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.621 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.5 -26.79 11.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.933 0.397 . . . . 0.0 110.772 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.47 -22.08 48.09 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.676 -179.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 80.7 p -78.69 -31.69 46.68 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.457 -179.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.18 30.96 7.88 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.759 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 66.73 10.5 7.55 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 111.852 0.315 . . . . 0.0 111.852 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 157.49 58.75 0.01 OUTLIER Glycine 0 CA--C 1.519 0.284 0 C-N-CA 120.592 -0.813 . . . . 0.0 112.939 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.4 m -177.36 74.19 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.781 0.324 . . . . 0.0 110.994 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.5 mp -69.54 -43.85 80.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.557 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -104.24 21.1 38.45 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.067 -179.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 55.45 40.88 31.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.96 0.41 . . . . 0.0 110.851 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 29.9 mtm-85 54.89 94.26 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.228 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo . . . . . 0 C--O 1.249 1.04 0 C-N-CA 122.524 2.15 . . . . 0.0 112.269 179.892 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 1.026 HG12 ' H ' ' A' ' 2' ' ' ASN . 86.5 t . . . . . 0 N--CA 1.448 -0.529 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 1.026 ' H ' HG12 ' A' ' 1' ' ' VAL . 5.2 t-20 78.44 -58.3 0.44 Allowed 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.056 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 69.65 -75.0 0.07 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.091 -178.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 92.51 -37.26 3.43 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.343 178.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -162.76 32.97 0.1 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.798 0.299 . . . . 0.0 111.137 -179.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -105.88 -43.09 1.58 Allowed Glycine 0 CA--C 1.52 0.345 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.596 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.0 m -88.13 104.57 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 178.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.6 t -143.65 -146.88 0.2 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 179.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.8 p -63.11 -37.63 87.97 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.565 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.42 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 2.2 m -137.16 151.54 48.92 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.337 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.609 ' HG3' ' O ' ' A' ' 11' ' ' LYS . 13.6 tppt? -77.43 -5.12 48.65 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.3 m -150.78 69.02 0.96 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.308 0.575 . . . . 0.0 110.112 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.42 ' O ' ' HB2' ' A' ' 10' ' ' SER . 4.6 tttt 74.61 170.15 0.29 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.168 -0.923 . . . . 0.0 108.651 -177.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -120.6 56.31 1.0 Allowed 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.12 26.87 1.49 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.851 -1.068 . . . . 0.0 112.338 -178.656 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.7 p -164.55 130.04 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.092 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 39.2 p-10 -63.83 -162.77 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.873 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 75.8 21.27 1.66 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.764 0.316 . . . . 0.0 110.828 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -91.87 -46.24 3.71 Favored Glycine 0 C--N 1.332 0.322 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.4 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -65.11 -27.85 69.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.696 0.284 . . . . 0.0 110.843 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.76 -67.2 0.36 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.866 179.289 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.711 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 44.4 t80 -54.58 -27.14 36.86 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -179.492 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.517 ' HA ' ' CD1' ' A' ' 26' ' ' TYR . 29.9 mm-40 -75.17 -38.8 60.73 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.849 -178.274 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -78.16 -44.47 25.85 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.2 0.524 . . . . 0.0 109.926 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -56.22 23.92 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.61 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.711 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -63.44 -37.39 87.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.891 -1.049 . . . . 0.0 113.639 -177.094 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.506 ' O ' ' N ' ' A' ' 31' ' ' ASN . 4.3 p -65.68 -45.1 84.16 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.448 -0.501 . . . . 0.0 109.706 177.656 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -43.34 64.79 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.847 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.37 -43.95 11.98 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.497 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 35.7 mm -72.84 -54.0 17.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 121.007 0.432 . . . . 0.0 111.176 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.506 ' N ' ' O ' ' A' ' 27' ' ' THR . 3.3 t-20 -56.36 -50.19 72.25 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.771 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.6 m -54.23 -40.3 67.58 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.688 0.28 . . . . 0.0 111.089 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.11 -35.7 67.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 -179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.3 t -74.8 -60.36 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.93 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.9 m -57.05 -38.09 72.73 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.081 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.54 -43.06 97.9 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.674 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 20.3 m -80.79 -29.51 11.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.044 0.45 . . . . 0.0 110.318 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -22.47 47.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.227 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.5 m -69.56 -37.0 76.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.381 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.96 -0.08 8.31 Favored Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.761 -0.733 . . . . 0.0 113.11 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 57.24 22.06 7.27 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.911 0.355 . . . . 0.0 111.594 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.14 -81.52 0.49 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.65 -179.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 2.8 m 178.26 62.86 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.866 0.365 . . . . 0.0 110.894 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 35.3 mt -119.54 -41.65 2.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.703 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.94 -27.23 59.27 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.774 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 tpt180 61.6 69.05 0.67 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.9 0.381 . . . . 0.0 110.52 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.413 ' N ' ' HD2' ' A' ' 48' ' ' PRO . 15.0 mtt85 -81.83 -51.55 0.81 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.295 -179.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.413 ' HD2' ' N ' ' A' ' 47' ' ' ARG . 81.5 Cg_endo . . . . . 0 C--O 1.25 1.085 0 C-N-CA 122.203 1.935 . . . . 0.0 112.297 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.846 HG21 ' H ' ' A' ' 2' ' ' ASN . 20.0 m . . . . . 0 N--CA 1.449 -0.519 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.846 ' H ' HG21 ' A' ' 1' ' ' VAL . 3.4 t-20 76.16 -60.06 0.49 Allowed 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.555 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 64.59 109.34 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.009 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -110.45 76.02 0.22 Allowed Glycine 0 C--O 1.229 -0.157 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -163.26 -54.79 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.204 0.526 . . . . 0.0 110.667 -179.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 133.17 102.65 0.81 Allowed Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 110.537 -1.025 . . . . 0.0 110.537 -178.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.421 ' O ' ' O ' ' A' ' 8' ' ' SER . 15.6 m -86.24 -33.02 7.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.494 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.421 ' O ' ' O ' ' A' ' 7' ' ' VAL . 52.3 p 51.3 109.68 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.058 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 9.0 m -94.29 170.09 9.75 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.353 179.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.5 t -98.47 -49.54 4.61 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.661 179.07 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.506 ' O ' ' CG2' ' A' ' 12' ' ' THR . 10.3 tttp -77.54 -8.33 57.65 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 113.885 1.069 . . . . 0.0 113.885 -179.29 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.506 ' CG2' ' O ' ' A' ' 11' ' ' LYS . 10.5 t 52.44 48.06 23.41 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.783 0.325 . . . . 0.0 111.515 -178.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.13 39.41 0.21 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.251 0.548 . . . . 0.0 109.99 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.8 m -89.16 -66.27 0.94 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.031 -179.428 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 9.7 t -110.0 175.06 5.58 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.767 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 p -164.27 33.73 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.161 0.505 . . . . 0.0 110.71 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 67.37 -71.74 0.1 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.485 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -52.61 -22.57 5.19 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.601 -179.162 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.47 -62.9 5.81 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.726 -0.749 . . . . 0.0 113.05 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 15.4 mm-40 -62.92 -30.78 71.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.963 0.411 . . . . 0.0 110.517 -179.534 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.86 -65.38 0.69 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.543 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -53.31 -42.35 66.59 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 -178.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.67 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.8 tt0 -68.38 -36.86 79.77 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.991 -177.321 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -72.93 -28.88 62.71 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -80.45 -53.94 6.14 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.506 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.67 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.58 -54.25 8.62 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.273 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.503 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.8 m -57.66 -25.39 60.14 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.731 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.36 -33.36 49.07 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.438 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.94 -42.72 7.99 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.682 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.411 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 9.0 tp -67.37 -41.32 86.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.641 0.734 . . . . 0.0 111.339 -179.228 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -72.48 -41.72 65.71 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 58.4 m -65.24 -31.1 72.09 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -59.49 -40.58 87.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.984 0.421 . . . . 0.0 110.006 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.9 t -66.81 -63.38 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.221 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.1 m -56.44 -34.79 67.16 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.355 179.568 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.15 -43.3 98.87 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.322 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.9 m -80.23 -27.38 11.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.972 0.415 . . . . 0.0 110.268 179.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -76.8 -22.69 53.3 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.844 -179.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 74.4 m -76.43 -42.39 44.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.792 0.329 . . . . 0.0 111.1 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -83.35 -48.49 5.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.642 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -70.79 -60.63 2.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.799 0.333 . . . . 0.0 111.136 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 94.4 44.99 3.34 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.478 -179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.65 -55.56 32.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.669 0.271 . . . . 0.0 110.461 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.48 ' O ' ' HG2' ' A' ' 46' ' ' ARG . 0.4 OUTLIER -168.52 -40.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.4 179.626 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . 0.479 ' N ' HG21 ' A' ' 44' ' ' ILE . . . 53.03 13.83 2.49 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 115.125 0.81 . . . . 0.0 115.125 178.23 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 44' ' ' ILE . 19.9 mmt180 -121.07 -69.17 0.86 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 118.182 0.991 . . . . 0.0 111.192 179.422 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 15.8 ptm180 -108.53 148.75 38.32 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.081 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo . . . . . 0 C--O 1.249 1.071 0 C-N-CA 122.471 2.114 . . . . 0.0 112.286 179.986 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.431 ' O ' HG11 ' A' ' 1' ' ' VAL . 87.4 t . . . . . 0 N--CA 1.449 -0.501 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.474 ' O ' ' CD1' ' A' ' 3' ' ' TYR . 9.4 p30 -158.94 151.32 21.49 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.474 ' CD1' ' O ' ' A' ' 2' ' ' ASN . 28.4 m-85 -158.19 -175.21 5.21 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.64 -178.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -154.76 36.49 0.67 Allowed Glycine 0 CA--C 1.518 0.239 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.436 -179.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -162.67 -67.97 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.711 0.291 . . . . 0.0 110.753 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 130.98 76.19 0.14 Allowed Glycine 0 C--N 1.332 0.343 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.686 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 15.0 p -89.03 58.44 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 121.017 0.437 . . . . 0.0 111.091 179.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.6 p 61.31 126.76 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.464 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -147.52 -88.19 0.09 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.297 179.155 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 32.6 t 37.24 67.2 0.38 Allowed 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.327 0.584 . . . . 0.0 110.621 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.9 pttp -162.06 -21.11 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.201 -0.909 . . . . 0.0 111.236 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.9 t -150.86 -21.07 0.22 Allowed 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 120.675 0.274 . . . . 0.0 111.477 178.502 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.458 ' O ' ' HB2' ' A' ' 14' ' ' CYS . 3.3 tptt -158.35 -166.22 1.88 Allowed 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -178.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 11.3 m 74.22 137.06 0.06 Allowed 'General case' 0 C--N 1.329 -0.316 0 O-C-N 122.298 -0.251 . . . . 0.0 110.45 -178.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 10.7 p -172.06 175.51 3.76 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.384 0.611 . . . . 0.0 112.2 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.1 p -75.84 81.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.719 179.489 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -56.24 -24.85 45.03 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 115.518 -0.764 . . . . 0.0 112.313 -178.315 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 9.9 p90 -92.88 18.35 9.16 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.718 0.294 . . . . 0.0 111.064 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.15 -34.58 58.08 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 121.278 -0.487 . . . . 0.0 112.895 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -71.71 -31.77 67.09 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.684 0.278 . . . . 0.0 111.239 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.02 -70.02 0.17 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.547 179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.529 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.4 t80 -57.22 -33.35 67.44 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -179.143 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.704 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.1 tt0 -75.37 -37.24 60.72 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 121.121 -0.232 . . . . 0.0 111.035 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -70.64 -30.8 67.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.526 0.679 . . . . 0.0 109.627 179.776 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -79.82 -58.31 3.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.144 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.704 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -68.48 -58.53 4.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.132 -0.94 . . . . 0.0 113.3 -177.93 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.526 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.4 m -54.38 -37.45 65.02 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.893 -0.323 . . . . 0.0 110.912 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.99 -48.9 75.02 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.176 179.267 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.42 -53.66 8.52 Favored Glycine 0 CA--C 1.52 0.369 0 C-N-CA 120.595 -0.812 . . . . 0.0 113.097 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.407 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 2.5 tt -61.41 -29.45 45.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.138 0.494 . . . . 0.0 111.915 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -69.51 -48.92 59.0 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 122.035 -0.415 . . . . 0.0 110.169 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 16.6 m -54.04 -38.85 65.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.241 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -59.11 -37.73 77.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.195 0.522 . . . . 0.0 110.49 179.59 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.589 ' O ' HG11 ' A' ' 37' ' ' VAL . 4.2 t -67.49 -59.87 3.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.892 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 73.1 m -45.32 -55.65 5.74 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.471 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.93 -47.49 85.39 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.349 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.589 HG11 ' O ' ' A' ' 34' ' ' VAL . 5.0 p -65.95 -24.98 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.849 0.357 . . . . 0.0 110.439 -179.887 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.446 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -78.92 -24.03 44.34 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.549 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 t -56.5 -28.46 59.91 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.393 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 112.93 39.59 1.15 Allowed Glycine 0 C--N 1.33 0.214 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.453 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -61.26 -41.29 96.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.829 0.347 . . . . 0.0 111.134 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 115.08 89.18 1.61 Allowed Glycine 0 C--N 1.33 0.218 0 C-N-CA 120.978 -0.629 . . . . 0.0 112.512 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 51.7 p -171.29 -51.52 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 0.0 110.75 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -150.56 -79.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.812 179.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 59.08 27.79 62.98 Favored Glycine 0 C--N 1.33 0.219 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.557 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 70.8 mtt180 -128.57 32.46 4.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.794 0.33 . . . . 0.0 110.648 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -101.87 141.51 22.7 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.695 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo . . . . . 0 C--O 1.25 1.075 0 C-N-CA 122.397 2.065 . . . . 0.0 112.212 -179.497 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 1.114 HG13 ' N ' ' A' ' 2' ' ' ASN . 11.5 t . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 1.114 ' N ' HG13 ' A' ' 1' ' ' VAL . 3.2 m-20 -162.13 -160.13 0.65 Allowed 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.578 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 61.25 163.66 0.08 Allowed 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 120.751 0.31 . . . . 0.0 110.772 -179.204 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.499 ' O ' ' HB2' ' A' ' 5' ' ' ASN . . . 159.95 96.99 0.12 Allowed Glycine 0 C--N 1.337 0.604 0 C-N-CA 120.307 -0.949 . . . . 0.0 113.543 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.499 ' HB2' ' O ' ' A' ' 4' ' ' GLY . 21.1 m-20 73.38 60.51 0.1 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.945 0.402 . . . . 0.0 110.386 178.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 158.81 46.36 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.034 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.3 m -150.94 -177.18 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.588 -0.306 . . . . 0.0 110.534 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 40.2 t -81.22 -148.93 0.07 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 62.7 m -49.43 125.07 10.41 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.148 0.499 . . . . 0.0 110.326 179.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.3 m -119.75 -40.89 2.71 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.43 -0.804 . . . . 0.0 111.223 -178.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 31.7 mttt -161.45 -77.74 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.589 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 16.5 p -90.42 -32.66 16.33 Favored 'General case' 0 C--N 1.333 -0.152 0 N-CA-C 112.883 0.698 . . . . 0.0 112.883 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.7 tmtt? -79.92 84.41 5.69 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 -177.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 5.6 t -161.41 -74.5 0.06 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.789 179.12 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.403 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.7 OUTLIER -153.79 122.64 6.38 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.835 178.888 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 15' ' ' SER . 16.9 t 77.45 131.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 N-CA-C 110.504 -0.184 . . . . 0.0 110.504 179.259 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -70.33 126.46 29.7 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.947 0.403 . . . . 0.0 111.032 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 1.7 t-105 -92.23 -39.63 11.43 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.67 179.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.57 -49.33 7.15 Favored Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.258 -0.496 . . . . 0.0 113.265 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -65.56 -35.01 79.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.843 0.354 . . . . 0.0 111.004 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.0 -67.21 0.46 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.198 179.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.875 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 28.4 t80 -55.33 -17.92 5.6 Favored 'General case' 0 CA--C 1.508 -0.644 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.26 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.692 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 49.0 tt0 -84.38 -45.26 12.93 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.334 -178.004 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -69.28 -33.68 73.58 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -67.89 -55.46 12.78 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.125 179.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.875 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.3 OUTLIER -68.21 -36.93 80.29 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.543 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.603 ' HA ' HG23 ' A' ' 30' ' ' ILE . 1.1 p -59.79 -46.19 89.96 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 120.198 -0.601 . . . . 0.0 109.575 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -41.38 63.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.229 179.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.06 -52.01 7.18 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.54 179.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.603 HG23 ' HA ' ' A' ' 27' ' ' THR . 1.2 tt -70.91 -50.33 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 120.78 0.324 . . . . 0.0 111.836 -179.165 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.514 ' N ' ' O ' ' A' ' 27' ' ' THR . 2.1 t-20 -55.34 -50.97 68.27 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 120.805 0.336 . . . . 0.0 110.417 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 44.0 m -49.66 -44.33 47.68 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.631 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -53.38 -34.73 58.77 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.089 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 3.2 t -72.2 -61.65 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.345 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.3 m -51.49 -39.17 57.06 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.763 179.619 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.15 98.73 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.818 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.9 m -80.95 -29.52 11.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.073 0.463 . . . . 0.0 110.432 179.237 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -70.54 -30.03 66.66 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.626 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.8 p -81.02 -45.27 16.81 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.397 179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -127.11 45.17 1.17 Allowed Glycine 0 C--N 1.334 0.428 0 C-N-CA 120.877 -0.677 . . . . 0.0 113.083 -179.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -50.25 -28.32 7.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.677 0.275 . . . . 0.0 111.697 179.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.98 -67.94 1.91 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.795 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.8 t 58.49 69.4 0.73 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.152 0.501 . . . . 0.0 111.068 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.522 ' O ' ' HG2' ' A' ' 47' ' ' ARG . 24.6 pt 44.09 39.09 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.043 179.372 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.76 -54.78 31.16 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 120.547 -0.835 . . . . 0.0 113.411 179.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 17.0 mmt180 -62.67 -33.74 75.68 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.522 ' HG2' ' O ' ' A' ' 44' ' ' ILE . 10.9 mtt180 56.07 89.63 0.1 Allowed Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 120.646 0.26 . . . . 0.0 111.318 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--O 1.25 1.113 0 C-N-CA 122.366 2.044 . . . . 0.0 112.119 -179.964 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 1.692 HG22 ' CD2' ' A' ' 3' ' ' TYR . 14.4 p . . . . . 0 N--CA 1.449 -0.494 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.98 ' N ' HG23 ' A' ' 1' ' ' VAL . 23.1 m120 -160.87 21.42 0.13 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.812 -179.419 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 1.692 ' CD2' HG22 ' A' ' 1' ' ' VAL . 7.8 m-85 -80.69 -153.28 0.09 Allowed 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.608 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 178.19 73.71 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 80.83 86.05 0.04 OUTLIER 'General case' 0 CA--C 1.521 -0.168 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -178.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 138.73 89.25 0.2 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.931 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t 60.58 118.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.704 0.288 . . . . 0.0 110.848 179.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 78.6 p -169.52 132.15 1.2 Allowed 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.997 0.427 . . . . 0.0 111.046 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.478 ' HA ' ' HB3' ' A' ' 13' ' ' LYS . 11.5 m 66.92 -54.92 0.44 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.611 -0.722 . . . . 0.0 112.381 179.088 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.443 ' OG ' ' O ' ' A' ' 9' ' ' CYS . 85.9 p 60.36 37.03 20.35 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 8.3 tttm 78.26 -59.67 0.42 Allowed 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 112.096 0.406 . . . . 0.0 112.096 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.3 t -88.12 66.62 8.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.977 -178.312 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.478 ' HB3' ' HA ' ' A' ' 9' ' ' CYS . 0.0 OUTLIER -159.17 -55.09 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.252 179.18 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 26.5 p -125.53 40.82 3.66 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.137 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.68 178.65 7.49 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.107 0.479 . . . . 0.0 110.987 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.2 p -163.59 100.42 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.27 0.557 . . . . 0.0 111.063 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -109.56 152.87 24.93 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.186 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -45.82 -33.45 3.14 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.106 0.479 . . . . 0.0 110.534 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.39 -53.67 43.59 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.786 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 10.0 mt-30 -56.65 -22.47 34.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.638 0.256 . . . . 0.0 111.689 -179.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.33 -71.48 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.752 0.311 . . . . 0.0 111.113 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.574 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 56.9 t80 -51.53 -31.31 23.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.573 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.2 mt-30 -80.15 -47.49 14.64 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.999 0.428 . . . . 0.0 111.27 -177.834 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.445 ' O ' ' CB ' ' A' ' 28' ' ' ALA . 45.8 tt0 -60.61 -27.06 67.46 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.461 0.648 . . . . 0.0 109.403 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.1 ttm-85 -81.09 -57.01 3.71 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.058 -0.974 . . . . 0.0 111.084 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.574 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -76.44 -45.1 32.86 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.679 -178.624 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.469 ' HA ' ' CG2' ' A' ' 30' ' ' ILE . 1.4 m -63.35 -39.09 93.59 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.307 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.445 ' CB ' ' O ' ' A' ' 24' ' ' GLU . . . -58.48 -49.62 76.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.751 0.31 . . . . 0.0 111.356 179.047 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.18 -43.04 82.05 Favored Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.533 -0.842 . . . . 0.0 113.019 -179.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.469 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 1.0 OUTLIER -72.17 -47.36 54.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.782 0.325 . . . . 0.0 111.152 -179.348 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -59.28 -41.22 88.42 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.757 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 24.0 p -57.33 -47.97 80.18 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.981 0.42 . . . . 0.0 109.918 179.661 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.475 ' CD1' ' N ' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -46.83 -39.2 11.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.268 179.031 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.475 ' N ' ' CD1' ' A' ' 33' ' ' PHE . 2.7 t -70.71 -66.01 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.423 -178.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 50.6 m -46.71 -53.75 11.09 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.866 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.79 -45.62 90.96 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.035 179.213 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.465 ' CG2' ' O ' ' A' ' 33' ' ' PHE . 47.3 t -71.96 -23.27 21.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.821 0.343 . . . . 0.0 110.509 179.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.457 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -81.18 -22.57 38.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.527 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.8 t -67.12 -31.96 72.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.379 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.39 5.1 11.61 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.933 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 63.9 14.97 8.79 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 111.963 0.357 . . . . 0.0 111.963 179.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -179.22 72.36 0.07 OUTLIER Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.787 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -107.27 -17.17 14.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.444 0.164 . . . . 0.0 111.381 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 48.2 pt 42.18 42.73 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-O 120.944 0.402 . . . . 0.0 111.514 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -146.8 59.9 0.48 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.3 179.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.459 ' O ' ' O ' ' A' ' 47' ' ' ARG . 0.1 OUTLIER -86.81 -39.12 16.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.385 0.136 . . . . 0.0 111.059 179.757 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.459 ' O ' ' O ' ' A' ' 46' ' ' ARG . 0.8 OUTLIER 35.36 105.13 0.01 OUTLIER Pre-proline 0 N--CA 1.472 0.641 0 N-CA-C 112.743 0.646 . . . . 0.0 112.743 179.67 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo . . . . . 0 C--O 1.249 1.04 0 C-N-CA 122.299 1.999 . . . . 0.0 112.246 179.569 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.756 ' CG2' ' O ' ' A' ' 1' ' ' VAL . 0.3 OUTLIER . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 44.2 m-20 -161.36 91.8 0.87 Allowed 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -79.45 145.87 33.06 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.633 -0.427 . . . . 0.0 110.123 -178.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 101.22 -83.12 0.5 Allowed Glycine 0 N--CA 1.452 -0.241 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -177.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -78.17 -48.34 16.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.798 0.333 . . . . 0.0 111.828 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -55.23 -67.82 2.01 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 121.079 -0.582 . . . . 0.0 113.337 -179.057 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.8 p -88.42 126.88 41.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 120.771 0.32 . . . . 0.0 110.795 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.4 t -77.97 82.8 4.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.56 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -64.82 -45.42 86.28 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.847 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 p 54.23 -84.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.881 -0.599 . . . . 0.0 112.565 179.495 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 3.6 mmmt -161.66 -24.11 0.05 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -178.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.411 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -88.02 86.36 7.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.981 0.419 . . . . 0.0 110.403 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.411 ' HG2' ' O ' ' A' ' 12' ' ' THR . 0.0 OUTLIER 47.51 -173.78 0.01 OUTLIER 'General case' 0 C--O 1.231 0.125 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.881 -179.246 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -133.97 -158.48 0.89 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.911 -0.315 . . . . 0.0 111.333 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -75.03 152.15 38.69 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 121.162 0.505 . . . . 0.0 110.614 -179.027 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.6 p -165.22 131.6 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.729 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -61.82 140.91 58.21 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.584 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 57.14 33.89 24.02 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.172 0.511 . . . . 0.0 109.818 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.18 -43.0 1.68 Allowed Glycine 0 C--N 1.332 0.309 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.726 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -64.66 -41.55 96.01 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.847 0.356 . . . . 0.0 110.269 179.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.98 -64.18 0.94 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.978 179.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.682 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 22.2 t80 -55.12 -31.28 61.13 Favored 'General case' 0 CA--C 1.509 -0.606 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 -179.366 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.704 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 9.2 tt0 -78.74 -34.58 45.66 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.419 -177.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.1 tp10 -73.56 -29.46 62.45 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.024 0.828 . . . . 0.0 109.515 179.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.27 -57.07 3.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.477 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.704 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -69.7 -57.72 4.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -177.884 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.507 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 0.6 OUTLIER -54.88 -41.29 70.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.744 0.307 . . . . 0.0 111.03 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -57.11 -45.78 83.14 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.347 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.87 -42.88 19.3 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.825 -0.702 . . . . 0.0 113.419 -179.2 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.403 ' CG2' ' HA ' ' A' ' 27' ' ' THR . 10.7 tp -71.05 -31.35 44.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.963 0.411 . . . . 0.0 111.839 -178.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -72.24 -45.03 61.91 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.785 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 65.9 p -62.76 -36.18 82.21 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.072 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.71 -35.72 73.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.934 0.397 . . . . 0.0 110.889 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 2.7 t -70.93 -63.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.519 -179.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -50.68 -38.17 45.28 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.737 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.37 -44.51 97.51 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.513 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 33.7 m -80.38 -26.62 11.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.934 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -80.42 -20.76 43.19 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.821 -179.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.5 t -60.78 -32.49 71.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.824 0.345 . . . . 0.0 111.115 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.59 51.03 0.05 OUTLIER Glycine 0 N--CA 1.453 -0.213 0 C-N-CA 120.688 -0.767 . . . . 0.0 112.262 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -69.67 -36.9 76.43 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.824 0.345 . . . . 0.0 110.86 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -101.72 -22.13 10.56 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.927 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.2 t -61.34 -54.58 41.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.661 0.267 . . . . 0.0 111.045 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.2 tt -126.65 -48.84 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.191 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 54.04 24.11 26.59 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.829 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.45 -45.05 11.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 111.1 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . 0.449 ' N ' ' HD2' ' A' ' 48' ' ' PRO . 40.3 mmm-85 -75.15 -50.08 3.9 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.704 -179.646 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.449 ' HD2' ' N ' ' A' ' 47' ' ' ARG . 96.0 Cg_endo . . . . . 0 C--O 1.248 1.003 0 C-N-CA 122.036 1.824 . . . . 0.0 112.135 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 1.48 ' CG1' ' HB2' ' A' ' 5' ' ' ASN . 4.6 p . . . . . 0 N--CA 1.449 -0.517 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 1.096 ' N ' HG21 ' A' ' 1' ' ' VAL . 4.5 t-20 -163.1 -46.43 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.511 0.672 . . . . 0.0 109.315 -179.633 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -80.52 17.13 1.15 Allowed 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.661 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.416 ' O ' ' HB3' ' A' ' 5' ' ' ASN . . . 124.28 -28.93 5.2 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.962 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 1.48 ' HB2' ' CG1' ' A' ' 1' ' ' VAL . 54.4 t30 74.89 63.19 0.07 Allowed 'General case' 0 CA--C 1.517 -0.291 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -178.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.89 91.5 2.11 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.646 -0.787 . . . . 0.0 111.171 -178.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.425 ' O ' ' HB2' ' A' ' 8' ' ' SER . 12.0 p -149.68 -42.76 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.474 0.178 . . . . 0.0 111.062 -179.135 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.425 ' HB2' ' O ' ' A' ' 7' ' ' VAL . 2.2 t 178.2 130.51 0.06 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.726 0.298 . . . . 0.0 111.15 178.505 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 11.0 p -102.93 -44.08 5.35 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.0 t 61.88 8.72 2.6 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.658 -0.701 . . . . 0.0 112.593 179.27 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 31.4 mttp -78.25 12.82 1.72 Allowed 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 58.36 16.41 4.06 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 179.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.0 tttp -160.13 -39.35 0.05 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.121 0.486 . . . . 0.0 110.216 -179.64 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 68.93 31.23 4.31 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.845 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 22.4 p -173.68 137.91 0.63 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.429 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.1 p -164.8 116.95 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.041 -179.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -72.44 -33.27 66.95 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.979 0.419 . . . . 0.0 110.677 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -51.49 -31.27 23.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.267 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.53 -43.71 97.35 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.566 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -64.01 -42.2 97.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.96 0.409 . . . . 0.0 110.601 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.56 -51.65 64.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.95 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.721 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 40.0 t80 -57.3 -27.74 62.42 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -179.037 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.486 ' O ' ' HD1' ' A' ' 26' ' ' TYR . 18.1 tt0 -71.46 -46.25 60.47 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.025 -178.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.81 -48.04 49.1 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.014 0.435 . . . . 0.0 110.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -56.13 -58.58 7.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.574 0.702 . . . . 0.0 111.457 179.576 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.721 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.18 -32.82 73.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.867 -1.061 . . . . 0.0 113.182 -177.442 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.577 ' HA ' HG21 ' A' ' 30' ' ' ILE . 1.2 p -66.7 -45.27 79.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.121 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -49.42 -46.3 47.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.47 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.85 -53.85 9.07 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.823 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.577 HG21 ' HA ' ' A' ' 27' ' ' THR . 7.2 tp -66.8 -49.65 72.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.779 0.29 . . . . 0.0 111.63 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.453 ' N ' ' O ' ' A' ' 27' ' ' THR . 8.3 t-20 -52.46 -40.11 61.9 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.826 0.346 . . . . 0.0 110.583 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.4 m -60.75 -43.92 97.36 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 110.522 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.459 ' CD1' HG21 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -56.59 -33.59 66.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.136 0.493 . . . . 0.0 110.981 179.779 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.459 HG21 ' CD1' ' A' ' 33' ' ' PHE . 3.4 t -69.06 -60.94 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.373 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -48.04 -58.0 5.04 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.021 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.73 -50.01 66.38 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.273 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 33' ' ' PHE . 75.2 t -68.53 -16.35 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.546 0.213 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.422 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -80.0 -26.17 39.98 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 120.831 0.348 . . . . 0.0 111.371 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.8 t -64.47 -30.25 71.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.007 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -103.15 -39.24 2.68 Favored Glycine 0 C--N 1.329 0.168 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.638 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -141.8 -77.37 0.27 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.773 0.321 . . . . 0.0 111.168 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.86 44.35 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.738 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.5 t -155.47 38.75 0.39 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.698 0.285 . . . . 0.0 110.803 179.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.7 pt -117.79 30.06 2.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.187 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -112.68 39.04 2.99 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.672 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -118.27 -40.44 2.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.695 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 7.6 ptt85 -152.94 105.38 2.65 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.808 179.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo . . . . . 0 C--O 1.248 0.993 0 C-N-CA 122.422 2.081 . . . . 0.0 112.305 179.817 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 1.078 HG13 ' N ' ' A' ' 2' ' ' ASN . 40.7 t . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 1.078 ' N ' HG13 ' A' ' 1' ' ' VAL . 47.3 t30 -161.76 -5.01 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 120.542 0.21 . . . . 0.0 111.055 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.482 ' H ' HG13 ' A' ' 1' ' ' VAL . 1.6 p90 -159.34 -179.96 8.43 Favored 'General case' 0 C--O 1.231 0.096 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.95 -55.09 0.03 OUTLIER Glycine 0 C--N 1.334 0.417 0 C-N-CA 120.185 -1.007 . . . . 0.0 113.302 -179.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.6 m120 -162.28 63.05 0.22 Allowed 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.123 0.487 . . . . 0.0 110.544 -179.432 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -153.8 -37.39 0.03 OUTLIER Glycine 0 N--CA 1.454 -0.151 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.94 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.4 p -88.5 140.01 16.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.556 0.217 . . . . 0.0 110.468 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -81.43 68.72 7.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.872 0.368 . . . . 0.0 111.174 -179.091 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -171.77 101.03 0.18 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.2 p -78.52 -102.23 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 1.6 ptpt -162.7 37.71 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.64 0.257 . . . . 0.0 111.319 178.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.09 -77.66 0.13 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.1 mtmm -80.95 -57.49 3.51 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.3 m 57.89 170.71 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.794 0.33 . . . . 0.0 110.743 -179.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t -81.62 -27.93 33.95 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.046 0.451 . . . . 0.0 110.533 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.0 m -76.45 105.84 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.408 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 32.1 m120 -42.34 -33.86 0.71 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.71 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -89.17 36.49 0.82 Allowed 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.553 179.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.95 -42.4 5.35 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.323 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -63.3 -43.27 98.34 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.019 0.437 . . . . 0.0 110.486 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -68.66 -57.66 5.37 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.88 179.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.834 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 38.1 t80 -57.78 -21.0 39.41 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.209 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.706 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 7.5 tm0? -81.49 -48.01 12.41 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.689 -178.205 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -64.73 -30.74 71.76 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.558 179.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.04 -51.61 11.93 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.563 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.834 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -77.44 -55.55 5.29 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -177.811 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.469 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.2 m -55.94 -21.97 23.65 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.932 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.84 -58.11 3.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.066 0.46 . . . . 0.0 110.495 179.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.88 -43.55 65.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.173 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.44 HG21 HD11 ' A' ' 30' ' ' ILE . 42.0 mm -56.57 -51.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.923 0.392 . . . . 0.0 110.957 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -50.09 -53.16 29.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.904 0.383 . . . . 0.0 110.408 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 p -63.17 -36.15 82.67 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.763 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -55.99 -38.55 70.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.029 0.442 . . . . 0.0 110.703 179.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 4.1 t -63.97 -58.98 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.42 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.368 179.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 70.7 m -53.92 -42.81 69.19 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.677 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.14 -47.06 92.65 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.0 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 32.7 m -76.6 -26.62 16.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.886 0.374 . . . . 0.0 110.703 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -71.85 -24.52 61.71 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.718 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 66.3 m -64.64 -34.21 77.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.864 0.364 . . . . 0.0 111.04 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 160.28 54.53 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.454 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -60.32 -32.06 70.87 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 111.401 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -70.15 -15.58 72.29 Favored Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.821 -0.704 . . . . 0.0 113.242 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 54.0 m -58.36 -57.37 13.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.831 0.315 . . . . 0.0 111.341 -179.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 1.2 tp -133.78 -69.38 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.014 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 92.72 -37.09 3.47 Favored Glycine 0 C--N 1.332 0.318 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.148 179.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 10.2 tpp180 68.83 -65.01 0.3 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.752 0.31 . . . . 0.0 111.414 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.8 mmt85 57.36 73.22 0.8 Allowed Pre-proline 0 CA--C 1.532 0.262 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.066 -179.482 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo . . . . . 0 C--O 1.248 0.987 0 C-N-CA 122.24 1.96 . . . . 0.0 112.247 179.845 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 -0.105 0 CA-C-O 120.656 0.265 . . . . 0.0 111.619 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.586 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 34.8 t80 -50.02 -34.6 21.8 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 112.84 0.681 . . . . 0.0 112.84 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.594 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 1.8 tt0 -79.71 -32.24 41.28 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.237 -177.01 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.648 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.3 OUTLIER -76.24 -31.76 58.52 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.443 0.64 . . . . 0.0 109.295 179.503 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.1 ttt180 -77.16 -60.58 2.3 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 114.847 -1.07 . . . . 0.0 111.61 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.594 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -63.18 -54.53 36.12 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 113.056 0.761 . . . . 0.0 113.056 -178.03 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.45 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.5 m -58.93 -36.05 74.11 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.514 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.648 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -53.4 -49.54 67.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.04 0.448 . . . . 0.0 110.645 178.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 -33.87 28.66 Favored Glycine 0 C--N 1.33 0.229 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.449 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.52 HD12 ' HD1' ' A' ' 26' ' ' TYR . 5.2 mt -74.99 -29.59 22.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.746 0.308 . . . . 0.0 110.773 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.439 ' N ' ' O ' ' A' ' 27' ' ' THR . 37.9 t-20 -71.79 -49.14 41.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.038 0.447 . . . . 0.0 110.353 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.3 m -54.78 -45.17 74.24 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.524 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.455 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -48.43 -35.42 12.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.02 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 38' ' ' ALA . 3.0 t -70.66 -61.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.412 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -48.29 -58.44 4.57 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.49 -58.39 13.38 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.693 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.455 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 53.5 t -59.36 -22.25 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.617 0.246 . . . . 0.0 110.666 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.448 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.334 -0.106 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.276 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 -0.283 0 CA-C-O 121.003 0.43 . . . . 0.0 110.731 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.599 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.2 t80 -54.89 -34.02 62.59 Favored 'General case' 0 C--O 1.22 -0.496 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.646 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -76.94 -39.04 52.1 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.03 0.443 . . . . 0.0 110.537 -177.874 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 6.4 tp10 -68.08 -28.37 67.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.7 ttt-85 -80.61 -55.21 5.0 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.429 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.646 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -76.66 -55.09 5.82 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -177.948 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.0 m -54.8 -32.57 60.41 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.244 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.458 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -66.15 -50.77 62.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.536 179.038 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.87 -41.38 82.81 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.822 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.516 HG22 ' O ' ' A' ' 26' ' ' TYR . 10.4 tp -70.84 -42.99 77.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.93 0.395 . . . . 0.0 111.001 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.466 ' N ' HG23 ' A' ' 30' ' ' ILE . 37.9 t-20 -62.6 -43.72 98.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.414 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.4 m -59.3 -37.66 78.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.876 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.477 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.28 -35.29 73.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.883 179.853 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.0 t -72.55 -62.04 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.57 -178.453 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 72.2 m -47.77 -57.65 5.32 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.408 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.21 -51.26 57.07 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.16 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 33' ' ' PHE . 53.3 t -64.24 -25.36 37.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.63 0.252 . . . . 0.0 110.513 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.421 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.11 0 CA-C-O 120.742 0.306 . . . . 0.0 111.617 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.644 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 30.1 t80 -56.48 -28.54 60.03 Favored 'General case' 0 CA--C 1.509 -0.605 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.71 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.5 tt0 -77.23 -43.45 33.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 121.117 0.484 . . . . 0.0 110.068 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.401 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 40.1 tt0 -66.99 -29.49 69.33 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.832 178.792 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.48 -53.23 7.08 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.514 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.71 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.08 -55.75 5.42 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.066 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.8 m -55.34 -27.9 50.21 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.96 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.401 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -70.82 -51.99 23.3 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.892 0.377 . . . . 0.0 111.253 179.305 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.91 -44.13 56.49 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.896 -179.486 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.671 ' O ' HG23 ' A' ' 34' ' ' VAL . 2.5 tp -63.28 -44.01 98.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.968 0.414 . . . . 0.0 111.691 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.463 ' N ' HG23 ' A' ' 30' ' ' ILE . 36.0 t-20 -57.31 -49.21 76.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.858 0.361 . . . . 0.0 110.558 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 39.6 p -59.07 -41.07 87.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.072 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -57.08 -36.57 70.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.97 0.414 . . . . 0.0 110.808 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.671 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.5 t -62.42 -59.55 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.142 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.4 m -49.31 -47.2 47.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.197 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.3 -44.91 93.27 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.421 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.4 m -78.62 -25.88 13.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.818 0.342 . . . . 0.0 110.842 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.809 -179.454 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.086 0 CA-C-O 120.634 0.254 . . . . 0.0 111.551 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -52.68 -41.99 64.36 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.633 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 3.5 tm0? -65.92 -42.09 90.58 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.897 0.379 . . . . 0.0 111.106 -177.358 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -70.45 -30.07 66.8 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.307 0.575 . . . . 0.0 110.161 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -80.03 -54.05 6.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.513 -0.767 . . . . 0.0 111.504 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.633 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.86 -55.83 6.82 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -178.016 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.551 ' HA ' HG22 ' A' ' 30' ' ' ILE . 2.3 m -55.98 -32.28 63.77 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 120.694 -0.402 . . . . 0.0 110.807 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.41 -32.85 68.87 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.705 179.005 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.84 -42.82 8.0 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.632 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.551 HG22 ' HA ' ' A' ' 27' ' ' THR . 4.0 tp -68.87 -36.12 72.62 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.598 0.713 . . . . 0.0 110.863 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -77.3 -38.03 51.46 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.082 0.467 . . . . 0.0 109.901 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 47.2 t -66.68 -30.79 71.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.478 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.47 -40.67 87.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.865 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.537 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.3 t -65.98 -61.99 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.472 179.344 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -55.37 -34.71 64.55 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.49 -45.86 93.84 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.293 179.214 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.537 HG22 ' O ' ' A' ' 34' ' ' VAL . 31.3 m -76.8 -27.63 16.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-O 121.119 0.485 . . . . 0.0 110.055 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.199 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.289 -179.951 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 -0.192 0 CA-C-O 120.571 0.224 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.532 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.3 t80 -56.09 -35.26 66.81 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.047 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.684 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 40.0 mt-30 -73.99 -34.09 64.07 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 123.144 0.277 . . . . 0.0 111.099 -177.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.422 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 32.9 tt0 -75.74 -30.24 59.15 Favored 'General case' 0 C--N 1.33 -0.264 0 O-C-N 123.732 0.645 . . . . 0.0 109.946 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.2 ttt-85 -80.65 -57.9 3.36 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.114 -0.948 . . . . 0.0 111.096 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.684 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -65.64 -57.74 7.4 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.239 -0.892 . . . . 0.0 113.378 -178.105 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.515 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.3 m -56.84 -44.95 82.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.785 0.326 . . . . 0.0 111.27 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.422 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -52.27 -43.42 64.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.457 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.44 -51.51 8.35 Favored Glycine 0 CA--C 1.52 0.377 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.872 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.521 HG23 ' N ' ' A' ' 31' ' ' ASN . 9.8 tp -65.53 -46.15 90.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.018 0.437 . . . . 0.0 111.714 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.521 ' N ' HG23 ' A' ' 30' ' ' ILE . 1.1 t30 -63.04 -38.25 90.44 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.956 0.408 . . . . 0.0 110.199 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.5 m -57.14 -37.37 71.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.237 178.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.84 -37.82 77.34 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.106 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.571 ' O ' HG22 ' A' ' 37' ' ' VAL . 2.8 t -68.92 -63.08 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.732 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.5 m -47.9 -39.52 19.15 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.013 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.18 -50.31 69.05 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.592 179.376 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.571 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.0 m -72.14 -29.33 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.177 0.513 . . . . 0.0 109.982 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.129 -179.995 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 -0.264 0 CA-C-O 120.706 0.289 . . . . 0.0 111.333 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.722 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 60.3 t80 -51.05 -30.14 14.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.606 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.9 tt0 -81.6 -35.67 29.85 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 111.941 0.349 . . . . 0.0 111.941 -177.32 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.555 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.0 OUTLIER -76.18 -25.19 54.95 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.673 0.749 . . . . 0.0 109.086 -179.504 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.51 -59.09 2.89 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.111 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.722 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -68.11 -57.74 5.6 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 113.164 0.801 . . . . 0.0 113.164 -178.789 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.491 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 0.7 OUTLIER -53.79 -36.69 62.71 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.661 -179.756 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.555 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -55.81 -51.51 67.22 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.677 0.275 . . . . 0.0 110.647 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.79 -36.68 46.99 Favored Glycine 0 C--N 1.332 0.32 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.178 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 38.1 mm -70.2 -42.03 78.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 110.288 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -62.48 -39.74 94.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.054 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -55.3 -48.7 73.72 Favored 'General case' 0 CA--C 1.519 -0.221 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.332 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.518 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -44.68 -38.58 4.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.194 179.217 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.486 ' O ' ' N ' ' A' ' 38' ' ' ALA . 2.7 t -69.25 -64.21 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.34 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.404 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.6 m -45.56 -56.11 5.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.826 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.85 -54.03 35.95 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.499 -0.858 . . . . 0.0 111.835 179.025 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 33' ' ' PHE . 58.8 t -64.62 -19.16 24.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.715 0.293 . . . . 0.0 110.719 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.333 -0.14 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.027 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.711 0.291 . . . . 0.0 111.301 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.674 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 24.1 t80 -53.64 -30.8 44.64 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.725 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 29.5 tt0 -76.95 -39.87 49.1 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.769 -177.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.502 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 3.2 tp10 -71.52 -31.7 67.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.908 179.099 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.92 -54.14 6.96 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.509 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.725 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.21 -58.41 3.57 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -177.884 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.7 m -54.13 -31.66 52.97 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.579 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -64.68 -45.76 85.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.495 -0.321 . . . . 0.0 111.024 178.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.27 -43.78 12.54 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.05 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.476 ' O ' HG23 ' A' ' 34' ' ' VAL . 46.7 mm -62.33 -36.28 73.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.369 0.604 . . . . 0.0 110.442 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -67.67 -44.05 78.76 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -62.49 -37.87 87.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.992 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.513 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -55.7 -39.73 71.43 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.016 0.436 . . . . 0.0 109.987 179.625 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.506 ' O ' HG22 ' A' ' 37' ' ' VAL . 4.0 t -59.81 -59.17 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.893 178.731 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -57.37 -42.02 81.3 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.25 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.4 -43.17 95.91 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.954 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 33' ' ' PHE . 27.0 m -79.72 -27.22 12.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.106 0.479 . . . . 0.0 110.403 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.26 -179.719 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.106 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.651 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.6 t80 -52.54 -32.24 39.79 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 -178.07 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.691 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.8 tt0 -77.92 -36.4 49.45 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.745 -177.322 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.405 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.3 tp10 -75.05 -29.82 60.86 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.274 0.559 . . . . 0.0 109.538 179.155 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt85 -78.73 -52.36 8.5 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.12 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.691 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.05 -57.32 3.97 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.205 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.1 m -56.03 -20.48 16.97 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.102 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -79.49 -48.9 13.12 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.964 0.412 . . . . 0.0 110.075 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.83 -45.31 27.95 Favored Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.284 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.696 ' O ' HG23 ' A' ' 34' ' ' VAL . 50.5 mm -60.49 -45.44 96.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.778 0.323 . . . . 0.0 110.72 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -61.26 -37.07 81.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.776 0.322 . . . . 0.0 110.81 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.5 t -69.11 -38.88 79.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.793 0.33 . . . . 0.0 110.755 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.498 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.42 -34.45 72.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.208 0.528 . . . . 0.0 110.457 179.54 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.696 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.7 t -69.28 -61.81 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.785 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 52.4 m -47.12 -57.49 5.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.28 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.42 -48.69 78.85 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.011 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 33' ' ' PHE . 52.5 t -67.43 -21.83 28.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.765 0.317 . . . . 0.0 110.739 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.434 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.502 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 -0.095 0 CA-C-O 120.682 0.277 . . . . 0.0 111.103 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.65 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.4 t80 -51.67 -30.75 23.07 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -178.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.728 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.2 tt0 -76.45 -47.48 22.9 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 117.969 0.35 . . . . 0.0 110.762 -178.109 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.45 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 2.5 tm-20 -64.8 -27.52 68.94 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.444 0.64 . . . . 0.0 109.521 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.31 -52.73 7.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.86 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.728 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -77.74 -56.6 4.37 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -178.86 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.52 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.8 m -53.37 -23.46 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.857 179.569 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.45 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -74.52 -52.64 11.33 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.892 0.377 . . . . 0.0 110.484 178.79 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.05 -42.15 59.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.611 -0.805 . . . . 0.0 112.426 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.453 ' O ' HG23 ' A' ' 34' ' ' VAL . 48.1 mm -62.11 -46.35 96.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.122 0.486 . . . . 0.0 111.436 -179.293 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -56.99 -48.0 79.48 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.925 0.393 . . . . 0.0 110.568 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.3 t -60.72 -36.69 79.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.506 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -57.66 -38.71 75.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.983 0.421 . . . . 0.0 110.43 179.802 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.546 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.0 t -61.45 -62.49 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.305 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.5 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.2 m -54.83 -38.89 67.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -61.93 -41.64 99.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.749 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.546 HG22 ' O ' ' A' ' 34' ' ' VAL . 29.7 m -80.2 -27.21 11.91 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-O 121.027 0.441 . . . . 0.0 110.221 179.487 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.531 -179.747 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 -0.312 0 CA-C-O 120.889 0.375 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.583 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.7 t80 -53.55 -33.12 53.54 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -178.473 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.704 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 21.5 tt0 -76.38 -43.26 41.47 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.902 0.382 . . . . 0.0 110.81 -178.221 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.21 -33.23 75.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.439 0.638 . . . . 0.0 109.82 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.0 -54.35 6.11 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.57 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.704 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.37 -57.5 3.97 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -177.957 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.529 ' HA ' HG22 ' A' ' 30' ' ' ILE . 2.9 m -52.39 -33.53 43.86 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.98 -0.288 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.39 -47.77 75.2 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.736 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.08 -47.81 57.27 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.27 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.529 HG22 ' HA ' ' A' ' 27' ' ' THR . 17.7 tt -64.86 -36.46 77.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.21 0.528 . . . . 0.0 110.344 -179.77 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.423 ' ND2' HG22 ' A' ' 27' ' ' THR . 31.7 m-20 -57.71 -40.97 80.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.509 179.029 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.5 t -66.57 -36.98 83.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.118 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.41 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -58.55 -38.29 77.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.225 0.536 . . . . 0.0 110.328 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.504 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.2 t -62.59 -61.67 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.235 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 54.5 m -50.25 -56.11 12.54 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.369 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.11 -52.16 54.12 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.296 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.41 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 50.4 t -66.46 -21.19 28.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.706 0.288 . . . . 0.0 110.375 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.454 -0.228 0 CA-C-O 120.919 0.39 . . . . 0.0 110.676 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.173 0 CA-C-O 120.709 0.29 . . . . 0.0 111.574 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.666 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 32.4 t80 -52.1 -33.51 39.91 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -178.575 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.742 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 14.7 tt0 -79.21 -39.76 32.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.025 0.44 . . . . 0.0 110.38 -178.494 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.521 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 3.5 mt-10 -65.4 -30.61 71.44 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 178.594 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.64 -56.93 4.05 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.573 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.742 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.4 OUTLIER -73.89 -58.04 3.57 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -178.184 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.6 m -51.01 -33.67 25.93 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.621 179.808 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -62.19 -55.2 30.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.118 0.485 . . . . 0.0 110.932 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.8 -35.74 61.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.182 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.654 ' O ' HG23 ' A' ' 34' ' ' VAL . 42.6 mm -70.85 -35.67 61.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.3 0.572 . . . . 0.0 111.181 -179.587 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.2 t-20 -61.51 -50.34 73.08 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.085 0.469 . . . . 0.0 109.821 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 86.2 p -57.28 -43.74 83.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.928 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -52.83 -39.34 62.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 110.681 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.6 t -58.66 -60.3 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.593 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -52.73 -42.29 64.74 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.735 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.06 -44.25 97.47 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.142 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.3 m -79.82 -24.95 12.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.913 0.387 . . . . 0.0 110.809 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.693 -179.397 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.946 0.403 . . . . 0.0 111.485 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.63 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 26.3 t80 -54.19 -29.06 44.54 Favored 'General case' 0 C--O 1.219 -0.522 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -178.292 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.647 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.6 tt0 -78.81 -36.94 41.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 118.196 0.453 . . . . 0.0 111.341 -177.568 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.4 tm-20 -74.75 -33.1 62.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.299 0.571 . . . . 0.0 109.743 179.537 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.4 -57.44 3.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.862 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.647 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.0 OUTLIER -66.18 -58.74 4.75 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -177.8 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 3.2 m -54.08 -36.68 63.42 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.669 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.415 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -59.4 -41.66 89.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.846 178.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.29 -47.27 6.16 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.387 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.721 ' O ' HG23 ' A' ' 34' ' ' VAL . 9.2 mt -63.67 -26.04 39.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 121.008 0.432 . . . . 0.0 110.759 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -76.15 -53.8 7.76 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.917 0.389 . . . . 0.0 110.547 179.198 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.0 t -62.3 -35.71 79.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.203 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.442 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -57.38 -35.72 70.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.913 0.387 . . . . 0.0 110.849 -179.878 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.9 t -70.18 -62.84 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.086 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.7 m -52.15 -37.91 55.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.863 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.91 -43.91 98.76 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.621 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 34' ' ' VAL . 30.4 m -80.5 -26.79 11.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.933 0.397 . . . . 0.0 110.772 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.231 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.676 -179.407 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.836 0.35 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.691 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 44.4 t80 -54.58 -27.14 36.86 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -179.492 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.525 ' HA ' ' CD1' ' A' ' 26' ' ' TYR . 29.9 mm-40 -75.17 -38.8 60.73 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.849 -178.274 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -78.16 -44.47 25.85 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.2 0.524 . . . . 0.0 109.926 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -56.22 23.92 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.61 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.691 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -63.44 -37.39 87.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.891 -1.049 . . . . 0.0 113.639 -177.094 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.652 HG23 ' CE1' ' A' ' 26' ' ' TYR . 4.3 p -65.68 -45.1 84.16 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.448 -0.501 . . . . 0.0 109.706 177.656 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -43.34 64.79 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.847 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.37 -43.95 11.98 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.497 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.404 ' O ' HG23 ' A' ' 34' ' ' VAL . 35.7 mm -72.84 -54.0 17.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 121.007 0.432 . . . . 0.0 111.176 -179.726 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 27' ' ' THR . 3.3 t-20 -56.36 -50.19 72.25 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.771 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.6 m -54.23 -40.3 67.58 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.688 0.28 . . . . 0.0 111.089 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.653 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -56.11 -35.7 67.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 -179.781 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.557 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.3 t -74.8 -60.36 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.93 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.9 m -57.05 -38.09 72.73 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.081 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.54 -43.06 97.9 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.674 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 33' ' ' PHE . 20.3 m -80.79 -29.51 11.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.044 0.45 . . . . 0.0 110.318 179.481 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.227 -179.824 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.124 0 N-CA-C 111.543 0.201 . . . . 0.0 111.543 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -53.31 -42.35 66.59 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 -178.301 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.674 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.8 tt0 -68.38 -36.86 79.77 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.991 -177.321 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -72.93 -28.88 62.71 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.508 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -80.45 -53.94 6.14 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.506 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.674 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.58 -54.25 8.62 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.273 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.505 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.8 m -57.66 -25.39 60.14 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.731 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.36 -33.36 49.07 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.438 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.94 -42.72 7.99 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.682 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.505 HG22 ' HA ' ' A' ' 27' ' ' THR . 9.0 tp -67.37 -41.32 86.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.641 0.734 . . . . 0.0 111.339 -179.228 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.437 ' N ' HG23 ' A' ' 30' ' ' ILE . 2.0 t-20 -72.48 -41.72 65.71 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.762 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 58.4 m -65.24 -31.1 72.09 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.684 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.49 -40.58 87.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.984 0.421 . . . . 0.0 110.006 179.834 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.547 ' O ' HG22 ' A' ' 37' ' ' VAL . 2.9 t -66.81 -63.38 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.221 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.1 m -56.44 -34.79 67.16 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.355 179.568 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.15 -43.3 98.87 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.322 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.684 HG13 ' O ' ' A' ' 33' ' ' PHE . 19.9 m -80.23 -27.38 11.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.972 0.415 . . . . 0.0 110.268 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.141 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.844 -179.463 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 -0.267 0 CA-C-O 120.764 0.316 . . . . 0.0 110.547 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.536 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.4 t80 -57.22 -33.35 67.44 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -179.143 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.712 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.1 tt0 -75.37 -37.24 60.72 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 121.121 -0.232 . . . . 0.0 111.035 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -70.64 -30.8 67.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.526 0.679 . . . . 0.0 109.627 179.776 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -79.82 -58.31 3.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.144 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.712 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -68.48 -58.53 4.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.132 -0.94 . . . . 0.0 113.3 -177.93 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.55 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.4 m -54.38 -37.45 65.02 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.893 -0.323 . . . . 0.0 110.912 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -55.99 -48.9 75.02 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.176 179.267 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.42 -53.66 8.52 Favored Glycine 0 CA--C 1.52 0.369 0 C-N-CA 120.595 -0.812 . . . . 0.0 113.097 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.638 ' O ' HG23 ' A' ' 34' ' ' VAL . 2.5 tt -61.41 -29.45 45.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.138 0.494 . . . . 0.0 111.915 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -69.51 -48.92 59.0 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 122.035 -0.415 . . . . 0.0 110.169 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 16.6 m -54.04 -38.85 65.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.241 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.425 ' O ' HG12 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.11 -37.73 77.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.195 0.522 . . . . 0.0 110.49 179.59 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.646 ' HA ' HG12 ' A' ' 37' ' ' VAL . 4.2 t -67.49 -59.87 3.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.892 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 73.1 m -45.32 -55.65 5.74 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.471 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.93 -47.49 85.39 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.349 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.646 HG12 ' HA ' ' A' ' 34' ' ' VAL . 5.0 p -65.95 -24.98 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.849 0.357 . . . . 0.0 110.439 -179.887 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.446 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--O 1.231 0.113 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.549 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 -0.122 0 CA-C-O 120.79 0.329 . . . . 0.0 111.198 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.866 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 28.4 t80 -55.33 -17.92 5.6 Favored 'General case' 0 CA--C 1.508 -0.644 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.26 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.693 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 49.0 tt0 -84.38 -45.26 12.93 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.334 -178.004 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -69.28 -33.68 73.58 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -67.89 -55.46 12.78 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.125 179.044 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.866 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.3 OUTLIER -68.21 -36.93 80.29 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.543 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.615 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.1 p -59.79 -46.19 89.96 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 120.198 -0.601 . . . . 0.0 109.575 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -41.38 63.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.229 179.257 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.06 -52.01 7.18 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.54 179.538 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.615 HG22 ' HA ' ' A' ' 27' ' ' THR . 1.2 tt -70.91 -50.33 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 120.78 0.324 . . . . 0.0 111.836 -179.165 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.549 ' N ' HG23 ' A' ' 30' ' ' ILE . 2.1 t-20 -55.34 -50.97 68.27 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 120.805 0.336 . . . . 0.0 110.417 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 44.0 m -49.66 -44.33 47.68 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.631 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -53.38 -34.73 58.77 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.089 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.534 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.2 t -72.2 -61.65 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.345 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.3 m -51.49 -39.17 57.06 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.763 179.619 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.15 98.73 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.818 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.534 HG22 ' O ' ' A' ' 34' ' ' VAL . 32.9 m -80.95 -29.52 11.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.073 0.463 . . . . 0.0 110.432 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.448 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.626 179.768 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 -0.238 0 CA-C-O 120.752 0.311 . . . . 0.0 111.113 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.579 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 56.9 t80 -51.53 -31.31 23.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.575 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.2 mt-30 -80.15 -47.49 14.64 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.999 0.428 . . . . 0.0 111.27 -177.834 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.487 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 45.8 tt0 -60.61 -27.06 67.46 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.461 0.648 . . . . 0.0 109.403 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.1 ttm-85 -81.09 -57.01 3.71 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.058 -0.974 . . . . 0.0 111.084 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.579 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -76.44 -45.1 32.86 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.679 -178.624 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.526 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.4 m -63.35 -39.09 93.59 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.307 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -58.48 -49.62 76.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.751 0.31 . . . . 0.0 111.356 179.047 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.18 -43.04 82.05 Favored Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.533 -0.842 . . . . 0.0 113.019 -179.366 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.575 HG22 ' O ' ' A' ' 26' ' ' TYR . 1.0 OUTLIER -72.17 -47.36 54.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.782 0.325 . . . . 0.0 111.152 -179.348 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.539 ' N ' HG23 ' A' ' 30' ' ' ILE . 21.9 t-20 -59.28 -41.22 88.42 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.757 179.836 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 24.0 p -57.33 -47.97 80.18 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.981 0.42 . . . . 0.0 109.918 179.661 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.56 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -46.83 -39.2 11.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.268 179.031 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.475 ' N ' ' CD1' ' A' ' 33' ' ' PHE . 2.7 t -70.71 -66.01 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.423 -178.574 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 50.6 m -46.71 -53.75 11.09 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.866 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.79 -45.62 90.96 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.035 179.213 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 33' ' ' PHE . 47.3 t -71.96 -23.27 21.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.821 0.343 . . . . 0.0 110.509 179.59 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.457 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.332 -0.182 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.527 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.145 0 CA-C-O 120.643 0.258 . . . . 0.0 110.978 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.686 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 22.2 t80 -55.12 -31.28 61.13 Favored 'General case' 0 CA--C 1.509 -0.606 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 -179.366 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.705 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 9.2 tt0 -78.74 -34.58 45.66 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.419 -177.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.444 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 53.1 tp10 -73.56 -29.46 62.45 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.024 0.828 . . . . 0.0 109.515 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.27 -57.07 3.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.477 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.705 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -69.7 -57.72 4.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -177.884 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.555 ' HA ' HG22 ' A' ' 30' ' ' ILE . 0.6 OUTLIER -54.88 -41.29 70.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.744 0.307 . . . . 0.0 111.03 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.444 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -57.11 -45.78 83.14 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.347 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.87 -42.88 19.3 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.825 -0.702 . . . . 0.0 113.419 -179.2 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.586 ' O ' HG23 ' A' ' 34' ' ' VAL . 10.7 tp -71.05 -31.35 44.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.963 0.411 . . . . 0.0 111.839 -178.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.407 ' HB2' ' O ' ' A' ' 27' ' ' THR . 56.3 t30 -72.24 -45.03 61.91 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.785 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 65.9 p -62.76 -36.18 82.21 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.072 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.71 -35.72 73.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.934 0.397 . . . . 0.0 110.889 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.586 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.7 t -70.93 -63.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.519 -179.417 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -50.68 -38.17 45.28 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.737 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.37 -44.51 97.51 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.513 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.574 HG22 ' O ' ' A' ' 34' ' ' VAL . 33.7 m -80.38 -26.62 11.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.934 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.203 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.821 -179.245 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 -0.115 0 CA-C-O 120.843 0.354 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.698 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 40.0 t80 -57.3 -27.74 62.42 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -179.037 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.5 ' O ' ' HD1' ' A' ' 26' ' ' TYR . 18.1 tt0 -71.46 -46.25 60.47 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.025 -178.321 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.81 -48.04 49.1 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.014 0.435 . . . . 0.0 110.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -56.13 -58.58 7.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.574 0.702 . . . . 0.0 111.457 179.576 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.698 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.18 -32.82 73.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.867 -1.061 . . . . 0.0 113.182 -177.442 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.593 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.2 p -66.7 -45.27 79.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.121 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -49.42 -46.3 47.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.47 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.85 -53.85 9.07 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.823 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.593 HG22 ' HA ' ' A' ' 27' ' ' THR . 7.2 tp -66.8 -49.65 72.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.779 0.29 . . . . 0.0 111.63 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.53 ' N ' HG23 ' A' ' 30' ' ' ILE . 8.3 t-20 -52.46 -40.11 61.9 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.826 0.346 . . . . 0.0 110.583 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.4 m -60.75 -43.92 97.36 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 110.522 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.553 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -56.59 -33.59 66.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.136 0.493 . . . . 0.0 110.981 179.779 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.445 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.4 t -69.06 -60.94 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.373 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -48.04 -58.0 5.04 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.021 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.73 -50.01 66.38 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.273 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.553 HG23 ' O ' ' A' ' 33' ' ' PHE . 75.2 t -68.53 -16.35 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.546 0.213 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.419 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.333 -0.134 0 CA-C-O 120.831 0.348 . . . . 0.0 111.371 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.179 0 CA-C-O 120.976 0.417 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.845 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 38.1 t80 -57.78 -21.0 39.41 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.209 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.707 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 7.5 tm0? -81.49 -48.01 12.41 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.689 -178.205 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.9 tt0 -64.73 -30.74 71.76 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.558 179.15 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.04 -51.61 11.93 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.563 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.845 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -77.44 -55.55 5.29 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -177.811 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.469 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.2 m -55.94 -21.97 23.65 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.932 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.412 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -75.84 -58.11 3.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.066 0.46 . . . . 0.0 110.495 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.88 -43.55 65.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.173 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.601 ' O ' HG23 ' A' ' 34' ' ' VAL . 42.0 mm -56.57 -51.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.923 0.392 . . . . 0.0 110.957 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -50.09 -53.16 29.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.904 0.383 . . . . 0.0 110.408 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 p -63.17 -36.15 82.67 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.763 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -55.99 -38.55 70.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.029 0.442 . . . . 0.0 110.703 179.731 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 30' ' ' ILE . 4.1 t -63.97 -58.98 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.42 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.368 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 70.7 m -53.92 -42.81 69.19 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.677 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.14 -47.06 92.65 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.0 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 34' ' ' VAL . 32.7 m -76.6 -26.62 16.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.886 0.374 . . . . 0.0 110.703 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.217 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.718 -179.725 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 1.325 ' CG2' ' H ' ' A' ' 2' ' ' ASN . 0.3 OUTLIER . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 1.325 ' H ' ' CG2' ' A' ' 1' ' ' VAL . 27.6 m-80 45.18 42.03 6.5 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.489 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -80.66 106.71 12.88 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.503 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.63 -70.94 0.02 OUTLIER Glycine 0 C--N 1.331 0.275 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.674 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -162.63 29.64 0.1 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.717 0.294 . . . . 0.0 111.023 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -123.16 -15.1 3.88 Favored Glycine 0 CA--C 1.52 0.356 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.75 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.2 m -88.37 -32.06 5.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.769 0.319 . . . . 0.0 110.464 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.2 t -105.15 88.93 2.98 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.56 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.7 t -69.27 128.76 37.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.969 0.414 . . . . 0.0 111.507 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.556 ' O ' ' O ' ' A' ' 11' ' ' LYS . 1.9 p -56.04 154.91 6.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.21 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.556 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.9 mtpm? 45.21 163.45 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.147 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 t -90.05 58.82 4.29 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.116 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.473 ' O ' ' HB2' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -158.25 -90.38 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.261 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.473 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 53.2 m 75.27 93.71 0.07 Allowed 'General case' 0 C--O 1.232 0.147 0 CA-C-O 120.67 0.271 . . . . 0.0 110.827 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.1 m -162.2 -47.87 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.78 0.324 . . . . 0.0 111.498 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.501 ' O ' HG13 ' A' ' 16' ' ' VAL . 9.5 p -164.69 117.09 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.828 0.347 . . . . 0.0 111.552 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -85.48 157.19 20.51 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.974 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -63.55 -31.82 73.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.121 0.486 . . . . 0.0 109.868 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -45.28 -46.68 11.05 Favored Glycine 0 C--N 1.331 0.304 0 CA-C-N 115.551 -0.749 . . . . 0.0 113.002 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.67 -46.24 91.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.846 0.355 . . . . 0.0 110.821 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.57 -59.36 5.56 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.619 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.586 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 34.8 t80 -50.02 -34.6 21.8 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 112.84 0.681 . . . . 0.0 112.84 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.594 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 1.8 tt0 -79.71 -32.24 41.28 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.237 -177.01 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.648 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.3 OUTLIER -76.24 -31.76 58.52 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.443 0.64 . . . . 0.0 109.295 179.503 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.1 ttt180 -77.16 -60.58 2.3 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 114.847 -1.07 . . . . 0.0 111.61 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.594 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -63.18 -54.53 36.12 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 113.056 0.761 . . . . 0.0 113.056 -178.03 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.45 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.5 m -58.93 -36.05 74.11 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.514 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.648 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -53.4 -49.54 67.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.04 0.448 . . . . 0.0 110.645 178.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 -33.87 28.66 Favored Glycine 0 C--N 1.33 0.229 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.449 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.52 HD12 ' HD1' ' A' ' 26' ' ' TYR . 5.2 mt -74.99 -29.59 22.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.746 0.308 . . . . 0.0 110.773 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.439 ' N ' ' O ' ' A' ' 27' ' ' THR . 37.9 t-20 -71.79 -49.14 41.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.038 0.447 . . . . 0.0 110.353 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.3 m -54.78 -45.17 74.24 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.524 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.455 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -48.43 -35.42 12.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.02 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 38' ' ' ALA . 3.0 t -70.66 -61.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.412 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -48.29 -58.44 4.57 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.49 -58.39 13.38 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.693 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.455 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 53.5 t -59.36 -22.25 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.617 0.246 . . . . 0.0 110.666 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.448 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -75.26 -26.65 58.98 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.276 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.9 p -74.1 -45.06 51.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.152 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -72.91 -50.75 12.3 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.646 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 179.04 82.7 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 121.279 0.562 . . . . 0.0 111.144 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.08 26.41 24.02 Favored Glycine 0 C--N 1.317 -0.524 0 CA-C-N 115.144 -0.934 . . . . 0.0 112.66 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 96.9 p -108.45 30.54 6.35 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.671 0.272 . . . . 0.0 111.339 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.616 ' O ' HG23 ' A' ' 44' ' ' ILE . 6.6 tp -178.21 69.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.96 0.41 . . . . 0.0 111.216 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -179.72 32.99 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.619 179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 69.5 mtt180 -100.42 54.97 0.89 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.923 0.392 . . . . 0.0 110.689 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -132.9 91.97 27.5 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.694 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo . . . . . 0 C--O 1.249 1.054 0 C-N-CA 122.498 2.132 . . . . 0.0 112.159 179.74 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.52 ' O ' HG12 ' A' ' 1' ' ' VAL . 39.7 t . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.468 ' O ' ' HB2' ' A' ' 3' ' ' TYR . 4.3 p-10 -80.01 -36.53 35.77 Favored 'General case' 0 C--N 1.333 -0.136 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 179.374 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.468 ' HB2' ' O ' ' A' ' 2' ' ' ASN . 46.6 m-85 68.9 86.63 0.13 Allowed 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -177.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -156.16 61.77 0.34 Allowed Glycine 0 C--N 1.333 0.416 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.938 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -162.74 -64.82 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.955 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.481 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -167.87 -56.14 0.03 OUTLIER Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.499 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.435 HG21 ' HD1' ' A' ' 3' ' ' TYR . 21.8 t 62.98 -64.82 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 111.903 0.334 . . . . 0.0 111.903 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.481 ' N ' ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER 48.48 92.1 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 120.866 0.365 . . . . 0.0 110.99 -179.738 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.7 m 54.55 89.05 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.238 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.6 t -81.15 71.34 8.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.383 179.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 55.17 41.86 31.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.569 -179.316 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.581 HG22 ' HG2' ' A' ' 13' ' ' LYS . 41.6 m -88.95 -84.16 0.22 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.959 178.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.581 ' HG2' HG22 ' A' ' 12' ' ' THR . 2.8 pttt -158.37 38.63 0.24 Allowed 'General case' 0 C--O 1.233 0.222 0 C-N-CA 120.983 -0.287 . . . . 0.0 111.576 179.193 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.7 m -89.42 164.27 14.92 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.749 0.309 . . . . 0.0 111.779 179.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 47.5 m -119.49 -11.4 9.49 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 16' ' ' VAL . 12.4 p -163.65 99.9 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.757 0.789 . . . . 0.0 110.65 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.423 ' OD1' ' N ' ' A' ' 17' ' ' ASN . 6.4 p-10 -135.39 139.95 44.6 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.135 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -50.09 -28.25 6.91 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.043 0.449 . . . . 0.0 111.136 -179.551 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.58 -65.21 3.09 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.896 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 20.2 mm-40 -70.76 -33.05 70.39 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -179.139 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.94 -70.04 0.14 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.003 0.43 . . . . 0.0 110.731 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.599 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.2 t80 -54.89 -34.02 62.59 Favored 'General case' 0 C--O 1.22 -0.496 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.646 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -76.94 -39.04 52.1 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.03 0.443 . . . . 0.0 110.537 -177.874 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 6.4 tp10 -68.08 -28.37 67.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.7 ttt-85 -80.61 -55.21 5.0 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.429 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.646 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -76.66 -55.09 5.82 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -177.948 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.0 m -54.8 -32.57 60.41 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.244 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.458 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -66.15 -50.77 62.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.536 179.038 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.87 -41.38 82.81 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.822 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.516 HG22 ' O ' ' A' ' 26' ' ' TYR . 10.4 tp -70.84 -42.99 77.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.93 0.395 . . . . 0.0 111.001 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.466 ' N ' HG23 ' A' ' 30' ' ' ILE . 37.9 t-20 -62.6 -43.72 98.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.414 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.4 m -59.3 -37.66 78.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.876 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.477 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.28 -35.29 73.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.883 179.853 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.0 t -72.55 -62.04 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.57 -178.453 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 72.2 m -47.77 -57.65 5.32 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.408 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.21 -51.26 57.07 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.16 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 33' ' ' PHE . 53.3 t -64.24 -25.36 37.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.63 0.252 . . . . 0.0 110.513 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -79.64 -24.07 42.12 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.421 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.43 -48.72 18.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.283 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -90.94 -27.94 17.32 Favored Glycine 0 CA--C 1.518 0.268 0 C-N-CA 120.661 -0.78 . . . . 0.0 113.166 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 65.91 74.89 0.35 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 121.352 0.596 . . . . 0.0 110.948 -179.504 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -113.28 37.99 3.39 Favored Glycine 0 C--N 1.319 -0.373 0 CA-C-N 115.106 -0.952 . . . . 0.0 112.617 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 32.9 p -106.72 9.76 31.08 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 111.599 0.222 . . . . 0.0 111.599 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.4 pt -123.49 -11.02 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 112.022 0.379 . . . . 0.0 112.022 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 89.54 -26.87 8.48 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.184 -179.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 66.13 118.76 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.495 0.188 . . . . 0.0 110.705 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 61.1 mtm180 -151.28 154.66 34.03 Favored Pre-proline 0 N--CA 1.464 0.273 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.446 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 C--O 1.251 1.148 0 C-N-CA 122.372 2.048 . . . . 0.0 112.217 -179.746 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.1 m . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -161.1 -45.12 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.868 0.366 . . . . 0.0 111.413 -179.435 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 14.9 p90 -80.59 -36.06 33.31 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.076 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 53.65 71.37 0.71 Allowed Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.983 -0.627 . . . . 0.0 113.274 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 62.1 37.65 14.43 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.764 0.316 . . . . 0.0 110.811 179.326 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -135.99 34.83 2.21 Favored Glycine 0 C--N 1.33 0.233 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.282 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.585 HG13 ' O ' ' A' ' 7' ' ' VAL . 10.9 p -88.28 110.34 20.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.66 0.267 . . . . 0.0 110.594 179.35 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 10.2 t -149.12 106.48 3.63 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.045 0.45 . . . . 0.0 110.662 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 37.7 t -155.49 103.91 2.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.324 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.9 m -163.59 92.28 0.7 Allowed 'General case' 0 N--CA 1.463 0.203 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER 75.34 8.73 3.86 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.255 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.65 158.48 44.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.976 0.417 . . . . 0.0 110.774 -179.467 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 68.6 -69.38 0.15 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.966 -179.576 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 4.0 m -71.06 91.4 0.89 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.37 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 62.96 176.39 0.15 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.358 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.584 ' O ' HG13 ' A' ' 16' ' ' VAL . 14.1 p -163.88 111.13 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.362 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.471 ' HB3' ' CE3' ' A' ' 18' ' ' TRP . 13.1 t30 -70.23 152.44 44.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.125 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.51 ' O ' ' CD1' ' A' ' 18' ' ' TRP . 6.6 p90 49.13 27.32 1.73 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.86 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.34 -46.05 4.5 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.568 -0.825 . . . . 0.0 111.505 179.192 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -68.04 -38.35 82.41 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.683 0.278 . . . . 0.0 111.262 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -73.12 -53.71 10.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.617 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.644 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 30.1 t80 -56.48 -28.54 60.03 Favored 'General case' 0 CA--C 1.509 -0.605 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.71 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.5 tt0 -77.23 -43.45 33.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 121.117 0.484 . . . . 0.0 110.068 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.401 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 40.1 tt0 -66.99 -29.49 69.33 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.832 178.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.48 -53.23 7.08 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.514 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.71 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.08 -55.75 5.42 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.066 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.8 m -55.34 -27.9 50.21 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.96 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.401 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -70.82 -51.99 23.3 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.892 0.377 . . . . 0.0 111.253 179.305 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.91 -44.13 56.49 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.896 -179.486 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.671 ' O ' HG23 ' A' ' 34' ' ' VAL . 2.5 tp -63.28 -44.01 98.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.968 0.414 . . . . 0.0 111.691 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.463 ' N ' HG23 ' A' ' 30' ' ' ILE . 36.0 t-20 -57.31 -49.21 76.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.858 0.361 . . . . 0.0 110.558 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 39.6 p -59.07 -41.07 87.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.072 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -57.08 -36.57 70.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.97 0.414 . . . . 0.0 110.808 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.671 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.5 t -62.42 -59.55 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.142 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.4 m -49.31 -47.2 47.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.197 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.3 -44.91 93.27 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.421 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.4 m -78.62 -25.88 13.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.818 0.342 . . . . 0.0 110.842 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -71.33 -24.85 62.19 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.809 -179.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -59.61 -27.49 66.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.375 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -121.77 -44.64 0.37 Allowed Glycine 0 C--N 1.33 0.221 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.824 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 178.95 83.63 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.318 0.58 . . . . 0.0 110.891 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.81 -16.18 73.46 Favored Glycine 0 C--N 1.318 -0.459 0 CA-C-N 115.23 -0.895 . . . . 0.0 113.666 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.0 m -67.22 -75.07 0.1 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 117.015 0.407 . . . . 0.0 110.787 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.58 ' O ' HG22 ' A' ' 44' ' ' ILE . 16.6 mt 66.77 11.75 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.222 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 55.4 14.49 6.62 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.736 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.8 tmm_? -116.28 122.84 46.12 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.861 0.362 . . . . 0.0 111.334 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.66 98.86 2.64 Favored Pre-proline 0 CA--C 1.53 0.178 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.872 179.733 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 C--O 1.249 1.071 0 C-N-CA 122.412 2.075 . . . . 0.0 112.261 179.744 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 1.532 ' CG1' HG12 ' A' ' 7' ' ' VAL . 6.7 p . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 1.099 ' H ' ' CG2' ' A' ' 1' ' ' VAL . 14.0 t30 -160.44 28.09 0.16 Allowed 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.249 0.547 . . . . 0.0 110.047 -178.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.804 ' HD2' HG11 ' A' ' 1' ' ' VAL . 5.3 m-85 -80.78 -52.69 7.23 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.065 -179.283 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 90.49 12.23 61.42 Favored Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.984 -0.626 . . . . 0.0 113.24 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -162.33 39.34 0.12 Allowed 'General case' 0 C--O 1.233 0.205 0 CA-C-O 121.124 0.488 . . . . 0.0 111.163 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 131.19 89.24 0.48 Allowed Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.927 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.532 HG12 ' CG1' ' A' ' 1' ' ' VAL . 19.9 m -87.34 -26.33 5.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.689 0.281 . . . . 0.0 111.1 -179.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.3 m -96.0 74.09 3.02 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.922 0.391 . . . . 0.0 110.52 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -176.74 131.37 0.19 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.565 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 m -76.9 79.39 3.47 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.131 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 4.0 mmmm 48.08 20.42 0.25 Allowed 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.859 -179.202 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.7 p -92.79 -24.64 18.47 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.3 mttp 80.25 -6.65 1.7 Allowed 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.764 0.426 . . . . 0.0 111.61 -178.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.0 m 69.1 -70.35 0.14 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.939 0.4 . . . . 0.0 111.515 179.172 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.8 m -57.34 -167.51 0.0 OUTLIER 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.73 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 16.3 t 81.15 -70.61 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.768 179.58 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.6 p30 173.36 -33.31 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.234 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -39.18 -33.99 0.16 Allowed 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.123 -178.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.09 -44.63 87.19 Favored Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.695 -0.764 . . . . 0.0 113.559 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -62.74 -38.21 89.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.919 0.39 . . . . 0.0 111.242 -179.091 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -67.64 -51.19 52.92 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.551 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -52.68 -41.99 64.36 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.633 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 3.5 tm0? -65.92 -42.09 90.58 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.897 0.379 . . . . 0.0 111.106 -177.358 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -70.45 -30.07 66.8 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.307 0.575 . . . . 0.0 110.161 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -80.03 -54.05 6.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.513 -0.767 . . . . 0.0 111.504 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.633 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.86 -55.83 6.82 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -178.016 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.551 ' HA ' HG22 ' A' ' 30' ' ' ILE . 2.3 m -55.98 -32.28 63.77 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 120.694 -0.402 . . . . 0.0 110.807 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.41 -32.85 68.87 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.705 179.005 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.84 -42.82 8.0 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.632 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.551 HG22 ' HA ' ' A' ' 27' ' ' THR . 4.0 tp -68.87 -36.12 72.62 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.598 0.713 . . . . 0.0 110.863 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -77.3 -38.03 51.46 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.082 0.467 . . . . 0.0 109.901 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 47.2 t -66.68 -30.79 71.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.478 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.47 -40.67 87.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.865 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.537 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.3 t -65.98 -61.99 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.472 179.344 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -55.37 -34.71 64.55 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.49 -45.86 93.84 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.293 179.214 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.537 HG22 ' O ' ' A' ' 34' ' ' VAL . 31.3 m -76.8 -27.63 16.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-O 121.119 0.485 . . . . 0.0 110.055 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -79.09 -23.05 44.39 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.289 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.9 t -79.81 -43.76 21.83 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.355 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.595 ' O ' ' HB3' ' A' ' 41' ' ' ALA . . . -174.53 -43.5 0.05 OUTLIER Glycine 0 CA--C 1.52 0.367 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.587 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.595 ' HB3' ' O ' ' A' ' 40' ' ' GLY . . . 83.37 -9.55 1.04 Allowed 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 179.484 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.13 28.62 53.27 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.384 -0.912 . . . . 0.0 113.047 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 19.1 m -104.03 -65.31 1.03 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.885 0.374 . . . . 0.0 110.816 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.0 tt -155.62 33.56 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.442 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -114.21 28.95 7.97 Favored Glycine 0 C--N 1.331 0.267 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.232 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -173.55 39.36 0.01 OUTLIER 'General case' 0 C--O 1.235 0.316 0 CA-C-O 120.667 0.27 . . . . 0.0 111.007 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 34.0 ptt85 42.24 85.67 0.16 Allowed Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.375 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo . . . . . 0 C--O 1.249 1.065 0 C-N-CA 122.223 1.949 . . . . 0.0 112.182 179.123 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.659 HG12 ' N ' ' A' ' 2' ' ' ASN . 77.4 t . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.659 ' N ' HG12 ' A' ' 1' ' ' VAL . 1.4 t30 71.11 -69.04 0.19 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.394 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 26.5 p90 -80.45 -179.33 7.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.419 -179.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 113.82 63.09 0.42 Allowed Glycine 0 CA--C 1.512 -0.112 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -178.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.47 -42.42 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.507 0.194 . . . . 0.0 111.412 -179.05 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -162.22 55.22 0.3 Allowed Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.828 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 m -89.4 22.92 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.9 m 60.81 95.34 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.675 0.274 . . . . 0.0 110.755 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -71.58 137.62 48.15 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.869 0.366 . . . . 0.0 110.411 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.54 17.7 14.24 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.411 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt -162.73 174.97 11.81 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-O 120.883 0.373 . . . . 0.0 110.896 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 49.3 p -89.5 26.0 1.82 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.982 -179.344 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.524 ' O ' ' HB2' ' A' ' 14' ' ' CYS . 12.6 tttt -158.5 -68.64 0.09 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.682 0.277 . . . . 0.0 110.366 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.524 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 62.9 m 74.31 66.25 0.08 Allowed 'General case' 0 CA--C 1.521 -0.163 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.1 m -121.67 -2.26 9.39 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.404 -0.817 . . . . 0.0 111.56 -179.169 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.581 HG12 ' H ' ' A' ' 19' ' ' GLY . 40.9 t -75.61 -54.01 14.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.716 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 63.36 -63.36 0.13 Allowed 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 178.702 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.439 ' N ' ' O ' ' A' ' 16' ' ' VAL . 4.7 p90 -67.6 -15.31 63.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -177.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.581 ' H ' HG12 ' A' ' 16' ' ' VAL . . . -51.96 -57.11 13.58 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.89 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -64.06 -26.47 68.57 Favored 'General case' 0 C--N 1.33 -0.254 0 O-C-N 122.717 -0.284 . . . . 0.0 111.614 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.5 -69.67 0.19 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.571 0.224 . . . . 0.0 110.817 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.532 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.3 t80 -56.09 -35.26 66.81 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.047 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.684 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 40.0 mt-30 -73.99 -34.09 64.07 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 123.144 0.277 . . . . 0.0 111.099 -177.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.422 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 32.9 tt0 -75.74 -30.24 59.15 Favored 'General case' 0 C--N 1.33 -0.264 0 O-C-N 123.732 0.645 . . . . 0.0 109.946 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.2 ttt-85 -80.65 -57.9 3.36 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.114 -0.948 . . . . 0.0 111.096 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.684 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -65.64 -57.74 7.4 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.239 -0.892 . . . . 0.0 113.378 -178.105 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.515 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.3 m -56.84 -44.95 82.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.785 0.326 . . . . 0.0 111.27 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.422 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -52.27 -43.42 64.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.457 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.44 -51.51 8.35 Favored Glycine 0 CA--C 1.52 0.377 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.872 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.521 HG23 ' N ' ' A' ' 31' ' ' ASN . 9.8 tp -65.53 -46.15 90.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.018 0.437 . . . . 0.0 111.714 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.521 ' N ' HG23 ' A' ' 30' ' ' ILE . 1.1 t30 -63.04 -38.25 90.44 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.956 0.408 . . . . 0.0 110.199 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.5 m -57.14 -37.37 71.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.237 178.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.84 -37.82 77.34 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.106 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.571 ' O ' HG22 ' A' ' 37' ' ' VAL . 2.8 t -68.92 -63.08 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.732 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.5 m -47.9 -39.52 19.15 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.013 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.18 -50.31 69.05 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.592 179.376 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.571 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.0 m -72.14 -29.33 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.177 0.513 . . . . 0.0 109.982 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -71.25 -22.58 61.96 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.129 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 54.2 m -55.94 -26.16 46.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.576 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 169.01 34.14 0.02 OUTLIER Glycine 0 CA--C 1.52 0.353 0 C-N-CA 119.637 -1.268 . . . . 0.0 114.358 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 37' ' ' VAL . . . -80.27 -31.95 38.26 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 117.49 0.645 . . . . 0.0 110.74 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 129.94 61.23 0.1 Allowed Glycine 0 C--N 1.331 0.281 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.325 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 58.2 p -173.06 77.05 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.917 0.389 . . . . 0.0 110.706 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.533 ' O ' HG23 ' A' ' 44' ' ' ILE . 1.0 OUTLIER -154.58 59.87 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.683 179.951 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 179.0 39.8 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.115 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.4 ' O ' ' O ' ' A' ' 47' ' ' ARG . 0.2 OUTLIER 58.76 -173.0 0.1 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.464 0.173 . . . . 0.0 110.574 -179.687 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.4 ' O ' ' O ' ' A' ' 46' ' ' ARG . 22.8 ptt85 44.9 101.17 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.859 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo . . . . . 0 C--O 1.249 1.034 0 C-N-CA 122.345 2.03 . . . . 0.0 112.353 179.767 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.915 HG22 ' O ' ' A' ' 1' ' ' VAL . 1.4 p . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 6.4 p-10 -160.78 69.5 0.37 Allowed 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.821 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -80.48 141.87 34.78 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.41 112.29 0.69 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.039 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 79.61 71.6 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.656 0.265 . . . . 0.0 110.45 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.67 83.43 1.0 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.894 -179.368 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.414 ' O ' HG23 ' A' ' 7' ' ' VAL . 12.3 m -88.25 107.63 17.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.223 0.535 . . . . 0.0 111.232 -179.693 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -178.87 68.67 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.181 -179.517 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.1 76.9 1.39 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.572 -179.562 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.601 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 25.4 p -98.05 148.22 23.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.971 -179.524 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.601 ' HB2' ' O ' ' A' ' 10' ' ' SER . 0.9 OUTLIER 77.63 129.24 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.491 -179.658 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.609 HG22 ' H ' ' A' ' 13' ' ' LYS . 2.3 m 60.0 176.83 0.09 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.457 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.609 ' H ' HG22 ' A' ' 12' ' ' THR . 2.6 tptt -81.08 161.86 23.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.162 179.6 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 3.4 t -107.39 115.61 30.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.931 0.396 . . . . 0.0 111.352 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.616 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.9 OUTLIER -85.11 -167.84 1.99 Allowed 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.664 179.669 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.616 HG23 ' C ' ' A' ' 15' ' ' SER . 2.2 t 81.01 90.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.209 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 49.1 m-20 -123.04 31.48 6.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.29 0.567 . . . . 0.0 110.45 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.405 ' O ' ' N ' ' A' ' 22' ' ' PHE . 0.6 OUTLIER -41.5 -29.56 0.17 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.223 -0.898 . . . . 0.0 112.118 -179.796 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.56 -60.69 3.16 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.871 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 mm-40 -71.53 -38.04 71.1 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.719 0.295 . . . . 0.0 111.482 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -65.51 -67.78 0.41 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.333 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.722 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 60.3 t80 -51.05 -30.14 14.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.606 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.9 tt0 -81.6 -35.67 29.85 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 111.941 0.349 . . . . 0.0 111.941 -177.32 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.555 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.0 OUTLIER -76.18 -25.19 54.95 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.673 0.749 . . . . 0.0 109.086 -179.504 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.51 -59.09 2.89 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.111 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.722 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -68.11 -57.74 5.6 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 113.164 0.801 . . . . 0.0 113.164 -178.789 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.491 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 0.7 OUTLIER -53.79 -36.69 62.71 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.661 -179.756 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.555 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -55.81 -51.51 67.22 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.677 0.275 . . . . 0.0 110.647 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.79 -36.68 46.99 Favored Glycine 0 C--N 1.332 0.32 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.178 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 38.1 mm -70.2 -42.03 78.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 110.288 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -62.48 -39.74 94.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.054 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -55.3 -48.7 73.72 Favored 'General case' 0 CA--C 1.519 -0.221 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.332 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.518 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -44.68 -38.58 4.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.194 179.217 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.486 ' O ' ' N ' ' A' ' 38' ' ' ALA . 2.7 t -69.25 -64.21 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.34 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.404 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.6 m -45.56 -56.11 5.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.826 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.85 -54.03 35.95 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.499 -0.858 . . . . 0.0 111.835 179.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 33' ' ' PHE . 58.8 t -64.62 -19.16 24.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.715 0.293 . . . . 0.0 110.719 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -78.56 -25.55 45.41 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.027 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.9 t -64.49 -43.61 93.59 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.366 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -80.57 -54.86 3.57 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.764 -0.732 . . . . 0.0 111.908 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 60.81 19.5 9.69 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.811 0.338 . . . . 0.0 111.712 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -158.37 31.41 0.48 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.614 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.45 28.11 3.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.671 0.272 . . . . 0.0 110.929 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.0 mt 72.64 79.87 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.97 0.414 . . . . 0.0 111.048 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -161.64 38.13 0.39 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.287 179.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -160.34 98.75 1.29 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.937 0.399 . . . . 0.0 110.8 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -139.84 153.67 70.04 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.646 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo . . . . . 0 C--O 1.248 1.014 0 C-N-CA 122.404 2.069 . . . . 0.0 112.099 -179.801 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.841 HG12 ' O ' ' A' ' 1' ' ' VAL . 71.7 t . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -78.89 164.66 24.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.927 0.394 . . . . 0.0 110.856 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -157.3 38.41 0.29 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.486 0.66 . . . . 0.0 109.27 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -133.9 52.86 0.8 Allowed Glycine 0 C--O 1.228 -0.263 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.039 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -161.55 -49.19 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.48 0.657 . . . . 0.0 109.974 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.04 86.06 0.07 OUTLIER Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.608 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.5 p -149.46 138.16 14.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.0 t -122.17 55.68 1.13 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.441 -178.245 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 52.7 t -153.5 125.98 8.12 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.775 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 t -93.17 -68.84 0.78 Allowed 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.404 ' O ' ' N ' ' A' ' 13' ' ' LYS . 13.6 pttm -162.77 170.81 17.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.227 179.166 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER 64.6 -65.11 0.14 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.507 179.397 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.404 ' N ' ' O ' ' A' ' 11' ' ' LYS . 8.5 mttp -81.05 86.2 6.17 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.764 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -166.56 42.41 0.06 Allowed 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.369 179.029 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.8 m -155.37 131.23 9.97 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.224 0.535 . . . . 0.0 111.481 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.2 p -165.0 130.21 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.651 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -107.36 135.78 48.28 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.732 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 2.5 t-105 54.13 34.97 21.26 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.905 0.383 . . . . 0.0 110.783 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -113.78 -43.5 0.8 Allowed Glycine 0 C--N 1.33 0.237 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.261 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -71.05 -34.72 71.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.891 0.377 . . . . 0.0 110.726 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.73 -59.14 3.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.301 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.674 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 24.1 t80 -53.64 -30.8 44.64 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.725 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 29.5 tt0 -76.95 -39.87 49.1 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.769 -177.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.502 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 3.2 tp10 -71.52 -31.7 67.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.908 179.099 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.92 -54.14 6.96 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.509 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.725 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.21 -58.41 3.57 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -177.884 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.7 m -54.13 -31.66 52.97 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.579 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -64.68 -45.76 85.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.495 -0.321 . . . . 0.0 111.024 178.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.27 -43.78 12.54 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.05 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.476 ' O ' HG23 ' A' ' 34' ' ' VAL . 46.7 mm -62.33 -36.28 73.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.369 0.604 . . . . 0.0 110.442 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -67.67 -44.05 78.76 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -62.49 -37.87 87.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.992 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.513 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -55.7 -39.73 71.43 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.016 0.436 . . . . 0.0 109.987 179.625 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.506 ' O ' HG22 ' A' ' 37' ' ' VAL . 4.0 t -59.81 -59.17 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.893 178.731 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -57.37 -42.02 81.3 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.25 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.4 -43.17 95.91 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.954 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 33' ' ' PHE . 27.0 m -79.72 -27.22 12.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.106 0.479 . . . . 0.0 110.403 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -76.2 -24.92 54.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.26 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -75.16 -47.5 28.14 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.087 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.7 39.92 0.23 Allowed Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.929 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 60.4 24.19 13.73 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.884 0.373 . . . . 0.0 111.606 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -54.82 -63.72 5.0 Favored Glycine 0 C--N 1.321 -0.305 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.727 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.3 t 62.83 66.43 0.75 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.893 0.378 . . . . 0.0 110.782 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.572 ' O ' HG22 ' A' ' 44' ' ' ILE . 11.6 mt -106.12 43.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.139 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -114.55 31.46 6.37 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.767 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.1 mmp_? -133.22 175.59 9.26 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.533 0.206 . . . . 0.0 110.666 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.2 mtp180 -140.01 55.02 5.98 Favored Pre-proline 0 N--CA 1.463 0.176 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.986 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo . . . . . 0 C--O 1.248 1.012 0 C-N-CA 122.444 2.096 . . . . 0.0 112.346 179.847 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.835 HG22 ' O ' ' A' ' 1' ' ' VAL . 0.3 OUTLIER . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.0 m-80 -80.17 68.46 6.32 Favored 'General case' 0 C--N 1.34 0.155 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.148 178.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.25 70.25 6.85 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.967 -0.293 . . . . 0.0 110.224 -179.459 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -124.1 43.61 1.39 Allowed Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.695 -0.764 . . . . 0.0 113.257 -179.466 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 29.5 t30 64.28 47.42 3.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.873 0.368 . . . . 0.0 110.731 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 170.29 55.67 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.76 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.7 p -89.18 -37.06 9.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.702 0.287 . . . . 0.0 110.995 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.3 t 64.4 101.02 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.812 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.3 m -93.11 172.31 8.39 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.839 0.352 . . . . 0.0 111.037 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -129.29 28.13 5.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.181 -0.463 . . . . 0.0 112.075 -179.478 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 5.1 tttm -163.3 -174.8 3.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.966 0.412 . . . . 0.0 111.142 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.2 p -88.98 -42.1 11.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.66 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.7 mtpt -81.24 -63.42 1.4 Allowed 'General case' 0 C--N 1.334 -0.099 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.892 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 55.98 54.54 7.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.028 0.442 . . . . 0.0 110.759 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.3 t -75.26 -149.53 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.023 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.617 ' O ' HG13 ' A' ' 16' ' ' VAL . 8.7 p -164.24 108.98 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-O 120.88 0.372 . . . . 0.0 110.597 -179.806 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 71.4 m-80 -121.68 -43.33 2.38 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.337 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -100.17 35.06 2.16 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.084 0.469 . . . . 0.0 110.569 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.41 -60.98 0.85 Allowed Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.936 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -66.49 -36.98 84.07 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.85 0.357 . . . . 0.0 111.304 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.45 -64.84 0.82 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.151 -0.477 . . . . 0.0 112.018 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.651 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.6 t80 -52.54 -32.24 39.79 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 -178.07 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.691 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.8 tt0 -77.92 -36.4 49.45 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.745 -177.322 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.405 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.3 tp10 -75.05 -29.82 60.86 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.274 0.559 . . . . 0.0 109.538 179.155 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt85 -78.73 -52.36 8.5 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.12 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.691 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.05 -57.32 3.97 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.205 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.1 m -56.03 -20.48 16.97 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.102 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -79.49 -48.9 13.12 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.964 0.412 . . . . 0.0 110.075 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.83 -45.31 27.95 Favored Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.284 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.696 ' O ' HG23 ' A' ' 34' ' ' VAL . 50.5 mm -60.49 -45.44 96.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.778 0.323 . . . . 0.0 110.72 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -61.26 -37.07 81.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.776 0.322 . . . . 0.0 110.81 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.5 t -69.11 -38.88 79.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.793 0.33 . . . . 0.0 110.755 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.498 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.42 -34.45 72.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.208 0.528 . . . . 0.0 110.457 179.54 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.696 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.7 t -69.28 -61.81 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.785 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 52.4 m -47.12 -57.49 5.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.28 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.42 -48.69 78.85 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.011 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 33' ' ' PHE . 52.5 t -67.43 -21.83 28.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.765 0.317 . . . . 0.0 110.739 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.434 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -78.18 -25.9 47.37 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.502 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 30.7 t -72.61 -34.72 67.55 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.286 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.83 51.98 0.19 Allowed Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.65 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -91.62 -32.03 15.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.939 0.4 . . . . 0.0 111.159 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -168.87 -61.49 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.0 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.9 p 52.03 58.93 4.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.924 0.392 . . . . 0.0 111.42 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.527 ' O ' HG23 ' A' ' 44' ' ' ILE . 2.9 tt -166.83 60.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.131 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -125.89 -38.19 0.48 Allowed Glycine 0 C--N 1.328 0.137 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.944 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 ttm-85 -179.81 99.34 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.78 0.324 . . . . 0.0 110.358 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.446 ' N ' ' CD ' ' A' ' 48' ' ' PRO . 44.6 mtp85 -64.03 -48.39 77.92 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.029 -179.661 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.446 ' CD ' ' N ' ' A' ' 47' ' ' ARG . 63.8 Cg_exo . . . . . 0 C--O 1.249 1.064 0 C-N-CA 122.284 1.989 . . . . 0.0 112.218 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.765 ' O ' HG23 ' A' ' 1' ' ' VAL . 2.4 m . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -79.96 67.82 5.88 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 113.405 0.891 . . . . 0.0 113.405 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -82.08 -37.19 26.73 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 179.733 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.52 150.09 6.01 Favored Glycine 0 CA--C 1.524 0.636 0 C-N-CA 120.928 -0.653 . . . . 0.0 113.732 -178.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 53.37 67.45 1.0 Allowed 'General case' 0 C--O 1.233 0.221 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 152.66 -24.74 0.84 Allowed Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.105 -1.045 . . . . 0.0 114.038 178.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 7' ' ' VAL . 2.9 m -150.25 98.41 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.4 m -149.05 113.25 5.21 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.229 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 29.9 p -119.74 176.46 5.38 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.476 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.4 m -56.12 -23.81 36.72 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.233 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 81.53 -1.72 1.64 Allowed 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.09 -179.386 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.553 HG23 ' N ' ' A' ' 13' ' ' LYS . 8.9 t -88.79 -61.63 1.66 Allowed 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.432 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.553 ' N ' HG23 ' A' ' 12' ' ' THR . 0.0 OUTLIER -82.85 17.29 1.93 Allowed 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 179.269 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.6 m -102.07 137.16 40.71 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.194 0.521 . . . . 0.0 112.125 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.468 ' O ' ' CG2' ' A' ' 16' ' ' VAL . 0.4 OUTLIER 61.5 -177.56 0.12 Allowed 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.982 -179.426 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.468 ' CG2' ' O ' ' A' ' 15' ' ' SER . 22.0 t -162.32 113.61 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.356 0.598 . . . . 0.0 111.434 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.4 t30 -127.75 -49.27 1.37 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.32 178.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -116.58 32.14 6.31 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.34 178.358 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -104.05 -43.58 1.75 Allowed Glycine 0 C--N 1.331 0.282 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.735 179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -65.2 -44.1 89.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.944 0.402 . . . . 0.0 110.349 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -65.05 -69.77 0.27 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 178.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.65 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.4 t80 -51.67 -30.75 23.07 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -178.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.728 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.2 tt0 -76.45 -47.48 22.9 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 117.969 0.35 . . . . 0.0 110.762 -178.109 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.45 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 2.5 tm-20 -64.8 -27.52 68.94 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.444 0.64 . . . . 0.0 109.521 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.31 -52.73 7.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.86 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.728 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -77.74 -56.6 4.37 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -178.86 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.52 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.8 m -53.37 -23.46 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.857 179.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.45 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -74.52 -52.64 11.33 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.892 0.377 . . . . 0.0 110.484 178.79 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.05 -42.15 59.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.611 -0.805 . . . . 0.0 112.426 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.453 ' O ' HG23 ' A' ' 34' ' ' VAL . 48.1 mm -62.11 -46.35 96.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.122 0.486 . . . . 0.0 111.436 -179.293 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -56.99 -48.0 79.48 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.925 0.393 . . . . 0.0 110.568 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.3 t -60.72 -36.69 79.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.506 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -57.66 -38.71 75.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.983 0.421 . . . . 0.0 110.43 179.802 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.546 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.0 t -61.45 -62.49 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.305 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.5 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.2 m -54.83 -38.89 67.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -61.93 -41.64 99.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.749 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.546 HG22 ' O ' ' A' ' 34' ' ' VAL . 29.7 m -80.2 -27.21 11.91 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-O 121.027 0.441 . . . . 0.0 110.221 179.487 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -80.15 -20.97 43.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.531 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 47.2 p -75.43 -39.23 59.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.471 -0.332 . . . . 0.0 111.407 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.54 -44.69 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.434 -0.889 . . . . 0.0 112.926 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -145.35 -59.35 0.34 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.612 0.244 . . . . 0.0 111.352 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 67.65 43.9 83.63 Favored Glycine 0 C--N 1.33 0.234 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.831 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.2 p -91.58 -29.51 16.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.652 0.263 . . . . 0.0 111.127 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.681 ' N ' HD13 ' A' ' 44' ' ' ILE . 0.2 OUTLIER -152.18 63.77 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.954 0.407 . . . . 0.0 111.102 179.922 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -95.78 -44.11 3.2 Favored Glycine 0 CA--C 1.518 0.275 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.692 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.2 mmt-85 -113.23 -31.62 6.55 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.625 0.25 . . . . 0.0 111.413 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.3 mtt85 -96.57 108.73 44.31 Favored Pre-proline 0 CA--C 1.531 0.241 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.625 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 C--O 1.25 1.076 0 C-N-CA 122.105 1.87 . . . . 0.0 112.137 179.714 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.79 HG12 ' O ' ' A' ' 1' ' ' VAL . 53.9 t . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 32.7 p-10 -79.15 116.21 19.29 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -82.03 173.19 12.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.872 0.368 . . . . 0.0 111.223 178.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 162.65 -158.28 30.43 Favored Glycine 0 C--O 1.227 -0.294 0 C-N-CA 121.007 -0.616 . . . . 0.0 111.812 179.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -77.1 -36.54 55.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.873 0.368 . . . . 0.0 111.294 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -60.62 -28.34 67.65 Favored Glycine 0 CA--C 1.522 0.503 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.418 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 7' ' ' VAL . 10.9 m -88.21 84.57 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 117.299 0.55 . . . . 0.0 110.952 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 30.6 t -136.61 73.07 1.44 Allowed 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.123 0.487 . . . . 0.0 111.397 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 53.3 t -166.59 82.59 0.26 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.135 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.5 m -72.14 -163.62 0.12 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.795 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 15.7 mmmt -76.85 -49.22 16.25 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 178.304 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.3 m -89.27 -47.9 7.74 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.436 178.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.645 ' O ' ' HB2' ' A' ' 14' ' ' CYS . 30.6 mtpt -80.85 115.66 20.45 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.241 -179.539 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.645 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 49.9 t 167.28 -46.43 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.719 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.4 p -139.9 128.21 22.62 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-O 121.111 0.482 . . . . 0.0 111.128 179.341 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.624 ' O ' HG13 ' A' ' 16' ' ' VAL . 7.4 p -164.5 86.98 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.117 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 -63.85 -31.92 73.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.833 179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -88.17 27.23 1.24 Allowed 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.54 -0.3 . . . . 0.0 111.789 -179.529 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.54 -81.48 1.46 Allowed Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.97 -179.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.28 -26.52 68.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.726 0.298 . . . . 0.0 111.406 -179.373 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.29 -71.55 0.13 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.889 0.375 . . . . 0.0 111.101 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.583 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.7 t80 -53.55 -33.12 53.54 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -178.473 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.704 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 21.5 tt0 -76.38 -43.26 41.47 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.902 0.382 . . . . 0.0 110.81 -178.221 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.21 -33.23 75.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.439 0.638 . . . . 0.0 109.82 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.0 -54.35 6.11 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.57 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.704 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.37 -57.5 3.97 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -177.957 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.529 ' HA ' HG22 ' A' ' 30' ' ' ILE . 2.9 m -52.39 -33.53 43.86 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.98 -0.288 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.39 -47.77 75.2 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.736 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.08 -47.81 57.27 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.27 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.529 HG22 ' HA ' ' A' ' 27' ' ' THR . 17.7 tt -64.86 -36.46 77.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.21 0.528 . . . . 0.0 110.344 -179.77 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.423 ' ND2' HG22 ' A' ' 27' ' ' THR . 31.7 m-20 -57.71 -40.97 80.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.509 179.029 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.5 t -66.57 -36.98 83.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.118 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.41 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -58.55 -38.29 77.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.225 0.536 . . . . 0.0 110.328 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.504 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.2 t -62.59 -61.67 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.235 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 54.5 m -50.25 -56.11 12.54 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.369 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.11 -52.16 54.12 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.296 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.41 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 50.4 t -66.46 -21.19 28.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.706 0.288 . . . . 0.0 110.375 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -70.22 -32.33 70.16 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-O 120.919 0.39 . . . . 0.0 110.676 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 87.9 p -72.52 -31.92 65.72 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.857 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 130.81 -25.09 4.23 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.734 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.525 ' HB3' HD11 ' A' ' 44' ' ' ILE . . . -178.88 -71.42 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.821 0.343 . . . . 0.0 111.538 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -162.86 44.94 0.34 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.687 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.1 m 64.83 71.19 0.46 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.905 0.383 . . . . 0.0 111.06 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.525 HD11 ' HB3' ' A' ' 41' ' ' ALA . 3.9 mt -83.24 -66.59 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.19 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.01 -14.94 57.51 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.291 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 62.22 95.89 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.811 0.306 . . . . 0.0 110.841 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 20.1 mtm180 -91.79 125.18 58.21 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.771 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--O 1.249 1.042 0 C-N-CA 122.223 1.948 . . . . 0.0 112.12 179.899 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.891 HG12 ' O ' ' A' ' 1' ' ' VAL . 63.7 t . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -79.27 91.87 5.07 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 179.693 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -80.75 96.75 7.04 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 178.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -104.25 -80.57 1.42 Allowed Glycine 0 CA--C 1.521 0.414 0 C-N-CA 120.805 -0.712 . . . . 0.0 114.205 -178.19 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -161.23 53.69 0.27 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.228 0.537 . . . . 0.0 109.866 -178.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.31 67.43 0.27 Allowed Glycine 0 CA--C 1.51 -0.257 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.5 m -150.33 37.4 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.246 0.546 . . . . 0.0 110.096 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 11.7 p -176.93 40.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.245 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 15.7 t 55.17 31.8 17.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.128 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 38.6 m -74.67 -73.36 0.24 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.07 0.462 . . . . 0.0 109.865 179.198 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.89 -25.17 48.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.991 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 82.4 p -88.48 135.49 33.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.127 0.489 . . . . 0.0 111.72 -179.023 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -80.89 124.46 29.12 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.329 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.2 m -93.48 -38.18 11.55 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.934 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -147.29 139.13 24.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.656 0.741 . . . . 0.0 111.825 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.683 ' O ' HG13 ' A' ' 16' ' ' VAL . 14.5 p -76.61 103.46 3.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.08 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -141.97 112.25 7.01 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.691 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -58.45 -51.15 71.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.055 0.455 . . . . 0.0 110.263 -179.726 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.07 -50.05 40.68 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.948 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 6.9 mp0 -62.61 -55.39 27.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.594 0.235 . . . . 0.0 111.561 -179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -55.37 -61.63 2.21 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.709 0.29 . . . . 0.0 111.574 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.666 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 32.4 t80 -52.1 -33.51 39.91 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -178.575 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.742 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 14.7 tt0 -79.21 -39.76 32.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.025 0.44 . . . . 0.0 110.38 -178.494 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.521 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 3.5 mt-10 -65.4 -30.61 71.44 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 178.594 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.64 -56.93 4.05 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.573 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.742 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.4 OUTLIER -73.89 -58.04 3.57 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -178.184 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.6 m -51.01 -33.67 25.93 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.621 179.808 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -62.19 -55.2 30.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.118 0.485 . . . . 0.0 110.932 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.8 -35.74 61.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.182 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.654 ' O ' HG23 ' A' ' 34' ' ' VAL . 42.6 mm -70.85 -35.67 61.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.3 0.572 . . . . 0.0 111.181 -179.587 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.2 t-20 -61.51 -50.34 73.08 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.085 0.469 . . . . 0.0 109.821 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 86.2 p -57.28 -43.74 83.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.928 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -52.83 -39.34 62.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 110.681 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.6 t -58.66 -60.3 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.593 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -52.73 -42.29 64.74 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.735 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.06 -44.25 97.47 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.142 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.3 m -79.82 -24.95 12.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.913 0.387 . . . . 0.0 110.809 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -72.03 -25.7 61.91 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.693 -179.397 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 72.1 p -61.36 -28.03 68.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.247 179.736 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.85 37.02 6.52 Favored Glycine 0 CA--C 1.518 0.258 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.772 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -157.29 -72.08 0.1 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.676 0.274 . . . . 0.0 111.227 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 146.26 89.06 0.08 OUTLIER Glycine 0 N--CA 1.453 -0.188 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.327 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.6 m -61.07 -69.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.663 0.268 . . . . 0.0 111.481 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -58.82 -67.77 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.074 -179.501 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 55.15 25.23 38.7 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.81 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.65 -49.3 5.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.774 0.321 . . . . 0.0 110.804 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -136.7 155.12 76.86 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.664 179.617 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 C--O 1.249 1.025 0 C-N-CA 122.413 2.075 . . . . 0.0 112.342 -179.904 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.7 m . . . . . 0 N--CA 1.449 -0.522 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -160.87 26.65 0.14 Allowed 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -179.511 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.419 ' CD2' ' HA ' ' A' ' 7' ' ' VAL . 31.0 m-85 -80.1 174.81 11.22 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-O 120.41 0.148 . . . . 0.0 111.304 -179.101 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.15 -36.34 0.71 Allowed Glycine 0 N--CA 1.465 0.627 0 C-N-CA 120.919 -0.657 . . . . 0.0 113.214 -177.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -162.59 58.3 0.22 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.697 0.761 . . . . 0.0 110.275 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.485 ' O ' ' CG2' ' A' ' 7' ' ' VAL . . . -161.38 -62.2 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.642 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.485 ' CG2' ' O ' ' A' ' 6' ' ' GLY . 6.8 m 51.12 88.3 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-O 121.023 0.44 . . . . 0.0 111.002 179.053 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -145.22 87.28 1.8 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.135 -179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.426 ' HB3' ' HB3' ' A' ' 14' ' ' CYS . 4.9 m -62.75 115.36 4.26 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.254 179.131 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.9 p -172.73 -39.2 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.33 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 27.5 ttmt -77.6 -50.87 11.63 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.945 0.402 . . . . 0.0 110.45 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.7 p -88.6 -172.38 3.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.33 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.3 pttm -81.0 124.32 29.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.638 -0.256 . . . . 0.0 111.048 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.426 ' HB3' ' HB3' ' A' ' 9' ' ' CYS . 0.5 OUTLIER -153.91 109.57 3.22 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.685 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 21.5 p -173.61 -174.22 0.96 Allowed 'General case' 0 CA--C 1.519 -0.214 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.884 179.329 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.47 HG13 ' N ' ' A' ' 17' ' ' ASN . 14.3 p -164.99 -43.29 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.802 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.186 178.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.47 ' N ' HG13 ' A' ' 16' ' ' VAL . 0.3 OUTLIER -64.36 91.93 0.08 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.542 0.687 . . . . 0.0 109.673 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -66.63 -42.87 86.07 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.511 -178.529 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.26 -60.35 8.28 Favored Glycine 0 C--N 1.332 0.337 0 CA-C-N 116.287 -0.415 . . . . 0.0 114.066 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.6 tp60 -53.16 -43.55 67.15 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.708 0.254 . . . . 0.0 111.434 -178.788 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -67.61 -62.08 1.59 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.946 0.403 . . . . 0.0 111.485 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.63 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 26.3 t80 -54.19 -29.06 44.54 Favored 'General case' 0 C--O 1.219 -0.522 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -178.292 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.647 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.6 tt0 -78.81 -36.94 41.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 118.196 0.453 . . . . 0.0 111.341 -177.568 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.4 tm-20 -74.75 -33.1 62.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.299 0.571 . . . . 0.0 109.743 179.537 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.4 -57.44 3.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.862 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.647 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.0 OUTLIER -66.18 -58.74 4.75 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -177.8 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 3.2 m -54.08 -36.68 63.42 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.669 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.415 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -59.4 -41.66 89.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.846 178.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.29 -47.27 6.16 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.387 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.721 ' O ' HG23 ' A' ' 34' ' ' VAL . 9.2 mt -63.67 -26.04 39.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 121.008 0.432 . . . . 0.0 110.759 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -76.15 -53.8 7.76 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.917 0.389 . . . . 0.0 110.547 179.198 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.0 t -62.3 -35.71 79.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.203 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.442 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -57.38 -35.72 70.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.913 0.387 . . . . 0.0 110.849 -179.878 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.9 t -70.18 -62.84 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.086 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.7 m -52.15 -37.91 55.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.863 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.91 -43.91 98.76 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.621 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 34' ' ' VAL . 30.4 m -80.5 -26.79 11.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.933 0.397 . . . . 0.0 110.772 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.47 -22.08 48.09 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.676 -179.407 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 80.7 p -78.69 -31.69 46.68 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.457 -179.8 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.406 ' O ' ' HB3' ' A' ' 41' ' ' ALA . . . 95.18 30.96 7.88 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.759 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 40' ' ' GLY . . . 66.73 10.5 7.55 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 111.852 0.315 . . . . 0.0 111.852 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 157.49 58.75 0.01 OUTLIER Glycine 0 CA--C 1.519 0.284 0 C-N-CA 120.592 -0.813 . . . . 0.0 112.939 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.4 m -177.36 74.19 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.781 0.324 . . . . 0.0 110.994 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.5 mp -69.54 -43.85 80.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.557 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -104.24 21.1 38.45 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.067 -179.459 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 55.45 40.88 31.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.96 0.41 . . . . 0.0 110.851 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 29.9 mtm-85 54.89 94.26 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.228 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo . . . . . 0 C--O 1.249 1.04 0 C-N-CA 122.524 2.15 . . . . 0.0 112.269 179.892 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 1.042 HG12 ' H ' ' A' ' 2' ' ' ASN . 86.5 t . . . . . 0 N--CA 1.448 -0.529 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 1.042 ' H ' HG12 ' A' ' 1' ' ' VAL . 5.2 t-20 78.44 -58.3 0.44 Allowed 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.056 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.406 ' HB2' ' O ' ' A' ' 2' ' ' ASN . 1.6 m-85 69.65 -75.0 0.07 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.091 -178.533 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 92.51 -37.26 3.43 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.343 178.827 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -162.76 32.97 0.1 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.798 0.299 . . . . 0.0 111.137 -179.518 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -105.88 -43.09 1.58 Allowed Glycine 0 CA--C 1.52 0.345 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.596 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.636 HG23 ' O ' ' A' ' 7' ' ' VAL . 17.0 m -88.13 104.57 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.6 t -143.65 -146.88 0.2 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 179.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.8 p -63.11 -37.63 87.97 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.565 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 2.2 m -137.16 151.54 48.92 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.337 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.602 ' O ' ' HG3' ' A' ' 11' ' ' LYS . 13.6 tppt? -77.43 -5.12 48.65 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.3 m -150.78 69.02 0.96 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.308 0.575 . . . . 0.0 110.112 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.446 ' O ' ' HB2' ' A' ' 10' ' ' SER . 4.6 tttt 74.61 170.15 0.29 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.168 -0.923 . . . . 0.0 108.651 -177.766 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -120.6 56.31 1.0 Allowed 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.12 26.87 1.49 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.851 -1.068 . . . . 0.0 112.338 -178.656 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.7 p -164.55 130.04 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.092 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 39.2 p-10 -63.83 -162.77 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.873 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 75.8 21.27 1.66 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.764 0.316 . . . . 0.0 110.828 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -91.87 -46.24 3.71 Favored Glycine 0 C--N 1.332 0.322 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.4 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -65.11 -27.85 69.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.696 0.284 . . . . 0.0 110.843 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.76 -67.2 0.36 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.866 179.289 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.691 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 44.4 t80 -54.58 -27.14 36.86 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -179.492 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.525 ' HA ' ' CD1' ' A' ' 26' ' ' TYR . 29.9 mm-40 -75.17 -38.8 60.73 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.849 -178.274 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -78.16 -44.47 25.85 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.2 0.524 . . . . 0.0 109.926 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -56.22 23.92 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.61 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.691 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -63.44 -37.39 87.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.891 -1.049 . . . . 0.0 113.639 -177.094 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.652 HG23 ' CE1' ' A' ' 26' ' ' TYR . 4.3 p -65.68 -45.1 84.16 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.448 -0.501 . . . . 0.0 109.706 177.656 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -43.34 64.79 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.847 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.37 -43.95 11.98 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.497 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.404 ' O ' HG23 ' A' ' 34' ' ' VAL . 35.7 mm -72.84 -54.0 17.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 121.007 0.432 . . . . 0.0 111.176 -179.726 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 27' ' ' THR . 3.3 t-20 -56.36 -50.19 72.25 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.771 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.6 m -54.23 -40.3 67.58 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.688 0.28 . . . . 0.0 111.089 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.653 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -56.11 -35.7 67.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 -179.781 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.557 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.3 t -74.8 -60.36 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.93 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.9 m -57.05 -38.09 72.73 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.081 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.54 -43.06 97.9 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.674 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 33' ' ' PHE . 20.3 m -80.79 -29.51 11.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.044 0.45 . . . . 0.0 110.318 179.481 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -22.47 47.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.227 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.5 m -69.56 -37.0 76.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.381 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.96 -0.08 8.31 Favored Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.761 -0.733 . . . . 0.0 113.11 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 57.24 22.06 7.27 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.911 0.355 . . . . 0.0 111.594 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.14 -81.52 0.49 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.65 -179.708 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 2.8 m 178.26 62.86 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.866 0.365 . . . . 0.0 110.894 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 35.3 mt -119.54 -41.65 2.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.703 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.94 -27.23 59.27 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.774 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 tpt180 61.6 69.05 0.67 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.9 0.381 . . . . 0.0 110.52 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.435 ' N ' ' HD2' ' A' ' 48' ' ' PRO . 15.0 mtt85 -81.83 -51.55 0.81 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.295 -179.694 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.435 ' HD2' ' N ' ' A' ' 47' ' ' ARG . 81.5 Cg_endo . . . . . 0 C--O 1.25 1.085 0 C-N-CA 122.203 1.935 . . . . 0.0 112.297 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.821 HG23 ' N ' ' A' ' 2' ' ' ASN . 20.0 m . . . . . 0 N--CA 1.449 -0.519 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.821 ' N ' HG23 ' A' ' 1' ' ' VAL . 3.4 t-20 76.16 -60.06 0.49 Allowed 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.555 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 64.59 109.34 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.009 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -110.45 76.02 0.22 Allowed Glycine 0 C--O 1.229 -0.157 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -163.26 -54.79 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.204 0.526 . . . . 0.0 110.667 -179.402 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 133.17 102.65 0.81 Allowed Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 110.537 -1.025 . . . . 0.0 110.537 -178.795 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.421 ' O ' ' O ' ' A' ' 8' ' ' SER . 15.6 m -86.24 -33.02 7.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.494 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.421 ' O ' ' O ' ' A' ' 7' ' ' VAL . 52.3 p 51.3 109.68 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.058 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 9.0 m -94.29 170.09 9.75 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.353 179.419 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.5 t -98.47 -49.54 4.61 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.661 179.07 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 12' ' ' THR . 10.3 tttp -77.54 -8.33 57.65 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 113.885 1.069 . . . . 0.0 113.885 -179.29 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.578 HG22 ' O ' ' A' ' 11' ' ' LYS . 10.5 t 52.44 48.06 23.41 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.783 0.325 . . . . 0.0 111.515 -178.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.13 39.41 0.21 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.251 0.548 . . . . 0.0 109.99 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.8 m -89.16 -66.27 0.94 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.031 -179.428 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 9.7 t -110.0 175.06 5.58 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.767 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.62 ' O ' HG22 ' A' ' 16' ' ' VAL . 12.6 p -164.27 33.73 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.161 0.505 . . . . 0.0 110.71 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 67.37 -71.74 0.1 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.485 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -52.61 -22.57 5.19 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.601 -179.162 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.47 -62.9 5.81 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.726 -0.749 . . . . 0.0 113.05 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 15.4 mm-40 -62.92 -30.78 71.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.963 0.411 . . . . 0.0 110.517 -179.534 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.86 -65.38 0.69 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.543 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -53.31 -42.35 66.59 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 -178.301 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.674 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.8 tt0 -68.38 -36.86 79.77 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.991 -177.321 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -72.93 -28.88 62.71 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.508 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -80.45 -53.94 6.14 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.506 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.674 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.58 -54.25 8.62 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.273 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.505 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.8 m -57.66 -25.39 60.14 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.731 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.36 -33.36 49.07 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.438 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.94 -42.72 7.99 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.682 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.505 HG22 ' HA ' ' A' ' 27' ' ' THR . 9.0 tp -67.37 -41.32 86.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.641 0.734 . . . . 0.0 111.339 -179.228 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.437 ' N ' HG23 ' A' ' 30' ' ' ILE . 2.0 t-20 -72.48 -41.72 65.71 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.762 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 58.4 m -65.24 -31.1 72.09 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.684 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.49 -40.58 87.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.984 0.421 . . . . 0.0 110.006 179.834 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.547 ' O ' HG22 ' A' ' 37' ' ' VAL . 2.9 t -66.81 -63.38 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.221 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.1 m -56.44 -34.79 67.16 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.355 179.568 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.15 -43.3 98.87 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.322 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.684 HG13 ' O ' ' A' ' 33' ' ' PHE . 19.9 m -80.23 -27.38 11.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.972 0.415 . . . . 0.0 110.268 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -76.8 -22.69 53.3 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.844 -179.463 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 74.4 m -76.43 -42.39 44.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.792 0.329 . . . . 0.0 111.1 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -83.35 -48.49 5.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.642 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -70.79 -60.63 2.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.799 0.333 . . . . 0.0 111.136 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 94.4 44.99 3.34 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.478 -179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.65 -55.56 32.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.669 0.271 . . . . 0.0 110.461 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.726 HG23 ' H ' ' A' ' 46' ' ' ARG . 0.4 OUTLIER -168.52 -40.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.4 179.626 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 53.03 13.83 2.49 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 115.125 0.81 . . . . 0.0 115.125 178.23 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.726 ' H ' HG23 ' A' ' 44' ' ' ILE . 19.9 mmt180 -121.07 -69.17 0.86 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 118.182 0.991 . . . . 0.0 111.192 179.422 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 15.8 ptm180 -108.53 148.75 38.32 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.081 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo . . . . . 0 C--O 1.249 1.071 0 C-N-CA 122.471 2.114 . . . . 0.0 112.286 179.986 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.611 ' O ' HG12 ' A' ' 1' ' ' VAL . 87.4 t . . . . . 0 N--CA 1.449 -0.501 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.474 ' O ' ' CD1' ' A' ' 3' ' ' TYR . 9.4 p30 -158.94 151.32 21.49 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.474 ' CD1' ' O ' ' A' ' 2' ' ' ASN . 28.4 m-85 -158.19 -175.21 5.21 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.64 -178.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -154.76 36.49 0.67 Allowed Glycine 0 CA--C 1.518 0.239 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.436 -179.131 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -162.67 -67.97 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.711 0.291 . . . . 0.0 110.753 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 130.98 76.19 0.14 Allowed Glycine 0 C--N 1.332 0.343 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.686 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.579 ' O ' HG13 ' A' ' 7' ' ' VAL . 15.0 p -89.03 58.44 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 121.017 0.437 . . . . 0.0 111.091 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.6 p 61.31 126.76 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.464 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -147.52 -88.19 0.09 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.297 179.155 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 32.6 t 37.24 67.2 0.38 Allowed 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.327 0.584 . . . . 0.0 110.621 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.9 pttp -162.06 -21.11 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.201 -0.909 . . . . 0.0 111.236 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.9 t -150.86 -21.07 0.22 Allowed 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 120.675 0.274 . . . . 0.0 111.477 178.502 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.422 ' O ' ' CB ' ' A' ' 14' ' ' CYS . 3.3 tptt -158.35 -166.22 1.88 Allowed 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -178.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.422 ' CB ' ' O ' ' A' ' 13' ' ' LYS . 11.3 m 74.22 137.06 0.06 Allowed 'General case' 0 C--N 1.329 -0.316 0 O-C-N 122.298 -0.251 . . . . 0.0 110.45 -178.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 10.7 p -172.06 175.51 3.76 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.384 0.611 . . . . 0.0 112.2 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 16' ' ' VAL . 7.1 p -75.84 81.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.719 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -56.24 -24.85 45.03 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 115.518 -0.764 . . . . 0.0 112.313 -178.315 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 9.9 p90 -92.88 18.35 9.16 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.718 0.294 . . . . 0.0 111.064 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.15 -34.58 58.08 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 121.278 -0.487 . . . . 0.0 112.895 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -71.71 -31.77 67.09 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.684 0.278 . . . . 0.0 111.239 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.02 -70.02 0.17 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.547 179.754 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.536 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.4 t80 -57.22 -33.35 67.44 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -179.143 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.712 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.1 tt0 -75.37 -37.24 60.72 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 121.121 -0.232 . . . . 0.0 111.035 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -70.64 -30.8 67.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.526 0.679 . . . . 0.0 109.627 179.776 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -79.82 -58.31 3.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.144 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.712 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -68.48 -58.53 4.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.132 -0.94 . . . . 0.0 113.3 -177.93 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.55 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.4 m -54.38 -37.45 65.02 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.893 -0.323 . . . . 0.0 110.912 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -55.99 -48.9 75.02 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.176 179.267 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.42 -53.66 8.52 Favored Glycine 0 CA--C 1.52 0.369 0 C-N-CA 120.595 -0.812 . . . . 0.0 113.097 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.638 ' O ' HG23 ' A' ' 34' ' ' VAL . 2.5 tt -61.41 -29.45 45.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.138 0.494 . . . . 0.0 111.915 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -69.51 -48.92 59.0 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 122.035 -0.415 . . . . 0.0 110.169 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 16.6 m -54.04 -38.85 65.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.241 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.425 ' O ' HG12 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.11 -37.73 77.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.195 0.522 . . . . 0.0 110.49 179.59 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.646 ' HA ' HG12 ' A' ' 37' ' ' VAL . 4.2 t -67.49 -59.87 3.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.892 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 73.1 m -45.32 -55.65 5.74 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.471 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.93 -47.49 85.39 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.349 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.646 HG12 ' HA ' ' A' ' 34' ' ' VAL . 5.0 p -65.95 -24.98 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.849 0.357 . . . . 0.0 110.439 -179.887 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.446 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -78.92 -24.03 44.34 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.549 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 t -56.5 -28.46 59.91 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.393 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 112.93 39.59 1.15 Allowed Glycine 0 C--N 1.33 0.214 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.453 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -61.26 -41.29 96.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.829 0.347 . . . . 0.0 111.134 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 115.08 89.18 1.61 Allowed Glycine 0 C--N 1.33 0.218 0 C-N-CA 120.978 -0.629 . . . . 0.0 112.512 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 51.7 p -171.29 -51.52 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 0.0 110.75 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -150.56 -79.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.812 179.432 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 59.08 27.79 62.98 Favored Glycine 0 C--N 1.33 0.219 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.557 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 70.8 mtt180 -128.57 32.46 4.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.794 0.33 . . . . 0.0 110.648 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -101.87 141.51 22.7 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.695 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo . . . . . 0 C--O 1.25 1.075 0 C-N-CA 122.397 2.065 . . . . 0.0 112.212 -179.497 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.64 ' CG1' ' N ' ' A' ' 2' ' ' ASN . 11.5 t . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.64 ' N ' ' CG1' ' A' ' 1' ' ' VAL . 3.2 m-20 -162.13 -160.13 0.65 Allowed 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.578 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.448 ' HB3' HG11 ' A' ' 7' ' ' VAL . 3.2 m-85 61.25 163.66 0.08 Allowed 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 120.751 0.31 . . . . 0.0 110.772 -179.204 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.504 ' O ' ' HB2' ' A' ' 5' ' ' ASN . . . 159.95 96.99 0.12 Allowed Glycine 0 C--N 1.337 0.604 0 C-N-CA 120.307 -0.949 . . . . 0.0 113.543 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.504 ' HB2' ' O ' ' A' ' 4' ' ' GLY . 21.1 m-20 73.38 60.51 0.1 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.945 0.402 . . . . 0.0 110.386 178.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 158.81 46.36 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.034 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.448 HG11 ' HB3' ' A' ' 3' ' ' TYR . 8.3 m -150.94 -177.18 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.588 -0.306 . . . . 0.0 110.534 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 40.2 t -81.22 -148.93 0.07 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 62.7 m -49.43 125.07 10.41 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.148 0.499 . . . . 0.0 110.326 179.642 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.401 ' O ' ' HG3' ' A' ' 11' ' ' LYS . 9.3 m -119.75 -40.89 2.71 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.43 -0.804 . . . . 0.0 111.223 -178.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.401 ' HG3' ' O ' ' A' ' 10' ' ' SER . 31.7 mttt -161.45 -77.74 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.589 179.56 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 16.5 p -90.42 -32.66 16.33 Favored 'General case' 0 C--N 1.333 -0.152 0 N-CA-C 112.883 0.698 . . . . 0.0 112.883 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.7 tmtt? -79.92 84.41 5.69 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 -177.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 5.6 t -161.41 -74.5 0.06 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.789 179.12 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.402 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.7 OUTLIER -153.79 122.64 6.38 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.835 178.888 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 15' ' ' SER . 16.9 t 77.45 131.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 N-CA-C 110.504 -0.184 . . . . 0.0 110.504 179.259 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -70.33 126.46 29.7 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.947 0.403 . . . . 0.0 111.032 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 1.7 t-105 -92.23 -39.63 11.43 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.67 179.685 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.57 -49.33 7.15 Favored Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.258 -0.496 . . . . 0.0 113.265 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -65.56 -35.01 79.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.843 0.354 . . . . 0.0 111.004 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.0 -67.21 0.46 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.198 179.567 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.866 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 28.4 t80 -55.33 -17.92 5.6 Favored 'General case' 0 CA--C 1.508 -0.644 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.26 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.693 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 49.0 tt0 -84.38 -45.26 12.93 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.334 -178.004 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -69.28 -33.68 73.58 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -67.89 -55.46 12.78 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.125 179.044 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.866 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.3 OUTLIER -68.21 -36.93 80.29 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.543 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.615 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.1 p -59.79 -46.19 89.96 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 120.198 -0.601 . . . . 0.0 109.575 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -41.38 63.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.229 179.257 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.06 -52.01 7.18 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.54 179.538 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.615 HG22 ' HA ' ' A' ' 27' ' ' THR . 1.2 tt -70.91 -50.33 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 120.78 0.324 . . . . 0.0 111.836 -179.165 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.549 ' N ' HG23 ' A' ' 30' ' ' ILE . 2.1 t-20 -55.34 -50.97 68.27 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 120.805 0.336 . . . . 0.0 110.417 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 44.0 m -49.66 -44.33 47.68 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.631 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -53.38 -34.73 58.77 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.089 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.534 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.2 t -72.2 -61.65 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.345 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.3 m -51.49 -39.17 57.06 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.763 179.619 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.15 98.73 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.818 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.569 ' O ' ' HB2' ' A' ' 41' ' ' ALA . 32.9 m -80.95 -29.52 11.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.073 0.463 . . . . 0.0 110.432 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -70.54 -30.03 66.66 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.626 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.8 p -81.02 -45.27 16.81 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.397 179.585 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -127.11 45.17 1.17 Allowed Glycine 0 C--N 1.334 0.428 0 C-N-CA 120.877 -0.677 . . . . 0.0 113.083 -179.541 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.569 ' HB2' ' O ' ' A' ' 37' ' ' VAL . . . -50.25 -28.32 7.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.677 0.275 . . . . 0.0 111.697 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.98 -67.94 1.91 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.795 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.8 t 58.49 69.4 0.73 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.152 0.501 . . . . 0.0 111.068 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.543 ' O ' ' HG2' ' A' ' 47' ' ' ARG . 24.6 pt 44.09 39.09 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.043 179.372 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.76 -54.78 31.16 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 120.547 -0.835 . . . . 0.0 113.411 179.386 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 17.0 mmt180 -62.67 -33.74 75.68 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.543 ' HG2' ' O ' ' A' ' 44' ' ' ILE . 10.9 mtt180 56.07 89.63 0.1 Allowed Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 120.646 0.26 . . . . 0.0 111.318 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--O 1.25 1.113 0 C-N-CA 122.366 2.044 . . . . 0.0 112.119 -179.964 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 1.693 HG21 ' CD2' ' A' ' 3' ' ' TYR . 14.4 p . . . . . 0 N--CA 1.449 -0.494 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.955 ' N ' HG22 ' A' ' 1' ' ' VAL . 23.1 m120 -160.87 21.42 0.13 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.812 -179.419 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 1.693 ' CD2' HG21 ' A' ' 1' ' ' VAL . 7.8 m-85 -80.69 -153.28 0.09 Allowed 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.608 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 178.19 73.71 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 80.83 86.05 0.04 OUTLIER 'General case' 0 CA--C 1.521 -0.168 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -178.719 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 138.73 89.25 0.2 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.931 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t 60.58 118.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.704 0.288 . . . . 0.0 110.848 179.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 78.6 p -169.52 132.15 1.2 Allowed 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.997 0.427 . . . . 0.0 111.046 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.502 ' HA ' ' HB3' ' A' ' 13' ' ' LYS . 11.5 m 66.92 -54.92 0.44 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.611 -0.722 . . . . 0.0 112.381 179.088 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 85.9 p 60.36 37.03 20.35 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -179.71 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 8.3 tttm 78.26 -59.67 0.42 Allowed 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 112.096 0.406 . . . . 0.0 112.096 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.3 t -88.12 66.62 8.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.977 -178.312 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.502 ' HB3' ' HA ' ' A' ' 9' ' ' CYS . 0.0 OUTLIER -159.17 -55.09 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.252 179.18 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 26.5 p -125.53 40.82 3.66 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.137 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.68 178.65 7.49 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.107 0.479 . . . . 0.0 110.987 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.605 HG13 ' O ' ' A' ' 16' ' ' VAL . 7.2 p -163.59 100.42 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.27 0.557 . . . . 0.0 111.063 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -109.56 152.87 24.93 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.186 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -45.82 -33.45 3.14 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.106 0.479 . . . . 0.0 110.534 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.39 -53.67 43.59 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.786 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 10.0 mt-30 -56.65 -22.47 34.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.638 0.256 . . . . 0.0 111.689 -179.208 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.33 -71.48 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.752 0.311 . . . . 0.0 111.113 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.579 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 56.9 t80 -51.53 -31.31 23.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.575 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.2 mt-30 -80.15 -47.49 14.64 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.999 0.428 . . . . 0.0 111.27 -177.834 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.487 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 45.8 tt0 -60.61 -27.06 67.46 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.461 0.648 . . . . 0.0 109.403 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.1 ttm-85 -81.09 -57.01 3.71 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.058 -0.974 . . . . 0.0 111.084 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.579 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -76.44 -45.1 32.86 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.679 -178.624 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.526 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.4 m -63.35 -39.09 93.59 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.307 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -58.48 -49.62 76.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.751 0.31 . . . . 0.0 111.356 179.047 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.18 -43.04 82.05 Favored Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.533 -0.842 . . . . 0.0 113.019 -179.366 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.575 HG22 ' O ' ' A' ' 26' ' ' TYR . 1.0 OUTLIER -72.17 -47.36 54.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.782 0.325 . . . . 0.0 111.152 -179.348 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.539 ' N ' HG23 ' A' ' 30' ' ' ILE . 21.9 t-20 -59.28 -41.22 88.42 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.757 179.836 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 24.0 p -57.33 -47.97 80.18 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.981 0.42 . . . . 0.0 109.918 179.661 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.56 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -46.83 -39.2 11.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.268 179.031 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.475 ' N ' ' CD1' ' A' ' 33' ' ' PHE . 2.7 t -70.71 -66.01 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.423 -178.574 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 50.6 m -46.71 -53.75 11.09 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.866 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.79 -45.62 90.96 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.035 179.213 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 33' ' ' PHE . 47.3 t -71.96 -23.27 21.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.821 0.343 . . . . 0.0 110.509 179.59 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.457 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -81.18 -22.57 38.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.527 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.8 t -67.12 -31.96 72.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.379 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.39 5.1 11.61 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.933 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 63.9 14.97 8.79 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 111.963 0.357 . . . . 0.0 111.963 179.727 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -179.22 72.36 0.07 OUTLIER Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.787 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -107.27 -17.17 14.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.444 0.164 . . . . 0.0 111.381 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 48.2 pt 42.18 42.73 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-O 120.944 0.402 . . . . 0.0 111.514 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -146.8 59.9 0.48 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.3 179.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.459 ' O ' ' O ' ' A' ' 47' ' ' ARG . 0.1 OUTLIER -86.81 -39.12 16.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.385 0.136 . . . . 0.0 111.059 179.757 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.459 ' O ' ' O ' ' A' ' 46' ' ' ARG . 0.8 OUTLIER 35.36 105.13 0.01 OUTLIER Pre-proline 0 N--CA 1.472 0.641 0 N-CA-C 112.743 0.646 . . . . 0.0 112.743 179.67 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo . . . . . 0 C--O 1.249 1.04 0 C-N-CA 122.299 1.999 . . . . 0.0 112.246 179.569 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.969 HG22 ' O ' ' A' ' 1' ' ' VAL . 0.3 OUTLIER . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 44.2 m-20 -161.36 91.8 0.87 Allowed 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -79.45 145.87 33.06 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.633 -0.427 . . . . 0.0 110.123 -178.43 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 101.22 -83.12 0.5 Allowed Glycine 0 N--CA 1.452 -0.241 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -177.606 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -78.17 -48.34 16.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.798 0.333 . . . . 0.0 111.828 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -55.23 -67.82 2.01 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 121.079 -0.582 . . . . 0.0 113.337 -179.057 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.8 p -88.42 126.88 41.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 120.771 0.32 . . . . 0.0 110.795 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.4 t -77.97 82.8 4.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.56 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -64.82 -45.42 86.28 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.847 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.4 ' O ' ' HG2' ' A' ' 11' ' ' LYS . 1.6 p 54.23 -84.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.881 -0.599 . . . . 0.0 112.565 179.495 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.4 ' HG2' ' O ' ' A' ' 10' ' ' SER . 3.6 mmmt -161.66 -24.11 0.05 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -178.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.404 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -88.02 86.36 7.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.981 0.419 . . . . 0.0 110.403 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.404 ' HG2' ' O ' ' A' ' 12' ' ' THR . 0.0 OUTLIER 47.51 -173.78 0.01 OUTLIER 'General case' 0 C--O 1.231 0.125 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.881 -179.246 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -133.97 -158.48 0.89 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.911 -0.315 . . . . 0.0 111.333 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -75.03 152.15 38.69 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 121.162 0.505 . . . . 0.0 110.614 -179.027 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.631 HG13 ' HA3' ' A' ' 19' ' ' GLY . 8.6 p -165.22 131.6 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.729 -179.728 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -61.82 140.91 58.21 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.584 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 57.14 33.89 24.02 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.172 0.511 . . . . 0.0 109.818 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.631 ' HA3' HG13 ' A' ' 16' ' ' VAL . . . -105.18 -43.0 1.68 Allowed Glycine 0 C--N 1.332 0.309 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.726 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -64.66 -41.55 96.01 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.847 0.356 . . . . 0.0 110.269 179.76 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.98 -64.18 0.94 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.978 179.053 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.686 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 22.2 t80 -55.12 -31.28 61.13 Favored 'General case' 0 CA--C 1.509 -0.606 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 -179.366 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.705 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 9.2 tt0 -78.74 -34.58 45.66 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.419 -177.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.444 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 53.1 tp10 -73.56 -29.46 62.45 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.024 0.828 . . . . 0.0 109.515 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.27 -57.07 3.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.477 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.705 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -69.7 -57.72 4.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -177.884 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.555 ' HA ' HG22 ' A' ' 30' ' ' ILE . 0.6 OUTLIER -54.88 -41.29 70.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.744 0.307 . . . . 0.0 111.03 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.444 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -57.11 -45.78 83.14 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.347 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.87 -42.88 19.3 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.825 -0.702 . . . . 0.0 113.419 -179.2 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.586 ' O ' HG23 ' A' ' 34' ' ' VAL . 10.7 tp -71.05 -31.35 44.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.963 0.411 . . . . 0.0 111.839 -178.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.407 ' HB2' ' O ' ' A' ' 27' ' ' THR . 56.3 t30 -72.24 -45.03 61.91 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.785 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 65.9 p -62.76 -36.18 82.21 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.072 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.71 -35.72 73.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.934 0.397 . . . . 0.0 110.889 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.586 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.7 t -70.93 -63.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.519 -179.417 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -50.68 -38.17 45.28 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.737 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.37 -44.51 97.51 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.513 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.574 HG22 ' O ' ' A' ' 34' ' ' VAL . 33.7 m -80.38 -26.62 11.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.934 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -80.42 -20.76 43.19 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.821 -179.245 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.5 t -60.78 -32.49 71.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.824 0.345 . . . . 0.0 111.115 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.59 51.03 0.05 OUTLIER Glycine 0 N--CA 1.453 -0.213 0 C-N-CA 120.688 -0.767 . . . . 0.0 112.262 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -69.67 -36.9 76.43 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.824 0.345 . . . . 0.0 110.86 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -101.72 -22.13 10.56 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.927 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.2 t -61.34 -54.58 41.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.661 0.267 . . . . 0.0 111.045 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.513 HG23 ' N ' ' A' ' 45' ' ' GLY . 2.2 tt -126.65 -48.84 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.191 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.513 ' N ' HG23 ' A' ' 44' ' ' ILE . . . 54.04 24.11 26.59 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.829 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.45 -45.05 11.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 111.1 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ARG . . . . . 0.474 ' N ' ' HD2' ' A' ' 48' ' ' PRO . 40.3 mmm-85 -75.15 -50.08 3.9 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.704 -179.646 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.474 ' HD2' ' N ' ' A' ' 47' ' ' ARG . 96.0 Cg_endo . . . . . 0 C--O 1.248 1.003 0 C-N-CA 122.036 1.824 . . . . 0.0 112.135 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 1.469 ' CG1' ' HB2' ' A' ' 5' ' ' ASN . 4.6 p . . . . . 0 N--CA 1.449 -0.517 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 1.022 ' H ' HG22 ' A' ' 1' ' ' VAL . 4.5 t-20 -163.1 -46.43 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.511 0.672 . . . . 0.0 109.315 -179.633 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -80.52 17.13 1.15 Allowed 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.661 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.437 ' O ' ' HB3' ' A' ' 5' ' ' ASN . . . 124.28 -28.93 5.2 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.962 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 1.469 ' HB2' ' CG1' ' A' ' 1' ' ' VAL . 54.4 t30 74.89 63.19 0.07 Allowed 'General case' 0 CA--C 1.517 -0.291 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -178.826 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.89 91.5 2.11 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.646 -0.787 . . . . 0.0 111.171 -178.417 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.453 HG13 ' N ' ' A' ' 8' ' ' SER . 12.0 p -149.68 -42.76 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.474 0.178 . . . . 0.0 111.062 -179.135 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.453 ' N ' HG13 ' A' ' 7' ' ' VAL . 2.2 t 178.2 130.51 0.06 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.726 0.298 . . . . 0.0 111.15 178.505 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 11.0 p -102.93 -44.08 5.35 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.211 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.0 t 61.88 8.72 2.6 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.658 -0.701 . . . . 0.0 112.593 179.27 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 31.4 mttp -78.25 12.82 1.72 Allowed 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 58.36 16.41 4.06 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 179.381 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.0 tttp -160.13 -39.35 0.05 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.121 0.486 . . . . 0.0 110.216 -179.64 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 68.93 31.23 4.31 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.845 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 22.4 p -173.68 137.91 0.63 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.429 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 16' ' ' VAL . 7.1 p -164.8 116.95 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.041 -179.727 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -72.44 -33.27 66.95 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.979 0.419 . . . . 0.0 110.677 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -51.49 -31.27 23.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.267 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.53 -43.71 97.35 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.566 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -64.01 -42.2 97.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.96 0.409 . . . . 0.0 110.601 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.56 -51.65 64.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.95 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.698 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 40.0 t80 -57.3 -27.74 62.42 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -179.037 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.5 ' O ' ' HD1' ' A' ' 26' ' ' TYR . 18.1 tt0 -71.46 -46.25 60.47 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.025 -178.321 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.81 -48.04 49.1 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.014 0.435 . . . . 0.0 110.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -56.13 -58.58 7.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.574 0.702 . . . . 0.0 111.457 179.576 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.698 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.18 -32.82 73.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.867 -1.061 . . . . 0.0 113.182 -177.442 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.593 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.2 p -66.7 -45.27 79.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.121 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -49.42 -46.3 47.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.47 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.85 -53.85 9.07 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.823 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.593 HG22 ' HA ' ' A' ' 27' ' ' THR . 7.2 tp -66.8 -49.65 72.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.779 0.29 . . . . 0.0 111.63 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.53 ' N ' HG23 ' A' ' 30' ' ' ILE . 8.3 t-20 -52.46 -40.11 61.9 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.826 0.346 . . . . 0.0 110.583 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.4 m -60.75 -43.92 97.36 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 110.522 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.553 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -56.59 -33.59 66.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.136 0.493 . . . . 0.0 110.981 179.779 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.445 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.4 t -69.06 -60.94 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.373 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -48.04 -58.0 5.04 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.021 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.73 -50.01 66.38 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.273 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.553 HG23 ' O ' ' A' ' 33' ' ' PHE . 75.2 t -68.53 -16.35 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.546 0.213 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.419 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -80.0 -26.17 39.98 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 120.831 0.348 . . . . 0.0 111.371 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.8 t -64.47 -30.25 71.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.007 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -103.15 -39.24 2.68 Favored Glycine 0 C--N 1.329 0.168 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.638 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -141.8 -77.37 0.27 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.773 0.321 . . . . 0.0 111.168 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.86 44.35 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.738 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.5 t -155.47 38.75 0.39 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.698 0.285 . . . . 0.0 110.803 179.617 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.7 pt -117.79 30.06 2.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.187 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -112.68 39.04 2.99 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.672 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -118.27 -40.44 2.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.695 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 7.6 ptt85 -152.94 105.38 2.65 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.808 179.711 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo . . . . . 0 C--O 1.248 0.993 0 C-N-CA 122.422 2.081 . . . . 0.0 112.305 179.817 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.862 HG12 ' N ' ' A' ' 2' ' ' ASN . 40.7 t . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.862 ' N ' HG12 ' A' ' 1' ' ' VAL . 47.3 t30 -161.76 -5.01 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 120.542 0.21 . . . . 0.0 111.055 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.412 ' H ' ' H ' ' A' ' 2' ' ' ASN . 1.6 p90 -159.34 -179.96 8.43 Favored 'General case' 0 C--O 1.231 0.096 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.95 -55.09 0.03 OUTLIER Glycine 0 C--N 1.334 0.417 0 C-N-CA 120.185 -1.007 . . . . 0.0 113.302 -179.395 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.6 m120 -162.28 63.05 0.22 Allowed 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.123 0.487 . . . . 0.0 110.544 -179.432 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -153.8 -37.39 0.03 OUTLIER Glycine 0 N--CA 1.454 -0.151 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.94 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.4 p -88.5 140.01 16.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.556 0.217 . . . . 0.0 110.468 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -81.43 68.72 7.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.872 0.368 . . . . 0.0 111.174 -179.091 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -171.77 101.03 0.18 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.2 p -78.52 -102.23 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 1.6 ptpt -162.7 37.71 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.64 0.257 . . . . 0.0 111.319 178.7 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.09 -77.66 0.13 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.1 mtmm -80.95 -57.49 3.51 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.3 m 57.89 170.71 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.794 0.33 . . . . 0.0 110.743 -179.335 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t -81.62 -27.93 33.95 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.046 0.451 . . . . 0.0 110.533 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.415 ' O ' HG23 ' A' ' 16' ' ' VAL . 8.0 m -76.45 105.84 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.408 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 32.1 m120 -42.34 -33.86 0.71 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.71 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -89.17 36.49 0.82 Allowed 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.553 179.738 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.95 -42.4 5.35 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.323 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -63.3 -43.27 98.34 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.019 0.437 . . . . 0.0 110.486 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -68.66 -57.66 5.37 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.88 179.051 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.845 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 38.1 t80 -57.78 -21.0 39.41 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.209 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.707 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 7.5 tm0? -81.49 -48.01 12.41 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.689 -178.205 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.9 tt0 -64.73 -30.74 71.76 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.558 179.15 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.04 -51.61 11.93 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.563 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.845 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -77.44 -55.55 5.29 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -177.811 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.469 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.2 m -55.94 -21.97 23.65 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.932 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.412 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -75.84 -58.11 3.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.066 0.46 . . . . 0.0 110.495 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.88 -43.55 65.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.173 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.601 ' O ' HG23 ' A' ' 34' ' ' VAL . 42.0 mm -56.57 -51.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.923 0.392 . . . . 0.0 110.957 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -50.09 -53.16 29.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.904 0.383 . . . . 0.0 110.408 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 p -63.17 -36.15 82.67 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.763 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -55.99 -38.55 70.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.029 0.442 . . . . 0.0 110.703 179.731 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 30' ' ' ILE . 4.1 t -63.97 -58.98 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.42 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.368 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 70.7 m -53.92 -42.81 69.19 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.677 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.14 -47.06 92.65 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.0 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 34' ' ' VAL . 32.7 m -76.6 -26.62 16.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.886 0.374 . . . . 0.0 110.703 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -71.85 -24.52 61.71 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.718 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 66.3 m -64.64 -34.21 77.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.864 0.364 . . . . 0.0 111.04 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 160.28 54.53 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.454 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -60.32 -32.06 70.87 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 111.401 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -70.15 -15.58 72.29 Favored Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.821 -0.704 . . . . 0.0 113.242 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 54.0 m -58.36 -57.37 13.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.831 0.315 . . . . 0.0 111.341 -179.805 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.698 HG23 ' H ' ' A' ' 45' ' ' GLY . 1.2 tp -133.78 -69.38 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.014 -179.748 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.698 ' H ' HG23 ' A' ' 44' ' ' ILE . . . 92.72 -37.09 3.47 Favored Glycine 0 C--N 1.332 0.318 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.148 179.112 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 10.2 tpp180 68.83 -65.01 0.3 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.752 0.31 . . . . 0.0 111.414 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.8 mmt85 57.36 73.22 0.8 Allowed Pre-proline 0 CA--C 1.532 0.262 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.066 -179.482 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo . . . . . 0 C--O 1.248 0.987 0 C-N-CA 122.24 1.96 . . . . 0.0 112.247 179.845 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 -0.105 0 CA-C-O 120.656 0.265 . . . . 0.0 111.619 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.586 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 34.8 t80 -50.02 -34.6 21.8 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 112.84 0.681 . . . . 0.0 112.84 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.594 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 1.8 tt0 -79.71 -32.24 41.28 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.237 -177.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.648 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.3 OUTLIER -76.24 -31.76 58.52 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.443 0.64 . . . . 0.0 109.295 179.503 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.1 ttt180 -77.16 -60.58 2.3 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 114.847 -1.07 . . . . 0.0 111.61 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.594 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -63.18 -54.53 36.12 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 113.056 0.761 . . . . 0.0 113.056 -178.03 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.45 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.5 m -58.93 -36.05 74.11 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.514 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.648 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -53.4 -49.54 67.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.04 0.448 . . . . 0.0 110.645 178.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 -33.87 28.66 Favored Glycine 0 C--N 1.33 0.229 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.449 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.52 HD12 ' HD1' ' A' ' 26' ' ' TYR . 5.2 mt -74.99 -29.59 22.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.746 0.308 . . . . 0.0 110.773 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.439 ' N ' ' O ' ' A' ' 27' ' ' THR . 37.9 t-20 -71.79 -49.14 41.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.038 0.447 . . . . 0.0 110.353 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.3 m -54.78 -45.17 74.24 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.524 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.455 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -48.43 -35.42 12.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.02 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 38' ' ' ALA . 3.0 t -70.66 -61.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.412 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -48.29 -58.44 4.57 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.49 -58.39 13.38 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.693 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.455 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 53.5 t -59.36 -22.25 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.617 0.246 . . . . 0.0 110.666 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.448 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.334 -0.106 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.276 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 -0.283 0 CA-C-O 121.003 0.43 . . . . 0.0 110.731 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.599 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.2 t80 -54.89 -34.02 62.59 Favored 'General case' 0 C--O 1.22 -0.496 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.646 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -76.94 -39.04 52.1 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.03 0.443 . . . . 0.0 110.537 -177.874 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 6.4 tp10 -68.08 -28.37 67.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.7 ttt-85 -80.61 -55.21 5.0 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.429 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.646 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -76.66 -55.09 5.82 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -177.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.0 m -54.8 -32.57 60.41 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.244 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.458 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -66.15 -50.77 62.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.536 179.038 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.87 -41.38 82.81 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.822 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.516 HG22 ' O ' ' A' ' 26' ' ' TYR . 10.4 tp -70.84 -42.99 77.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.93 0.395 . . . . 0.0 111.001 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.466 ' N ' HG23 ' A' ' 30' ' ' ILE . 37.9 t-20 -62.6 -43.72 98.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.414 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.4 m -59.3 -37.66 78.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.876 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.477 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.28 -35.29 73.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.883 179.853 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.0 t -72.55 -62.04 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.57 -178.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 72.2 m -47.77 -57.65 5.32 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.408 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.21 -51.26 57.07 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.16 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 33' ' ' PHE . 53.3 t -64.24 -25.36 37.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.63 0.252 . . . . 0.0 110.513 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.421 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.11 0 CA-C-O 120.742 0.306 . . . . 0.0 111.617 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.644 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 30.1 t80 -56.48 -28.54 60.03 Favored 'General case' 0 CA--C 1.509 -0.605 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.71 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.5 tt0 -77.23 -43.45 33.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 121.117 0.484 . . . . 0.0 110.068 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.401 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 40.1 tt0 -66.99 -29.49 69.33 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.832 178.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.48 -53.23 7.08 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.514 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.71 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.08 -55.75 5.42 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.066 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.8 m -55.34 -27.9 50.21 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.96 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.401 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -70.82 -51.99 23.3 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.892 0.377 . . . . 0.0 111.253 179.305 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.91 -44.13 56.49 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.896 -179.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.671 ' O ' HG23 ' A' ' 34' ' ' VAL . 2.5 tp -63.28 -44.01 98.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.968 0.414 . . . . 0.0 111.691 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.463 ' N ' HG23 ' A' ' 30' ' ' ILE . 36.0 t-20 -57.31 -49.21 76.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.858 0.361 . . . . 0.0 110.558 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 39.6 p -59.07 -41.07 87.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.072 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -57.08 -36.57 70.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.97 0.414 . . . . 0.0 110.808 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.671 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.5 t -62.42 -59.55 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.142 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.4 m -49.31 -47.2 47.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.197 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.3 -44.91 93.27 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.421 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.4 m -78.62 -25.88 13.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.818 0.342 . . . . 0.0 110.842 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.809 -179.454 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.086 0 CA-C-O 120.634 0.254 . . . . 0.0 111.551 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -52.68 -41.99 64.36 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.633 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 3.5 tm0? -65.92 -42.09 90.58 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.897 0.379 . . . . 0.0 111.106 -177.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -70.45 -30.07 66.8 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.307 0.575 . . . . 0.0 110.161 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -80.03 -54.05 6.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.513 -0.767 . . . . 0.0 111.504 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.633 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.86 -55.83 6.82 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -178.016 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.551 ' HA ' HG22 ' A' ' 30' ' ' ILE . 2.3 m -55.98 -32.28 63.77 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 120.694 -0.402 . . . . 0.0 110.807 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.41 -32.85 68.87 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.705 179.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.84 -42.82 8.0 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.632 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.551 HG22 ' HA ' ' A' ' 27' ' ' THR . 4.0 tp -68.87 -36.12 72.62 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.598 0.713 . . . . 0.0 110.863 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -77.3 -38.03 51.46 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.082 0.467 . . . . 0.0 109.901 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 47.2 t -66.68 -30.79 71.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.478 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.47 -40.67 87.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.865 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.537 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.3 t -65.98 -61.99 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.472 179.344 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -55.37 -34.71 64.55 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.49 -45.86 93.84 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.293 179.214 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.537 HG22 ' O ' ' A' ' 34' ' ' VAL . 31.3 m -76.8 -27.63 16.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-O 121.119 0.485 . . . . 0.0 110.055 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.199 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.289 -179.951 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 -0.192 0 CA-C-O 120.571 0.224 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.532 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.3 t80 -56.09 -35.26 66.81 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.684 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 40.0 mt-30 -73.99 -34.09 64.07 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 123.144 0.277 . . . . 0.0 111.099 -177.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.422 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 32.9 tt0 -75.74 -30.24 59.15 Favored 'General case' 0 C--N 1.33 -0.264 0 O-C-N 123.732 0.645 . . . . 0.0 109.946 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.2 ttt-85 -80.65 -57.9 3.36 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.114 -0.948 . . . . 0.0 111.096 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.684 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -65.64 -57.74 7.4 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.239 -0.892 . . . . 0.0 113.378 -178.105 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.515 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.3 m -56.84 -44.95 82.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.785 0.326 . . . . 0.0 111.27 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.422 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -52.27 -43.42 64.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.457 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.44 -51.51 8.35 Favored Glycine 0 CA--C 1.52 0.377 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.872 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.521 HG23 ' N ' ' A' ' 31' ' ' ASN . 9.8 tp -65.53 -46.15 90.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.018 0.437 . . . . 0.0 111.714 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.521 ' N ' HG23 ' A' ' 30' ' ' ILE . 1.1 t30 -63.04 -38.25 90.44 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.956 0.408 . . . . 0.0 110.199 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.5 m -57.14 -37.37 71.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.237 178.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.84 -37.82 77.34 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.106 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.571 ' O ' HG22 ' A' ' 37' ' ' VAL . 2.8 t -68.92 -63.08 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.732 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.5 m -47.9 -39.52 19.15 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.013 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.18 -50.31 69.05 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.592 179.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.571 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.0 m -72.14 -29.33 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.177 0.513 . . . . 0.0 109.982 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.129 -179.995 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 -0.264 0 CA-C-O 120.706 0.289 . . . . 0.0 111.333 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.722 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 60.3 t80 -51.05 -30.14 14.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.606 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.9 tt0 -81.6 -35.67 29.85 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 111.941 0.349 . . . . 0.0 111.941 -177.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.555 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.0 OUTLIER -76.18 -25.19 54.95 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.673 0.749 . . . . 0.0 109.086 -179.504 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.51 -59.09 2.89 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.111 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.722 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -68.11 -57.74 5.6 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 113.164 0.801 . . . . 0.0 113.164 -178.789 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.491 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 0.7 OUTLIER -53.79 -36.69 62.71 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.661 -179.756 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.555 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -55.81 -51.51 67.22 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.677 0.275 . . . . 0.0 110.647 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.79 -36.68 46.99 Favored Glycine 0 C--N 1.332 0.32 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.178 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 38.1 mm -70.2 -42.03 78.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 110.288 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -62.48 -39.74 94.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.054 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -55.3 -48.7 73.72 Favored 'General case' 0 CA--C 1.519 -0.221 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.332 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.518 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -44.68 -38.58 4.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.194 179.217 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.486 ' O ' ' N ' ' A' ' 38' ' ' ALA . 2.7 t -69.25 -64.21 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.34 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.404 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.6 m -45.56 -56.11 5.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.826 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.85 -54.03 35.95 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.499 -0.858 . . . . 0.0 111.835 179.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 33' ' ' PHE . 58.8 t -64.62 -19.16 24.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.715 0.293 . . . . 0.0 110.719 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.333 -0.14 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.027 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.711 0.291 . . . . 0.0 111.301 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.674 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 24.1 t80 -53.64 -30.8 44.64 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.725 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 29.5 tt0 -76.95 -39.87 49.1 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.769 -177.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.502 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 3.2 tp10 -71.52 -31.7 67.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.908 179.099 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.92 -54.14 6.96 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.509 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.725 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.21 -58.41 3.57 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -177.884 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.7 m -54.13 -31.66 52.97 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.579 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -64.68 -45.76 85.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.495 -0.321 . . . . 0.0 111.024 178.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.27 -43.78 12.54 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.05 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.476 ' O ' HG23 ' A' ' 34' ' ' VAL . 46.7 mm -62.33 -36.28 73.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.369 0.604 . . . . 0.0 110.442 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -67.67 -44.05 78.76 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -62.49 -37.87 87.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.992 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.513 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -55.7 -39.73 71.43 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.016 0.436 . . . . 0.0 109.987 179.625 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.506 ' O ' HG22 ' A' ' 37' ' ' VAL . 4.0 t -59.81 -59.17 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.893 178.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -57.37 -42.02 81.3 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.25 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.4 -43.17 95.91 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.954 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 33' ' ' PHE . 27.0 m -79.72 -27.22 12.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.106 0.479 . . . . 0.0 110.403 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.26 -179.719 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.106 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.651 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.6 t80 -52.54 -32.24 39.79 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 -178.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.691 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.8 tt0 -77.92 -36.4 49.45 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.745 -177.322 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.405 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.3 tp10 -75.05 -29.82 60.86 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.274 0.559 . . . . 0.0 109.538 179.155 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt85 -78.73 -52.36 8.5 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.12 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.691 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.05 -57.32 3.97 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.205 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.1 m -56.03 -20.48 16.97 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.102 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -79.49 -48.9 13.12 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.964 0.412 . . . . 0.0 110.075 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.83 -45.31 27.95 Favored Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.284 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.696 ' O ' HG23 ' A' ' 34' ' ' VAL . 50.5 mm -60.49 -45.44 96.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.778 0.323 . . . . 0.0 110.72 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -61.26 -37.07 81.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.776 0.322 . . . . 0.0 110.81 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.5 t -69.11 -38.88 79.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.793 0.33 . . . . 0.0 110.755 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.498 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.42 -34.45 72.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.208 0.528 . . . . 0.0 110.457 179.54 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.696 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.7 t -69.28 -61.81 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.785 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 52.4 m -47.12 -57.49 5.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.28 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.42 -48.69 78.85 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.011 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 33' ' ' PHE . 52.5 t -67.43 -21.83 28.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.765 0.317 . . . . 0.0 110.739 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.434 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.502 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 -0.095 0 CA-C-O 120.682 0.277 . . . . 0.0 111.103 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.65 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.4 t80 -51.67 -30.75 23.07 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -178.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.728 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.2 tt0 -76.45 -47.48 22.9 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 117.969 0.35 . . . . 0.0 110.762 -178.109 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.45 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 2.5 tm-20 -64.8 -27.52 68.94 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.444 0.64 . . . . 0.0 109.521 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.31 -52.73 7.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.86 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.728 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -77.74 -56.6 4.37 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -178.86 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.52 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.8 m -53.37 -23.46 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.857 179.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.45 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -74.52 -52.64 11.33 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.892 0.377 . . . . 0.0 110.484 178.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.05 -42.15 59.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.611 -0.805 . . . . 0.0 112.426 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.453 ' O ' HG23 ' A' ' 34' ' ' VAL . 48.1 mm -62.11 -46.35 96.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.122 0.486 . . . . 0.0 111.436 -179.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -56.99 -48.0 79.48 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.925 0.393 . . . . 0.0 110.568 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.3 t -60.72 -36.69 79.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.506 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -57.66 -38.71 75.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.983 0.421 . . . . 0.0 110.43 179.802 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.546 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.0 t -61.45 -62.49 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.305 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.5 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.2 m -54.83 -38.89 67.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -61.93 -41.64 99.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.749 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.546 HG22 ' O ' ' A' ' 34' ' ' VAL . 29.7 m -80.2 -27.21 11.91 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-O 121.027 0.441 . . . . 0.0 110.221 179.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.531 -179.747 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 -0.312 0 CA-C-O 120.889 0.375 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.583 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.7 t80 -53.55 -33.12 53.54 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -178.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.704 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 21.5 tt0 -76.38 -43.26 41.47 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.902 0.382 . . . . 0.0 110.81 -178.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.21 -33.23 75.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.439 0.638 . . . . 0.0 109.82 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.0 -54.35 6.11 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.57 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.704 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.37 -57.5 3.97 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -177.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.529 ' HA ' HG22 ' A' ' 30' ' ' ILE . 2.9 m -52.39 -33.53 43.86 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.98 -0.288 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.39 -47.77 75.2 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.736 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.08 -47.81 57.27 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.27 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.529 HG22 ' HA ' ' A' ' 27' ' ' THR . 17.7 tt -64.86 -36.46 77.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.21 0.528 . . . . 0.0 110.344 -179.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.423 ' ND2' HG22 ' A' ' 27' ' ' THR . 31.7 m-20 -57.71 -40.97 80.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.509 179.029 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.5 t -66.57 -36.98 83.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.118 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.41 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -58.55 -38.29 77.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.225 0.536 . . . . 0.0 110.328 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.504 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.2 t -62.59 -61.67 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.235 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 54.5 m -50.25 -56.11 12.54 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.369 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.11 -52.16 54.12 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.296 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.41 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 50.4 t -66.46 -21.19 28.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.706 0.288 . . . . 0.0 110.375 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 N--CA 1.454 -0.228 0 CA-C-O 120.919 0.39 . . . . 0.0 110.676 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.173 0 CA-C-O 120.709 0.29 . . . . 0.0 111.574 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.666 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 32.4 t80 -52.1 -33.51 39.91 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -178.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.742 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 14.7 tt0 -79.21 -39.76 32.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.025 0.44 . . . . 0.0 110.38 -178.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.521 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 3.5 mt-10 -65.4 -30.61 71.44 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 178.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.64 -56.93 4.05 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.573 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.742 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.4 OUTLIER -73.89 -58.04 3.57 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -178.184 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.6 m -51.01 -33.67 25.93 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.621 179.808 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -62.19 -55.2 30.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.118 0.485 . . . . 0.0 110.932 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.8 -35.74 61.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.182 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.654 ' O ' HG23 ' A' ' 34' ' ' VAL . 42.6 mm -70.85 -35.67 61.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.3 0.572 . . . . 0.0 111.181 -179.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.2 t-20 -61.51 -50.34 73.08 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.085 0.469 . . . . 0.0 109.821 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 86.2 p -57.28 -43.74 83.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.928 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -52.83 -39.34 62.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 110.681 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.6 t -58.66 -60.3 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.593 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -52.73 -42.29 64.74 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.735 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.06 -44.25 97.47 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.142 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.3 m -79.82 -24.95 12.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.913 0.387 . . . . 0.0 110.809 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.693 -179.397 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.946 0.403 . . . . 0.0 111.485 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.63 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 26.3 t80 -54.19 -29.06 44.54 Favored 'General case' 0 C--O 1.219 -0.522 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -178.292 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.647 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.6 tt0 -78.81 -36.94 41.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 118.196 0.453 . . . . 0.0 111.341 -177.568 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.4 tm-20 -74.75 -33.1 62.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.299 0.571 . . . . 0.0 109.743 179.537 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.4 -57.44 3.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.862 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.647 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.0 OUTLIER -66.18 -58.74 4.75 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -177.8 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 3.2 m -54.08 -36.68 63.42 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.669 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.415 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -59.4 -41.66 89.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.846 178.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.29 -47.27 6.16 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.387 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.721 ' O ' HG23 ' A' ' 34' ' ' VAL . 9.2 mt -63.67 -26.04 39.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 121.008 0.432 . . . . 0.0 110.759 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -76.15 -53.8 7.76 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.917 0.389 . . . . 0.0 110.547 179.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.0 t -62.3 -35.71 79.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.203 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.442 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -57.38 -35.72 70.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.913 0.387 . . . . 0.0 110.849 -179.878 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.9 t -70.18 -62.84 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.086 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.7 m -52.15 -37.91 55.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.863 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.91 -43.91 98.76 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.621 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 34' ' ' VAL . 30.4 m -80.5 -26.79 11.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.933 0.397 . . . . 0.0 110.772 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.231 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.676 -179.407 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.836 0.35 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.691 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 44.4 t80 -54.58 -27.14 36.86 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -179.492 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.525 ' HA ' ' CD1' ' A' ' 26' ' ' TYR . 29.9 mm-40 -75.17 -38.8 60.73 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.849 -178.274 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -78.16 -44.47 25.85 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.2 0.524 . . . . 0.0 109.926 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -56.22 23.92 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.61 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.691 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -63.44 -37.39 87.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.891 -1.049 . . . . 0.0 113.639 -177.094 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.652 HG23 ' CE1' ' A' ' 26' ' ' TYR . 4.3 p -65.68 -45.1 84.16 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.448 -0.501 . . . . 0.0 109.706 177.656 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -43.34 64.79 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.847 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.37 -43.95 11.98 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.497 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.404 ' O ' HG23 ' A' ' 34' ' ' VAL . 35.7 mm -72.84 -54.0 17.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 121.007 0.432 . . . . 0.0 111.176 -179.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 27' ' ' THR . 3.3 t-20 -56.36 -50.19 72.25 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.771 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.6 m -54.23 -40.3 67.58 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.688 0.28 . . . . 0.0 111.089 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.653 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -56.11 -35.7 67.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 -179.781 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.557 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.3 t -74.8 -60.36 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.93 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.9 m -57.05 -38.09 72.73 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.081 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.54 -43.06 97.9 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.674 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 33' ' ' PHE . 20.3 m -80.79 -29.51 11.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.044 0.45 . . . . 0.0 110.318 179.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.227 -179.824 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.124 0 N-CA-C 111.543 0.201 . . . . 0.0 111.543 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -53.31 -42.35 66.59 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 -178.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.674 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.8 tt0 -68.38 -36.86 79.77 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.991 -177.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -72.93 -28.88 62.71 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -80.45 -53.94 6.14 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.506 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.674 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.58 -54.25 8.62 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.273 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.505 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.8 m -57.66 -25.39 60.14 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.731 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.36 -33.36 49.07 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.438 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.94 -42.72 7.99 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.682 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.505 HG22 ' HA ' ' A' ' 27' ' ' THR . 9.0 tp -67.37 -41.32 86.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.641 0.734 . . . . 0.0 111.339 -179.228 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.437 ' N ' HG23 ' A' ' 30' ' ' ILE . 2.0 t-20 -72.48 -41.72 65.71 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 58.4 m -65.24 -31.1 72.09 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.684 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.49 -40.58 87.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.984 0.421 . . . . 0.0 110.006 179.834 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.547 ' O ' HG22 ' A' ' 37' ' ' VAL . 2.9 t -66.81 -63.38 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.221 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.1 m -56.44 -34.79 67.16 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.355 179.568 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.15 -43.3 98.87 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.322 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.684 HG13 ' O ' ' A' ' 33' ' ' PHE . 19.9 m -80.23 -27.38 11.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.972 0.415 . . . . 0.0 110.268 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.141 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.844 -179.463 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 -0.267 0 CA-C-O 120.764 0.316 . . . . 0.0 110.547 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.536 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.4 t80 -57.22 -33.35 67.44 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -179.143 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.712 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.1 tt0 -75.37 -37.24 60.72 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 121.121 -0.232 . . . . 0.0 111.035 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -70.64 -30.8 67.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.526 0.679 . . . . 0.0 109.627 179.776 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -79.82 -58.31 3.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.144 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.712 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -68.48 -58.53 4.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.132 -0.94 . . . . 0.0 113.3 -177.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.55 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.4 m -54.38 -37.45 65.02 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.893 -0.323 . . . . 0.0 110.912 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -55.99 -48.9 75.02 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.176 179.267 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.42 -53.66 8.52 Favored Glycine 0 CA--C 1.52 0.369 0 C-N-CA 120.595 -0.812 . . . . 0.0 113.097 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.638 ' O ' HG23 ' A' ' 34' ' ' VAL . 2.5 tt -61.41 -29.45 45.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.138 0.494 . . . . 0.0 111.915 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -69.51 -48.92 59.0 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 122.035 -0.415 . . . . 0.0 110.169 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 16.6 m -54.04 -38.85 65.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.241 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.425 ' O ' HG12 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.11 -37.73 77.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.195 0.522 . . . . 0.0 110.49 179.59 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.646 ' HA ' HG12 ' A' ' 37' ' ' VAL . 4.2 t -67.49 -59.87 3.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.892 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 73.1 m -45.32 -55.65 5.74 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.471 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.93 -47.49 85.39 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.349 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.646 HG12 ' HA ' ' A' ' 34' ' ' VAL . 5.0 p -65.95 -24.98 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.849 0.357 . . . . 0.0 110.439 -179.887 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.446 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--O 1.231 0.113 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.549 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 -0.122 0 CA-C-O 120.79 0.329 . . . . 0.0 111.198 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.866 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 28.4 t80 -55.33 -17.92 5.6 Favored 'General case' 0 CA--C 1.508 -0.644 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.26 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.693 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 49.0 tt0 -84.38 -45.26 12.93 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.334 -178.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -69.28 -33.68 73.58 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -67.89 -55.46 12.78 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.125 179.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.866 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.3 OUTLIER -68.21 -36.93 80.29 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.543 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.615 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.1 p -59.79 -46.19 89.96 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 120.198 -0.601 . . . . 0.0 109.575 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -41.38 63.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.229 179.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.06 -52.01 7.18 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.54 179.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.615 HG22 ' HA ' ' A' ' 27' ' ' THR . 1.2 tt -70.91 -50.33 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 120.78 0.324 . . . . 0.0 111.836 -179.165 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.549 ' N ' HG23 ' A' ' 30' ' ' ILE . 2.1 t-20 -55.34 -50.97 68.27 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 120.805 0.336 . . . . 0.0 110.417 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 44.0 m -49.66 -44.33 47.68 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.631 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -53.38 -34.73 58.77 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.089 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.534 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.2 t -72.2 -61.65 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.345 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.3 m -51.49 -39.17 57.06 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.763 179.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.15 98.73 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.818 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.534 HG22 ' O ' ' A' ' 34' ' ' VAL . 32.9 m -80.95 -29.52 11.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.073 0.463 . . . . 0.0 110.432 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.448 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.626 179.768 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 -0.238 0 CA-C-O 120.752 0.311 . . . . 0.0 111.113 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.579 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 56.9 t80 -51.53 -31.31 23.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.575 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.2 mt-30 -80.15 -47.49 14.64 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.999 0.428 . . . . 0.0 111.27 -177.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.487 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 45.8 tt0 -60.61 -27.06 67.46 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.461 0.648 . . . . 0.0 109.403 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.1 ttm-85 -81.09 -57.01 3.71 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.058 -0.974 . . . . 0.0 111.084 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.579 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -76.44 -45.1 32.86 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.679 -178.624 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.526 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.4 m -63.35 -39.09 93.59 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.307 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -58.48 -49.62 76.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.751 0.31 . . . . 0.0 111.356 179.047 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.18 -43.04 82.05 Favored Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.533 -0.842 . . . . 0.0 113.019 -179.366 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.575 HG22 ' O ' ' A' ' 26' ' ' TYR . 1.0 OUTLIER -72.17 -47.36 54.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.782 0.325 . . . . 0.0 111.152 -179.348 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.539 ' N ' HG23 ' A' ' 30' ' ' ILE . 21.9 t-20 -59.28 -41.22 88.42 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.757 179.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 24.0 p -57.33 -47.97 80.18 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.981 0.42 . . . . 0.0 109.918 179.661 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.56 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -46.83 -39.2 11.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.268 179.031 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.475 ' N ' ' CD1' ' A' ' 33' ' ' PHE . 2.7 t -70.71 -66.01 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.423 -178.574 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 50.6 m -46.71 -53.75 11.09 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.866 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.79 -45.62 90.96 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.035 179.213 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 33' ' ' PHE . 47.3 t -71.96 -23.27 21.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.821 0.343 . . . . 0.0 110.509 179.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.457 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.332 -0.182 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.527 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.456 -0.145 0 CA-C-O 120.643 0.258 . . . . 0.0 110.978 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.686 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 22.2 t80 -55.12 -31.28 61.13 Favored 'General case' 0 CA--C 1.509 -0.606 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 -179.366 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.705 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 9.2 tt0 -78.74 -34.58 45.66 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.419 -177.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.444 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 53.1 tp10 -73.56 -29.46 62.45 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.024 0.828 . . . . 0.0 109.515 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.27 -57.07 3.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.477 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.705 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -69.7 -57.72 4.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -177.884 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.555 ' HA ' HG22 ' A' ' 30' ' ' ILE . 0.6 OUTLIER -54.88 -41.29 70.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.744 0.307 . . . . 0.0 111.03 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.444 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -57.11 -45.78 83.14 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.347 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.87 -42.88 19.3 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.825 -0.702 . . . . 0.0 113.419 -179.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.586 ' O ' HG23 ' A' ' 34' ' ' VAL . 10.7 tp -71.05 -31.35 44.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.963 0.411 . . . . 0.0 111.839 -178.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.407 ' HB2' ' O ' ' A' ' 27' ' ' THR . 56.3 t30 -72.24 -45.03 61.91 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.785 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 65.9 p -62.76 -36.18 82.21 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.072 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.71 -35.72 73.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.934 0.397 . . . . 0.0 110.889 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.586 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.7 t -70.93 -63.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.519 -179.417 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -50.68 -38.17 45.28 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.737 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.37 -44.51 97.51 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.513 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.574 HG22 ' O ' ' A' ' 34' ' ' VAL . 33.7 m -80.38 -26.62 11.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.934 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.203 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.821 -179.245 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 -0.115 0 CA-C-O 120.843 0.354 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.698 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 40.0 t80 -57.3 -27.74 62.42 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -179.037 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.5 ' O ' ' HD1' ' A' ' 26' ' ' TYR . 18.1 tt0 -71.46 -46.25 60.47 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.025 -178.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.81 -48.04 49.1 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.014 0.435 . . . . 0.0 110.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -56.13 -58.58 7.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.574 0.702 . . . . 0.0 111.457 179.576 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.698 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.18 -32.82 73.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.867 -1.061 . . . . 0.0 113.182 -177.442 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.593 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.2 p -66.7 -45.27 79.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.121 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -49.42 -46.3 47.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.47 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.85 -53.85 9.07 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.823 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.593 HG22 ' HA ' ' A' ' 27' ' ' THR . 7.2 tp -66.8 -49.65 72.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.779 0.29 . . . . 0.0 111.63 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.53 ' N ' HG23 ' A' ' 30' ' ' ILE . 8.3 t-20 -52.46 -40.11 61.9 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.826 0.346 . . . . 0.0 110.583 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.4 m -60.75 -43.92 97.36 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 110.522 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.553 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -56.59 -33.59 66.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.136 0.493 . . . . 0.0 110.981 179.779 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.445 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.4 t -69.06 -60.94 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.373 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -48.04 -58.0 5.04 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.021 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.73 -50.01 66.38 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.273 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.553 HG23 ' O ' ' A' ' 33' ' ' PHE . 75.2 t -68.53 -16.35 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.546 0.213 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.419 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . . . . . . 0 C--N 1.333 -0.134 0 CA-C-O 120.831 0.348 . . . . 0.0 111.371 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.179 0 CA-C-O 120.976 0.417 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.845 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 38.1 t80 -57.78 -21.0 39.41 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.209 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.707 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 7.5 tm0? -81.49 -48.01 12.41 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.689 -178.205 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.9 tt0 -64.73 -30.74 71.76 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.558 179.15 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.04 -51.61 11.93 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.563 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.845 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -77.44 -55.55 5.29 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -177.811 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.469 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.2 m -55.94 -21.97 23.65 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.932 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.412 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -75.84 -58.11 3.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.066 0.46 . . . . 0.0 110.495 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.88 -43.55 65.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.173 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.601 ' O ' HG23 ' A' ' 34' ' ' VAL . 42.0 mm -56.57 -51.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.923 0.392 . . . . 0.0 110.957 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -50.09 -53.16 29.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.904 0.383 . . . . 0.0 110.408 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 p -63.17 -36.15 82.67 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.763 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -55.99 -38.55 70.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.029 0.442 . . . . 0.0 110.703 179.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 30' ' ' ILE . 4.1 t -63.97 -58.98 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.42 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.368 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 70.7 m -53.92 -42.81 69.19 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.677 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.14 -47.06 92.65 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.0 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 34' ' ' VAL . 32.7 m -76.6 -26.62 16.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.886 0.374 . . . . 0.0 110.703 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.217 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.718 -179.725 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 1.325 ' CG2' ' H ' ' A' ' 2' ' ' ASN . 0.3 OUTLIER . . . . . 0 N--CA 1.448 -0.53 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 1.325 ' H ' ' CG2' ' A' ' 1' ' ' VAL . 27.6 m-80 45.18 42.03 6.5 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.489 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -80.66 106.71 12.88 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.503 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.63 -70.94 0.02 OUTLIER Glycine 0 C--N 1.331 0.275 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.674 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 25.6 m-80 -162.63 29.64 0.1 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.717 0.294 . . . . 0.0 111.023 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -123.16 -15.1 3.88 Favored Glycine 0 CA--C 1.52 0.356 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.75 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.2 m -88.37 -32.06 5.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.769 0.319 . . . . 0.0 110.464 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.2 t -105.15 88.93 2.98 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.56 179.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 5.7 t -69.27 128.76 37.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.969 0.414 . . . . 0.0 111.507 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.556 ' O ' ' O ' ' A' ' 11' ' ' LYS . 1.9 p -56.04 154.91 6.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.21 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.556 ' O ' ' O ' ' A' ' 10' ' ' SER . 1.9 mtpm? 45.21 163.45 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.147 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 t -90.05 58.82 4.29 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.116 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.473 ' O ' ' HB2' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -158.25 -90.38 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.261 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.473 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 53.2 m 75.27 93.71 0.07 Allowed 'General case' 0 C--O 1.232 0.147 0 CA-C-O 120.67 0.271 . . . . 0.0 110.827 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.1 m -162.2 -47.87 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.78 0.324 . . . . 0.0 111.498 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.501 ' O ' HG13 ' A' ' 16' ' ' VAL . 9.5 p -164.69 117.09 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.828 0.347 . . . . 0.0 111.552 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -85.48 157.19 20.51 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.974 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -63.55 -31.82 73.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.121 0.486 . . . . 0.0 109.868 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -45.28 -46.68 11.05 Favored Glycine 0 C--N 1.331 0.304 0 CA-C-N 115.551 -0.749 . . . . 0.0 113.002 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.67 -46.24 91.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.846 0.355 . . . . 0.0 110.821 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.57 -59.36 5.56 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.619 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.586 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 34.8 t80 -50.02 -34.6 21.8 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 112.84 0.681 . . . . 0.0 112.84 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.594 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 1.8 tt0 -79.71 -32.24 41.28 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.237 -177.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.648 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.3 OUTLIER -76.24 -31.76 58.52 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.443 0.64 . . . . 0.0 109.295 179.503 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.1 ttt180 -77.16 -60.58 2.3 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 114.847 -1.07 . . . . 0.0 111.61 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.594 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -63.18 -54.53 36.12 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 113.056 0.761 . . . . 0.0 113.056 -178.03 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.45 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.5 m -58.93 -36.05 74.11 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.514 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.648 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -53.4 -49.54 67.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.04 0.448 . . . . 0.0 110.645 178.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.94 -33.87 28.66 Favored Glycine 0 C--N 1.33 0.229 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.449 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.52 HD12 ' HD1' ' A' ' 26' ' ' TYR . 5.2 mt -74.99 -29.59 22.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.746 0.308 . . . . 0.0 110.773 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.439 ' N ' ' O ' ' A' ' 27' ' ' THR . 37.9 t-20 -71.79 -49.14 41.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.038 0.447 . . . . 0.0 110.353 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.3 m -54.78 -45.17 74.24 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.524 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.455 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -48.43 -35.42 12.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.02 179.898 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' A' ' 38' ' ' ALA . 3.0 t -70.66 -61.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.412 -179.118 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -48.29 -58.44 4.57 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.49 -58.39 13.38 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.693 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.455 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 53.5 t -59.36 -22.25 22.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.617 0.246 . . . . 0.0 110.666 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.448 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -75.26 -26.65 58.98 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.276 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.9 p -74.1 -45.06 51.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.152 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -72.91 -50.75 12.3 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.646 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 179.04 82.7 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 121.279 0.562 . . . . 0.0 111.144 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.08 26.41 24.02 Favored Glycine 0 C--N 1.317 -0.524 0 CA-C-N 115.144 -0.934 . . . . 0.0 112.66 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 96.9 p -108.45 30.54 6.35 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.671 0.272 . . . . 0.0 111.339 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.616 ' O ' HG23 ' A' ' 44' ' ' ILE . 6.6 tp -178.21 69.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.96 0.41 . . . . 0.0 111.216 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -179.72 32.99 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.619 179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 69.5 mtt180 -100.42 54.97 0.89 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.923 0.392 . . . . 0.0 110.689 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -132.9 91.97 27.5 Favored Pre-proline 0 C--N 1.331 -0.234 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.694 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo . . . . . 0 C--O 1.249 1.054 0 C-N-CA 122.498 2.132 . . . . 0.0 112.159 179.74 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.52 ' O ' HG12 ' A' ' 1' ' ' VAL . 39.7 t . . . . . 0 N--CA 1.448 -0.532 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.468 ' O ' ' HB2' ' A' ' 3' ' ' TYR . 4.3 p-10 -80.01 -36.53 35.77 Favored 'General case' 0 C--N 1.333 -0.136 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 179.374 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.468 ' HB2' ' O ' ' A' ' 2' ' ' ASN . 46.6 m-85 68.9 86.63 0.13 Allowed 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -177.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -156.16 61.77 0.34 Allowed Glycine 0 C--N 1.333 0.416 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.938 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -162.74 -64.82 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.955 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.481 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -167.87 -56.14 0.03 OUTLIER Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.499 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.435 HG21 ' HD1' ' A' ' 3' ' ' TYR . 21.8 t 62.98 -64.82 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 111.903 0.334 . . . . 0.0 111.903 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.481 ' N ' ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER 48.48 92.1 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 120.866 0.365 . . . . 0.0 110.99 -179.738 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 3.7 m 54.55 89.05 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.238 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.6 t -81.15 71.34 8.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.383 179.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 55.17 41.86 31.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.569 -179.316 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.581 HG22 ' HG2' ' A' ' 13' ' ' LYS . 41.6 m -88.95 -84.16 0.22 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.959 178.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.581 ' HG2' HG22 ' A' ' 12' ' ' THR . 2.8 pttt -158.37 38.63 0.24 Allowed 'General case' 0 C--O 1.233 0.222 0 C-N-CA 120.983 -0.287 . . . . 0.0 111.576 179.193 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.7 m -89.42 164.27 14.92 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.749 0.309 . . . . 0.0 111.779 179.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 47.5 m -119.49 -11.4 9.49 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 16' ' ' VAL . 12.4 p -163.65 99.9 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.757 0.789 . . . . 0.0 110.65 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.423 ' OD1' ' N ' ' A' ' 17' ' ' ASN . 6.4 p-10 -135.39 139.95 44.6 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.135 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -50.09 -28.25 6.91 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.043 0.449 . . . . 0.0 111.136 -179.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.58 -65.21 3.09 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.896 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 20.2 mm-40 -70.76 -33.05 70.39 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -179.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.94 -70.04 0.14 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.003 0.43 . . . . 0.0 110.731 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.599 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.2 t80 -54.89 -34.02 62.59 Favored 'General case' 0 C--O 1.22 -0.496 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.646 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 0.0 OUTLIER -76.94 -39.04 52.1 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 121.03 0.443 . . . . 0.0 110.537 -177.874 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 6.4 tp10 -68.08 -28.37 67.29 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.7 ttt-85 -80.61 -55.21 5.0 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.429 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.646 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -76.66 -55.09 5.82 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -177.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.0 m -54.8 -32.57 60.41 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.944 -0.302 . . . . 0.0 110.244 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.458 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -66.15 -50.77 62.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.536 179.038 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.87 -41.38 82.81 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.822 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.516 HG22 ' O ' ' A' ' 26' ' ' TYR . 10.4 tp -70.84 -42.99 77.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.93 0.395 . . . . 0.0 111.001 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.466 ' N ' HG23 ' A' ' 30' ' ' ILE . 37.9 t-20 -62.6 -43.72 98.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.414 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.4 m -59.3 -37.66 78.28 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.876 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.477 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.28 -35.29 73.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.883 179.853 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.0 t -72.55 -62.04 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.57 -178.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 72.2 m -47.77 -57.65 5.32 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.408 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.21 -51.26 57.07 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.16 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 33' ' ' PHE . 53.3 t -64.24 -25.36 37.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.63 0.252 . . . . 0.0 110.513 179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -79.64 -24.07 42.12 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.421 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.43 -48.72 18.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.283 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -90.94 -27.94 17.32 Favored Glycine 0 CA--C 1.518 0.268 0 C-N-CA 120.661 -0.78 . . . . 0.0 113.166 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 65.91 74.89 0.35 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 121.352 0.596 . . . . 0.0 110.948 -179.504 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -113.28 37.99 3.39 Favored Glycine 0 C--N 1.319 -0.373 0 CA-C-N 115.106 -0.952 . . . . 0.0 112.617 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 32.9 p -106.72 9.76 31.08 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 111.599 0.222 . . . . 0.0 111.599 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.4 pt -123.49 -11.02 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 112.022 0.379 . . . . 0.0 112.022 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 89.54 -26.87 8.48 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.184 -179.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 66.13 118.76 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.495 0.188 . . . . 0.0 110.705 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 61.1 mtm180 -151.28 154.66 34.03 Favored Pre-proline 0 N--CA 1.464 0.273 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.446 179.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 C--O 1.251 1.148 0 C-N-CA 122.372 2.048 . . . . 0.0 112.217 -179.746 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.1 m . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -161.1 -45.12 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.868 0.366 . . . . 0.0 111.413 -179.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 14.9 p90 -80.59 -36.06 33.31 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.076 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 53.65 71.37 0.71 Allowed Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.983 -0.627 . . . . 0.0 113.274 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 62.1 37.65 14.43 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.764 0.316 . . . . 0.0 110.811 179.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -135.99 34.83 2.21 Favored Glycine 0 C--N 1.33 0.233 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.282 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.585 HG13 ' O ' ' A' ' 7' ' ' VAL . 10.9 p -88.28 110.34 20.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.66 0.267 . . . . 0.0 110.594 179.35 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 10.2 t -149.12 106.48 3.63 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.045 0.45 . . . . 0.0 110.662 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 37.7 t -155.49 103.91 2.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.324 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.9 m -163.59 92.28 0.7 Allowed 'General case' 0 N--CA 1.463 0.203 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER 75.34 8.73 3.86 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.255 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.65 158.48 44.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.976 0.417 . . . . 0.0 110.774 -179.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 68.6 -69.38 0.15 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.966 -179.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 4.0 m -71.06 91.4 0.89 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.37 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 62.96 176.39 0.15 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.358 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.584 ' O ' HG13 ' A' ' 16' ' ' VAL . 14.1 p -163.88 111.13 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.362 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.471 ' HB3' ' CE3' ' A' ' 18' ' ' TRP . 13.1 t30 -70.23 152.44 44.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.125 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.51 ' O ' ' CD1' ' A' ' 18' ' ' TRP . 6.6 p90 49.13 27.32 1.73 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.86 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.34 -46.05 4.5 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.568 -0.825 . . . . 0.0 111.505 179.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -68.04 -38.35 82.41 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.683 0.278 . . . . 0.0 111.262 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -73.12 -53.71 10.33 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.617 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.644 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 30.1 t80 -56.48 -28.54 60.03 Favored 'General case' 0 CA--C 1.509 -0.605 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.71 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.5 tt0 -77.23 -43.45 33.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 121.117 0.484 . . . . 0.0 110.068 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.401 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 40.1 tt0 -66.99 -29.49 69.33 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.832 178.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.48 -53.23 7.08 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.514 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.71 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.08 -55.75 5.42 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -178.066 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.8 m -55.34 -27.9 50.21 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.96 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.401 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -70.82 -51.99 23.3 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.892 0.377 . . . . 0.0 111.253 179.305 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.91 -44.13 56.49 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.896 -179.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.671 ' O ' HG23 ' A' ' 34' ' ' VAL . 2.5 tp -63.28 -44.01 98.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.968 0.414 . . . . 0.0 111.691 -179.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.463 ' N ' HG23 ' A' ' 30' ' ' ILE . 36.0 t-20 -57.31 -49.21 76.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.858 0.361 . . . . 0.0 110.558 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 39.6 p -59.07 -41.07 87.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.072 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -57.08 -36.57 70.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.97 0.414 . . . . 0.0 110.808 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.671 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.5 t -62.42 -59.55 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.142 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.4 m -49.31 -47.2 47.24 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.197 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.3 -44.91 93.27 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.421 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.4 m -78.62 -25.88 13.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.818 0.342 . . . . 0.0 110.842 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -71.33 -24.85 62.19 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.809 -179.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -59.61 -27.49 66.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.375 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -121.77 -44.64 0.37 Allowed Glycine 0 C--N 1.33 0.221 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.824 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 178.95 83.63 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.318 0.58 . . . . 0.0 110.891 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -81.81 -16.18 73.46 Favored Glycine 0 C--N 1.318 -0.459 0 CA-C-N 115.23 -0.895 . . . . 0.0 113.666 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.0 m -67.22 -75.07 0.1 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 117.015 0.407 . . . . 0.0 110.787 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.58 ' O ' HG22 ' A' ' 44' ' ' ILE . 16.6 mt 66.77 11.75 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.222 179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 55.4 14.49 6.62 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.736 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.8 tmm_? -116.28 122.84 46.12 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.861 0.362 . . . . 0.0 111.334 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.66 98.86 2.64 Favored Pre-proline 0 CA--C 1.53 0.178 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.872 179.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 C--O 1.249 1.071 0 C-N-CA 122.412 2.075 . . . . 0.0 112.261 179.744 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 1.532 ' CG1' HG12 ' A' ' 7' ' ' VAL . 6.7 p . . . . . 0 N--CA 1.449 -0.507 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 1.099 ' H ' ' CG2' ' A' ' 1' ' ' VAL . 14.0 t30 -160.44 28.09 0.16 Allowed 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.249 0.547 . . . . 0.0 110.047 -178.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.804 ' HD2' HG11 ' A' ' 1' ' ' VAL . 5.3 m-85 -80.78 -52.69 7.23 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.065 -179.283 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 90.49 12.23 61.42 Favored Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.984 -0.626 . . . . 0.0 113.24 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -162.33 39.34 0.12 Allowed 'General case' 0 C--O 1.233 0.205 0 CA-C-O 121.124 0.488 . . . . 0.0 111.163 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 131.19 89.24 0.48 Allowed Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.927 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.532 HG12 ' CG1' ' A' ' 1' ' ' VAL . 19.9 m -87.34 -26.33 5.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.689 0.281 . . . . 0.0 111.1 -179.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.3 m -96.0 74.09 3.02 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.922 0.391 . . . . 0.0 110.52 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -176.74 131.37 0.19 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.565 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.7 m -76.9 79.39 3.47 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.131 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 4.0 mmmm 48.08 20.42 0.25 Allowed 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.859 -179.202 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.7 p -92.79 -24.64 18.47 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.3 mttp 80.25 -6.65 1.7 Allowed 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.764 0.426 . . . . 0.0 111.61 -178.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.0 m 69.1 -70.35 0.14 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.939 0.4 . . . . 0.0 111.515 179.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.8 m -57.34 -167.51 0.0 OUTLIER 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.73 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 16.3 t 81.15 -70.61 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.768 179.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.6 p30 173.36 -33.31 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.234 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -39.18 -33.99 0.16 Allowed 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.123 -178.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.09 -44.63 87.19 Favored Glycine 0 C--N 1.334 0.436 0 C-N-CA 120.695 -0.764 . . . . 0.0 113.559 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -62.74 -38.21 89.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.919 0.39 . . . . 0.0 111.242 -179.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -67.64 -51.19 52.92 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.551 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -52.68 -41.99 64.36 Favored 'General case' 0 CA--C 1.512 -0.507 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.633 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 3.5 tm0? -65.92 -42.09 90.58 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.897 0.379 . . . . 0.0 111.106 -177.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -70.45 -30.07 66.8 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.307 0.575 . . . . 0.0 110.161 179.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -80.03 -54.05 6.15 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.513 -0.767 . . . . 0.0 111.504 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.633 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.86 -55.83 6.82 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -178.016 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.551 ' HA ' HG22 ' A' ' 30' ' ' ILE . 2.3 m -55.98 -32.28 63.77 Favored 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 120.694 -0.402 . . . . 0.0 110.807 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.41 -32.85 68.87 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.705 179.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.84 -42.82 8.0 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.632 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.551 HG22 ' HA ' ' A' ' 27' ' ' THR . 4.0 tp -68.87 -36.12 72.62 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-O 121.598 0.713 . . . . 0.0 110.863 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -77.3 -38.03 51.46 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.082 0.467 . . . . 0.0 109.901 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 47.2 t -66.68 -30.79 71.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.478 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.47 -40.67 87.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.865 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.537 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.3 t -65.98 -61.99 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.472 179.344 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -55.37 -34.71 64.55 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.49 -45.86 93.84 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.293 179.214 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.537 HG22 ' O ' ' A' ' 34' ' ' VAL . 31.3 m -76.8 -27.63 16.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-O 121.119 0.485 . . . . 0.0 110.055 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -79.09 -23.05 44.39 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.289 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.9 t -79.81 -43.76 21.83 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.355 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.595 ' O ' ' HB3' ' A' ' 41' ' ' ALA . . . -174.53 -43.5 0.05 OUTLIER Glycine 0 CA--C 1.52 0.367 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.587 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.595 ' HB3' ' O ' ' A' ' 40' ' ' GLY . . . 83.37 -9.55 1.04 Allowed 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 179.484 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.13 28.62 53.27 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.384 -0.912 . . . . 0.0 113.047 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 19.1 m -104.03 -65.31 1.03 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.885 0.374 . . . . 0.0 110.816 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.0 tt -155.62 33.56 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.442 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -114.21 28.95 7.97 Favored Glycine 0 C--N 1.331 0.267 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.232 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -173.55 39.36 0.01 OUTLIER 'General case' 0 C--O 1.235 0.316 0 CA-C-O 120.667 0.27 . . . . 0.0 111.007 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 34.0 ptt85 42.24 85.67 0.16 Allowed Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.375 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo . . . . . 0 C--O 1.249 1.065 0 C-N-CA 122.223 1.949 . . . . 0.0 112.182 179.123 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.659 HG12 ' N ' ' A' ' 2' ' ' ASN . 77.4 t . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.659 ' N ' HG12 ' A' ' 1' ' ' VAL . 1.4 t30 71.11 -69.04 0.19 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.394 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 26.5 p90 -80.45 -179.33 7.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.419 -179.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 113.82 63.09 0.42 Allowed Glycine 0 CA--C 1.512 -0.112 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -178.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -162.47 -42.42 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.507 0.194 . . . . 0.0 111.412 -179.05 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -162.22 55.22 0.3 Allowed Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.828 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 m -89.4 22.92 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.9 m 60.81 95.34 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.675 0.274 . . . . 0.0 110.755 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -71.58 137.62 48.15 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.869 0.366 . . . . 0.0 110.411 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.54 17.7 14.24 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.411 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt -162.73 174.97 11.81 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-O 120.883 0.373 . . . . 0.0 110.896 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 49.3 p -89.5 26.0 1.82 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.982 -179.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.524 ' O ' ' HB2' ' A' ' 14' ' ' CYS . 12.6 tttt -158.5 -68.64 0.09 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.682 0.277 . . . . 0.0 110.366 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.524 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 62.9 m 74.31 66.25 0.08 Allowed 'General case' 0 CA--C 1.521 -0.163 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.1 m -121.67 -2.26 9.39 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.404 -0.817 . . . . 0.0 111.56 -179.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.581 HG12 ' H ' ' A' ' 19' ' ' GLY . 40.9 t -75.61 -54.01 14.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.716 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 63.36 -63.36 0.13 Allowed 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 178.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.439 ' N ' ' O ' ' A' ' 16' ' ' VAL . 4.7 p90 -67.6 -15.31 63.59 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -177.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.581 ' H ' HG12 ' A' ' 16' ' ' VAL . . . -51.96 -57.11 13.58 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 120.598 -0.811 . . . . 0.0 112.89 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -64.06 -26.47 68.57 Favored 'General case' 0 C--N 1.33 -0.254 0 O-C-N 122.717 -0.284 . . . . 0.0 111.614 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.5 -69.67 0.19 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.571 0.224 . . . . 0.0 110.817 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.532 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.3 t80 -56.09 -35.26 66.81 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.684 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 40.0 mt-30 -73.99 -34.09 64.07 Favored 'General case' 0 N--CA 1.464 0.232 0 O-C-N 123.144 0.277 . . . . 0.0 111.099 -177.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.422 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 32.9 tt0 -75.74 -30.24 59.15 Favored 'General case' 0 C--N 1.33 -0.264 0 O-C-N 123.732 0.645 . . . . 0.0 109.946 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.2 ttt-85 -80.65 -57.9 3.36 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.114 -0.948 . . . . 0.0 111.096 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.684 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -65.64 -57.74 7.4 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.239 -0.892 . . . . 0.0 113.378 -178.105 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.515 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.3 m -56.84 -44.95 82.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.785 0.326 . . . . 0.0 111.27 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.422 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -52.27 -43.42 64.4 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.457 -179.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.44 -51.51 8.35 Favored Glycine 0 CA--C 1.52 0.377 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.872 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.521 HG23 ' N ' ' A' ' 31' ' ' ASN . 9.8 tp -65.53 -46.15 90.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.018 0.437 . . . . 0.0 111.714 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.521 ' N ' HG23 ' A' ' 30' ' ' ILE . 1.1 t30 -63.04 -38.25 90.44 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.956 0.408 . . . . 0.0 110.199 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.5 m -57.14 -37.37 71.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.237 178.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.84 -37.82 77.34 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.106 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.571 ' O ' HG22 ' A' ' 37' ' ' VAL . 2.8 t -68.92 -63.08 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.732 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.5 m -47.9 -39.52 19.15 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.013 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.18 -50.31 69.05 Favored Glycine 0 C--N 1.332 0.354 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.592 179.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.571 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.0 m -72.14 -29.33 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.177 0.513 . . . . 0.0 109.982 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -71.25 -22.58 61.96 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.129 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 54.2 m -55.94 -26.16 46.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.576 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 169.01 34.14 0.02 OUTLIER Glycine 0 CA--C 1.52 0.353 0 C-N-CA 119.637 -1.268 . . . . 0.0 114.358 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.403 ' CB ' ' O ' ' A' ' 37' ' ' VAL . . . -80.27 -31.95 38.26 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 117.49 0.645 . . . . 0.0 110.74 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 129.94 61.23 0.1 Allowed Glycine 0 C--N 1.331 0.281 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.325 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 58.2 p -173.06 77.05 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.917 0.389 . . . . 0.0 110.706 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.533 ' O ' HG23 ' A' ' 44' ' ' ILE . 1.0 OUTLIER -154.58 59.87 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.683 179.951 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 179.0 39.8 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.999 -0.62 . . . . 0.0 112.115 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.4 ' O ' ' O ' ' A' ' 47' ' ' ARG . 0.2 OUTLIER 58.76 -173.0 0.1 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.464 0.173 . . . . 0.0 110.574 -179.687 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.4 ' O ' ' O ' ' A' ' 46' ' ' ARG . 22.8 ptt85 44.9 101.17 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.859 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo . . . . . 0 C--O 1.249 1.034 0 C-N-CA 122.345 2.03 . . . . 0.0 112.353 179.767 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.915 HG22 ' O ' ' A' ' 1' ' ' VAL . 1.4 p . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 6.4 p-10 -160.78 69.5 0.37 Allowed 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.821 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -80.48 141.87 34.78 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.41 112.29 0.69 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.039 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 79.61 71.6 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 120.656 0.265 . . . . 0.0 110.45 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 84.67 83.43 1.0 Allowed Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.894 -179.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.414 ' O ' HG23 ' A' ' 7' ' ' VAL . 12.3 m -88.25 107.63 17.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.223 0.535 . . . . 0.0 111.232 -179.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -178.87 68.67 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.181 -179.517 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.1 76.9 1.39 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.572 -179.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.601 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 25.4 p -98.05 148.22 23.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.971 -179.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.601 ' HB2' ' O ' ' A' ' 10' ' ' SER . 0.9 OUTLIER 77.63 129.24 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.491 -179.658 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.609 HG22 ' H ' ' A' ' 13' ' ' LYS . 2.3 m 60.0 176.83 0.09 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.457 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.609 ' H ' HG22 ' A' ' 12' ' ' THR . 2.6 tptt -81.08 161.86 23.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.162 179.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 3.4 t -107.39 115.61 30.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.931 0.396 . . . . 0.0 111.352 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.616 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.9 OUTLIER -85.11 -167.84 1.99 Allowed 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.664 179.669 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.616 HG23 ' C ' ' A' ' 15' ' ' SER . 2.2 t 81.01 90.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.209 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 49.1 m-20 -123.04 31.48 6.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.29 0.567 . . . . 0.0 110.45 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.405 ' O ' ' N ' ' A' ' 22' ' ' PHE . 0.6 OUTLIER -41.5 -29.56 0.17 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.223 -0.898 . . . . 0.0 112.118 -179.796 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.56 -60.69 3.16 Favored Glycine 0 C--N 1.333 0.366 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.871 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 mm-40 -71.53 -38.04 71.1 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.719 0.295 . . . . 0.0 111.482 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -65.51 -67.78 0.41 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.333 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.722 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 60.3 t80 -51.05 -30.14 14.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.606 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.9 tt0 -81.6 -35.67 29.85 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 111.941 0.349 . . . . 0.0 111.941 -177.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.555 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.0 OUTLIER -76.18 -25.19 54.95 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.673 0.749 . . . . 0.0 109.086 -179.504 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.51 -59.09 2.89 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.111 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.722 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -68.11 -57.74 5.6 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 113.164 0.801 . . . . 0.0 113.164 -178.789 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.491 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 0.7 OUTLIER -53.79 -36.69 62.71 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.661 -179.756 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.555 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -55.81 -51.51 67.22 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.677 0.275 . . . . 0.0 110.647 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -74.79 -36.68 46.99 Favored Glycine 0 C--N 1.332 0.32 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.178 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 38.1 mm -70.2 -42.03 78.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 110.288 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -62.48 -39.74 94.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.054 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -55.3 -48.7 73.72 Favored 'General case' 0 CA--C 1.519 -0.221 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.332 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.518 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -44.68 -38.58 4.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.194 179.217 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.486 ' O ' ' N ' ' A' ' 38' ' ' ALA . 2.7 t -69.25 -64.21 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.34 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.404 -179.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.6 m -45.56 -56.11 5.5 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.826 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -54.85 -54.03 35.95 Favored Glycine 0 C--N 1.33 0.207 0 C-N-CA 120.499 -0.858 . . . . 0.0 111.835 179.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 33' ' ' PHE . 58.8 t -64.62 -19.16 24.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.715 0.293 . . . . 0.0 110.719 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -78.56 -25.55 45.41 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.027 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 6.9 t -64.49 -43.61 93.59 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.366 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -80.57 -54.86 3.57 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.764 -0.732 . . . . 0.0 111.908 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 60.81 19.5 9.69 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.811 0.338 . . . . 0.0 111.712 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -158.37 31.41 0.48 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.614 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.45 28.11 3.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.671 0.272 . . . . 0.0 110.929 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.0 mt 72.64 79.87 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.97 0.414 . . . . 0.0 111.048 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -161.64 38.13 0.39 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.287 179.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -160.34 98.75 1.29 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.937 0.399 . . . . 0.0 110.8 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -139.84 153.67 70.04 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.646 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo . . . . . 0 C--O 1.248 1.014 0 C-N-CA 122.404 2.069 . . . . 0.0 112.099 -179.801 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.841 HG12 ' O ' ' A' ' 1' ' ' VAL . 71.7 t . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -78.89 164.66 24.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.927 0.394 . . . . 0.0 110.856 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -157.3 38.41 0.29 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.486 0.66 . . . . 0.0 109.27 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -133.9 52.86 0.8 Allowed Glycine 0 C--O 1.228 -0.263 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.039 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -161.55 -49.19 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.48 0.657 . . . . 0.0 109.974 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.04 86.06 0.07 OUTLIER Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.608 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.5 p -149.46 138.16 14.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.0 t -122.17 55.68 1.13 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.441 -178.245 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 52.7 t -153.5 125.98 8.12 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.775 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 t -93.17 -68.84 0.78 Allowed 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.404 ' O ' ' N ' ' A' ' 13' ' ' LYS . 13.6 pttm -162.77 170.81 17.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.227 179.166 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER 64.6 -65.11 0.14 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.507 179.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.404 ' N ' ' O ' ' A' ' 11' ' ' LYS . 8.5 mttp -81.05 86.2 6.17 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -166.56 42.41 0.06 Allowed 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.369 179.029 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.8 m -155.37 131.23 9.97 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.224 0.535 . . . . 0.0 111.481 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.2 p -165.0 130.21 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.651 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -107.36 135.78 48.28 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.732 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 2.5 t-105 54.13 34.97 21.26 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.905 0.383 . . . . 0.0 110.783 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -113.78 -43.5 0.8 Allowed Glycine 0 C--N 1.33 0.237 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.261 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -71.05 -34.72 71.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.891 0.377 . . . . 0.0 110.726 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.73 -59.14 3.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.301 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.674 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 24.1 t80 -53.64 -30.8 44.64 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 113.186 0.81 . . . . 0.0 113.186 -179.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.725 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 29.5 tt0 -76.95 -39.87 49.1 Favored 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.769 -177.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.502 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 3.2 tp10 -71.52 -31.7 67.35 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.908 179.099 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.92 -54.14 6.96 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.509 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.725 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -71.21 -58.41 3.57 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -177.884 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.7 m -54.13 -31.66 52.97 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.579 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -64.68 -45.76 85.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.495 -0.321 . . . . 0.0 111.024 178.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.27 -43.78 12.54 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.05 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.476 ' O ' HG23 ' A' ' 34' ' ' VAL . 46.7 mm -62.33 -36.28 73.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 121.369 0.604 . . . . 0.0 110.442 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -67.67 -44.05 78.76 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.4 m -62.49 -37.87 87.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.992 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.513 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -55.7 -39.73 71.43 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.016 0.436 . . . . 0.0 109.987 179.625 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.506 ' O ' HG22 ' A' ' 37' ' ' VAL . 4.0 t -59.81 -59.17 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.409 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.893 178.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -57.37 -42.02 81.3 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.25 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.4 -43.17 95.91 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.954 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 33' ' ' PHE . 27.0 m -79.72 -27.22 12.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.106 0.479 . . . . 0.0 110.403 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -76.2 -24.92 54.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.26 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -75.16 -47.5 28.14 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.087 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.7 39.92 0.23 Allowed Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.929 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 60.4 24.19 13.73 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.884 0.373 . . . . 0.0 111.606 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -54.82 -63.72 5.0 Favored Glycine 0 C--N 1.321 -0.305 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.727 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.3 t 62.83 66.43 0.75 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.893 0.378 . . . . 0.0 110.782 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.572 ' O ' HG22 ' A' ' 44' ' ' ILE . 11.6 mt -106.12 43.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.139 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -114.55 31.46 6.37 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.767 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.1 mmp_? -133.22 175.59 9.26 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.533 0.206 . . . . 0.0 110.666 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.2 mtp180 -140.01 55.02 5.98 Favored Pre-proline 0 N--CA 1.463 0.176 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.986 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo . . . . . 0 C--O 1.248 1.012 0 C-N-CA 122.444 2.096 . . . . 0.0 112.346 179.847 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.835 HG22 ' O ' ' A' ' 1' ' ' VAL . 0.3 OUTLIER . . . . . 0 N--CA 1.45 -0.474 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.0 m-80 -80.17 68.46 6.32 Favored 'General case' 0 C--N 1.34 0.155 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.148 178.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -80.25 70.25 6.85 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.967 -0.293 . . . . 0.0 110.224 -179.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -124.1 43.61 1.39 Allowed Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.695 -0.764 . . . . 0.0 113.257 -179.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 29.5 t30 64.28 47.42 3.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.873 0.368 . . . . 0.0 110.731 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 170.29 55.67 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.76 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.7 p -89.18 -37.06 9.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.702 0.287 . . . . 0.0 110.995 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.3 t 64.4 101.02 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.812 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.3 m -93.11 172.31 8.39 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.839 0.352 . . . . 0.0 111.037 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -129.29 28.13 5.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.181 -0.463 . . . . 0.0 112.075 -179.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 5.1 tttm -163.3 -174.8 3.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.966 0.412 . . . . 0.0 111.142 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.2 p -88.98 -42.1 11.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.66 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.7 mtpt -81.24 -63.42 1.4 Allowed 'General case' 0 C--N 1.334 -0.099 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.892 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 55.98 54.54 7.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.028 0.442 . . . . 0.0 110.759 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.3 t -75.26 -149.53 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.023 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.617 ' O ' HG13 ' A' ' 16' ' ' VAL . 8.7 p -164.24 108.98 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-O 120.88 0.372 . . . . 0.0 110.597 -179.806 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 71.4 m-80 -121.68 -43.33 2.38 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.337 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -100.17 35.06 2.16 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.084 0.469 . . . . 0.0 110.569 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.41 -60.98 0.85 Allowed Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.936 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -66.49 -36.98 84.07 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.85 0.357 . . . . 0.0 111.304 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.45 -64.84 0.82 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.151 -0.477 . . . . 0.0 112.018 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.651 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.6 t80 -52.54 -32.24 39.79 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 -178.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.691 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 4.8 tt0 -77.92 -36.4 49.45 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.745 -177.322 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.405 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.3 tp10 -75.05 -29.82 60.86 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.274 0.559 . . . . 0.0 109.538 179.155 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt85 -78.73 -52.36 8.5 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.294 -0.866 . . . . 0.0 111.12 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.691 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -75.05 -57.32 3.97 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.205 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.496 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 2.1 m -56.03 -20.48 16.97 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.102 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.405 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -79.49 -48.9 13.12 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.964 0.412 . . . . 0.0 110.075 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.83 -45.31 27.95 Favored Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.284 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.696 ' O ' HG23 ' A' ' 34' ' ' VAL . 50.5 mm -60.49 -45.44 96.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.778 0.323 . . . . 0.0 110.72 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -61.26 -37.07 81.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.776 0.322 . . . . 0.0 110.81 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.5 t -69.11 -38.88 79.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.793 0.33 . . . . 0.0 110.755 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.498 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.42 -34.45 72.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.208 0.528 . . . . 0.0 110.457 179.54 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.696 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.7 t -69.28 -61.81 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.785 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 52.4 m -47.12 -57.49 5.04 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.28 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.42 -48.69 78.85 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.011 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 33' ' ' PHE . 52.5 t -67.43 -21.83 28.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.765 0.317 . . . . 0.0 110.739 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.434 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -78.18 -25.9 47.37 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.502 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 30.7 t -72.61 -34.72 67.55 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.286 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.83 51.98 0.19 Allowed Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.65 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -91.62 -32.03 15.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.939 0.4 . . . . 0.0 111.159 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -168.87 -61.49 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.0 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.9 p 52.03 58.93 4.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.924 0.392 . . . . 0.0 111.42 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.527 ' O ' HG23 ' A' ' 44' ' ' ILE . 2.9 tt -166.83 60.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.131 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -125.89 -38.19 0.48 Allowed Glycine 0 C--N 1.328 0.137 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.944 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 ttm-85 -179.81 99.34 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.78 0.324 . . . . 0.0 110.358 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.446 ' N ' ' CD ' ' A' ' 48' ' ' PRO . 44.6 mtp85 -64.03 -48.39 77.92 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.029 -179.661 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.446 ' CD ' ' N ' ' A' ' 47' ' ' ARG . 63.8 Cg_exo . . . . . 0 C--O 1.249 1.064 0 C-N-CA 122.284 1.989 . . . . 0.0 112.218 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.765 ' O ' HG23 ' A' ' 1' ' ' VAL . 2.4 m . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -79.96 67.82 5.88 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 113.405 0.891 . . . . 0.0 113.405 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -82.08 -37.19 26.73 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 179.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.52 150.09 6.01 Favored Glycine 0 CA--C 1.524 0.636 0 C-N-CA 120.928 -0.653 . . . . 0.0 113.732 -178.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 53.37 67.45 1.0 Allowed 'General case' 0 C--O 1.233 0.221 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 152.66 -24.74 0.84 Allowed Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.105 -1.045 . . . . 0.0 114.038 178.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 7' ' ' VAL . 2.9 m -150.25 98.41 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.4 m -149.05 113.25 5.21 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.229 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 29.9 p -119.74 176.46 5.38 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.476 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.4 m -56.12 -23.81 36.72 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.233 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 81.53 -1.72 1.64 Allowed 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.09 -179.386 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.553 HG23 ' N ' ' A' ' 13' ' ' LYS . 8.9 t -88.79 -61.63 1.66 Allowed 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.432 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.553 ' N ' HG23 ' A' ' 12' ' ' THR . 0.0 OUTLIER -82.85 17.29 1.93 Allowed 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 179.269 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.6 m -102.07 137.16 40.71 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.194 0.521 . . . . 0.0 112.125 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.468 ' O ' ' CG2' ' A' ' 16' ' ' VAL . 0.4 OUTLIER 61.5 -177.56 0.12 Allowed 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.982 -179.426 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.468 ' CG2' ' O ' ' A' ' 15' ' ' SER . 22.0 t -162.32 113.61 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.356 0.598 . . . . 0.0 111.434 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.4 t30 -127.75 -49.27 1.37 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.32 178.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -116.58 32.14 6.31 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.34 178.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -104.05 -43.58 1.75 Allowed Glycine 0 C--N 1.331 0.282 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.735 179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -65.2 -44.1 89.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.944 0.402 . . . . 0.0 110.349 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -65.05 -69.77 0.27 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 178.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.65 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 20.4 t80 -51.67 -30.75 23.07 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -178.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.728 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.2 tt0 -76.45 -47.48 22.9 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 117.969 0.35 . . . . 0.0 110.762 -178.109 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.45 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 2.5 tm-20 -64.8 -27.52 68.94 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.444 0.64 . . . . 0.0 109.521 179.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.31 -52.73 7.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.86 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.728 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.2 OUTLIER -77.74 -56.6 4.37 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -178.86 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.52 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.8 m -53.37 -23.46 9.62 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.857 179.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.45 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -74.52 -52.64 11.33 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.892 0.377 . . . . 0.0 110.484 178.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.05 -42.15 59.58 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.611 -0.805 . . . . 0.0 112.426 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.453 ' O ' HG23 ' A' ' 34' ' ' VAL . 48.1 mm -62.11 -46.35 96.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.122 0.486 . . . . 0.0 111.436 -179.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -56.99 -48.0 79.48 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.925 0.393 . . . . 0.0 110.568 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.3 t -60.72 -36.69 79.49 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.506 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -57.66 -38.71 75.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.983 0.421 . . . . 0.0 110.43 179.802 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.546 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.0 t -61.45 -62.49 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.305 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.5 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 26.2 m -54.83 -38.89 67.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -61.93 -41.64 99.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.749 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.546 HG22 ' O ' ' A' ' 34' ' ' VAL . 29.7 m -80.2 -27.21 11.91 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.21 0 CA-C-O 121.027 0.441 . . . . 0.0 110.221 179.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -80.15 -20.97 43.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.531 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 47.2 p -75.43 -39.23 59.15 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.471 -0.332 . . . . 0.0 111.407 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.54 -44.69 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.434 -0.889 . . . . 0.0 112.926 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -145.35 -59.35 0.34 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.612 0.244 . . . . 0.0 111.352 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 67.65 43.9 83.63 Favored Glycine 0 C--N 1.33 0.234 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.831 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.2 p -91.58 -29.51 16.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.652 0.263 . . . . 0.0 111.127 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.681 ' N ' HD13 ' A' ' 44' ' ' ILE . 0.2 OUTLIER -152.18 63.77 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.954 0.407 . . . . 0.0 111.102 179.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -95.78 -44.11 3.2 Favored Glycine 0 CA--C 1.518 0.275 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.692 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.2 mmt-85 -113.23 -31.62 6.55 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.625 0.25 . . . . 0.0 111.413 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 2.3 mtt85 -96.57 108.73 44.31 Favored Pre-proline 0 CA--C 1.531 0.241 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.625 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 C--O 1.25 1.076 0 C-N-CA 122.105 1.87 . . . . 0.0 112.137 179.714 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.79 HG12 ' O ' ' A' ' 1' ' ' VAL . 53.9 t . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 32.7 p-10 -79.15 116.21 19.29 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -82.03 173.19 12.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.872 0.368 . . . . 0.0 111.223 178.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 162.65 -158.28 30.43 Favored Glycine 0 C--O 1.227 -0.294 0 C-N-CA 121.007 -0.616 . . . . 0.0 111.812 179.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -77.1 -36.54 55.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.873 0.368 . . . . 0.0 111.294 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -60.62 -28.34 67.65 Favored Glycine 0 CA--C 1.522 0.503 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.418 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 7' ' ' VAL . 10.9 m -88.21 84.57 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 117.299 0.55 . . . . 0.0 110.952 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 30.6 t -136.61 73.07 1.44 Allowed 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.123 0.487 . . . . 0.0 111.397 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 53.3 t -166.59 82.59 0.26 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.135 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.5 m -72.14 -163.62 0.12 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.795 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 15.7 mmmt -76.85 -49.22 16.25 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 178.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.3 m -89.27 -47.9 7.74 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.436 178.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.645 ' O ' ' HB2' ' A' ' 14' ' ' CYS . 30.6 mtpt -80.85 115.66 20.45 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.241 -179.539 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.645 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 49.9 t 167.28 -46.43 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.719 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.4 p -139.9 128.21 22.62 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-O 121.111 0.482 . . . . 0.0 111.128 179.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.624 ' O ' HG13 ' A' ' 16' ' ' VAL . 7.4 p -164.5 86.98 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.117 -179.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 -63.85 -31.92 73.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.833 179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -88.17 27.23 1.24 Allowed 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.54 -0.3 . . . . 0.0 111.789 -179.529 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -105.54 -81.48 1.46 Allowed Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.97 -179.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.28 -26.52 68.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.726 0.298 . . . . 0.0 111.406 -179.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.29 -71.55 0.13 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.889 0.375 . . . . 0.0 111.101 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.583 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.7 t80 -53.55 -33.12 53.54 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -178.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.704 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 21.5 tt0 -76.38 -43.26 41.47 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.902 0.382 . . . . 0.0 110.81 -178.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -65.21 -33.23 75.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.439 0.638 . . . . 0.0 109.82 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.0 -54.35 6.11 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.57 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.704 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.37 -57.5 3.97 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -177.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.529 ' HA ' HG22 ' A' ' 30' ' ' ILE . 2.9 m -52.39 -33.53 43.86 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.98 -0.288 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.39 -47.77 75.2 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.736 179.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.08 -47.81 57.27 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.27 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.529 HG22 ' HA ' ' A' ' 27' ' ' THR . 17.7 tt -64.86 -36.46 77.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.21 0.528 . . . . 0.0 110.344 -179.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.423 ' ND2' HG22 ' A' ' 27' ' ' THR . 31.7 m-20 -57.71 -40.97 80.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.509 179.029 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 19.5 t -66.57 -36.98 83.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.118 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.41 ' O ' ' HB ' ' A' ' 37' ' ' VAL . 0.0 OUTLIER -58.55 -38.29 77.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.225 0.536 . . . . 0.0 110.328 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.504 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.2 t -62.59 -61.67 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.235 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 54.5 m -50.25 -56.11 12.54 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.369 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -58.11 -52.16 54.12 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.296 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.41 ' HB ' ' O ' ' A' ' 33' ' ' PHE . 50.4 t -66.46 -21.19 28.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 120.706 0.288 . . . . 0.0 110.375 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -70.22 -32.33 70.16 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-O 120.919 0.39 . . . . 0.0 110.676 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 87.9 p -72.52 -31.92 65.72 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.857 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 130.81 -25.09 4.23 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.734 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.525 ' HB3' HD11 ' A' ' 44' ' ' ILE . . . -178.88 -71.42 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.821 0.343 . . . . 0.0 111.538 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -162.86 44.94 0.34 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.687 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.1 m 64.83 71.19 0.46 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.905 0.383 . . . . 0.0 111.06 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.525 HD11 ' HB3' ' A' ' 41' ' ' ALA . 3.9 mt -83.24 -66.59 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.19 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -64.01 -14.94 57.51 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.291 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 62.22 95.89 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.811 0.306 . . . . 0.0 110.841 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 20.1 mtm180 -91.79 125.18 58.21 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.771 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--O 1.249 1.042 0 C-N-CA 122.223 1.948 . . . . 0.0 112.12 179.899 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.891 HG12 ' O ' ' A' ' 1' ' ' VAL . 63.7 t . . . . . 0 N--CA 1.449 -0.484 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -79.27 91.87 5.07 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 179.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -80.75 96.75 7.04 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 178.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -104.25 -80.57 1.42 Allowed Glycine 0 CA--C 1.521 0.414 0 C-N-CA 120.805 -0.712 . . . . 0.0 114.205 -178.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -161.23 53.69 0.27 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.228 0.537 . . . . 0.0 109.866 -178.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -159.31 67.43 0.27 Allowed Glycine 0 CA--C 1.51 -0.257 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 8.5 m -150.33 37.4 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.246 0.546 . . . . 0.0 110.096 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 11.7 p -176.93 40.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.245 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 15.7 t 55.17 31.8 17.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.128 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 38.6 m -74.67 -73.36 0.24 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.07 0.462 . . . . 0.0 109.865 179.198 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.89 -25.17 48.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.991 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 82.4 p -88.48 135.49 33.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.127 0.489 . . . . 0.0 111.72 -179.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -80.89 124.46 29.12 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.329 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.2 m -93.48 -38.18 11.55 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.934 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -147.29 139.13 24.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.656 0.741 . . . . 0.0 111.825 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.683 ' O ' HG13 ' A' ' 16' ' ' VAL . 14.5 p -76.61 103.46 3.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.08 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -141.97 112.25 7.01 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.691 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -58.45 -51.15 71.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.055 0.455 . . . . 0.0 110.263 -179.726 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.07 -50.05 40.68 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.948 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 6.9 mp0 -62.61 -55.39 27.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.594 0.235 . . . . 0.0 111.561 -179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -55.37 -61.63 2.21 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.709 0.29 . . . . 0.0 111.574 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.666 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 32.4 t80 -52.1 -33.51 39.91 Favored 'General case' 0 CA--C 1.514 -0.435 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -178.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.742 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 14.7 tt0 -79.21 -39.76 32.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.025 0.44 . . . . 0.0 110.38 -178.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.521 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 3.5 mt-10 -65.4 -30.61 71.44 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 178.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.64 -56.93 4.05 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.573 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.742 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.4 OUTLIER -73.89 -58.04 3.57 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -178.184 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.504 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.6 m -51.01 -33.67 25.93 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.621 179.808 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -62.19 -55.2 30.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.118 0.485 . . . . 0.0 110.932 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.8 -35.74 61.86 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.182 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.654 ' O ' HG23 ' A' ' 34' ' ' VAL . 42.6 mm -70.85 -35.67 61.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.3 0.572 . . . . 0.0 111.181 -179.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.2 t-20 -61.51 -50.34 73.08 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.085 0.469 . . . . 0.0 109.821 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 86.2 p -57.28 -43.74 83.39 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.928 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -52.83 -39.34 62.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 110.681 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.6 t -58.66 -60.3 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.593 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -52.73 -42.29 64.74 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.735 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.06 -44.25 97.47 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.142 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 34' ' ' VAL . 35.3 m -79.82 -24.95 12.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.913 0.387 . . . . 0.0 110.809 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -72.03 -25.7 61.91 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.693 -179.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 72.1 p -61.36 -28.03 68.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.247 179.736 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.85 37.02 6.52 Favored Glycine 0 CA--C 1.518 0.258 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.772 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -157.29 -72.08 0.1 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.676 0.274 . . . . 0.0 111.227 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 146.26 89.06 0.08 OUTLIER Glycine 0 N--CA 1.453 -0.188 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.327 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.6 m -61.07 -69.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.663 0.268 . . . . 0.0 111.481 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -58.82 -67.77 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.074 -179.501 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 55.15 25.23 38.7 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.81 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.65 -49.3 5.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.774 0.321 . . . . 0.0 110.804 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -136.7 155.12 76.86 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.664 179.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 C--O 1.249 1.025 0 C-N-CA 122.413 2.075 . . . . 0.0 112.342 -179.904 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.7 m . . . . . 0 N--CA 1.449 -0.522 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -160.87 26.65 0.14 Allowed 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -179.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.419 ' CD2' ' HA ' ' A' ' 7' ' ' VAL . 31.0 m-85 -80.1 174.81 11.22 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-O 120.41 0.148 . . . . 0.0 111.304 -179.101 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.15 -36.34 0.71 Allowed Glycine 0 N--CA 1.465 0.627 0 C-N-CA 120.919 -0.657 . . . . 0.0 113.214 -177.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -162.59 58.3 0.22 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.697 0.761 . . . . 0.0 110.275 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.485 ' O ' ' CG2' ' A' ' 7' ' ' VAL . . . -161.38 -62.2 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.761 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.642 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.485 ' CG2' ' O ' ' A' ' 6' ' ' GLY . 6.8 m 51.12 88.3 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-O 121.023 0.44 . . . . 0.0 111.002 179.053 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -145.22 87.28 1.8 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.135 -179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.426 ' HB3' ' HB3' ' A' ' 14' ' ' CYS . 4.9 m -62.75 115.36 4.26 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.254 179.131 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.9 p -172.73 -39.2 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.33 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 27.5 ttmt -77.6 -50.87 11.63 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.945 0.402 . . . . 0.0 110.45 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.7 p -88.6 -172.38 3.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.33 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 9.3 pttm -81.0 124.32 29.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.638 -0.256 . . . . 0.0 111.048 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.426 ' HB3' ' HB3' ' A' ' 9' ' ' CYS . 0.5 OUTLIER -153.91 109.57 3.22 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.685 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 21.5 p -173.61 -174.22 0.96 Allowed 'General case' 0 CA--C 1.519 -0.214 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.884 179.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.47 HG13 ' N ' ' A' ' 17' ' ' ASN . 14.3 p -164.99 -43.29 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.802 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.186 178.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.47 ' N ' HG13 ' A' ' 16' ' ' VAL . 0.3 OUTLIER -64.36 91.93 0.08 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.542 0.687 . . . . 0.0 109.673 179.935 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -66.63 -42.87 86.07 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.511 -178.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.26 -60.35 8.28 Favored Glycine 0 C--N 1.332 0.337 0 CA-C-N 116.287 -0.415 . . . . 0.0 114.066 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.6 tp60 -53.16 -43.55 67.15 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.708 0.254 . . . . 0.0 111.434 -178.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -67.61 -62.08 1.59 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.946 0.403 . . . . 0.0 111.485 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.63 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 26.3 t80 -54.19 -29.06 44.54 Favored 'General case' 0 C--O 1.219 -0.522 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -178.292 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.647 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 54.6 tt0 -78.81 -36.94 41.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 118.196 0.453 . . . . 0.0 111.341 -177.568 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.4 tm-20 -74.75 -33.1 62.27 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.299 0.571 . . . . 0.0 109.743 179.537 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.4 -57.44 3.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.862 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.647 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.0 OUTLIER -66.18 -58.74 4.75 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -177.8 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.513 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 3.2 m -54.08 -36.68 63.42 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.669 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.415 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -59.4 -41.66 89.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.83 0.348 . . . . 0.0 110.846 178.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.29 -47.27 6.16 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.387 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.721 ' O ' HG23 ' A' ' 34' ' ' VAL . 9.2 mt -63.67 -26.04 39.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 121.008 0.432 . . . . 0.0 110.759 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -76.15 -53.8 7.76 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.917 0.389 . . . . 0.0 110.547 179.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 33.0 t -62.3 -35.71 79.87 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.203 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.442 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -57.38 -35.72 70.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.913 0.387 . . . . 0.0 110.849 -179.878 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.9 t -70.18 -62.84 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.086 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.7 m -52.15 -37.91 55.95 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.863 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.91 -43.91 98.76 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.621 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 34' ' ' VAL . 30.4 m -80.5 -26.79 11.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.933 0.397 . . . . 0.0 110.772 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.47 -22.08 48.09 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.676 -179.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 80.7 p -78.69 -31.69 46.68 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.457 -179.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.406 ' O ' ' HB3' ' A' ' 41' ' ' ALA . . . 95.18 30.96 7.88 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.759 179.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 40' ' ' GLY . . . 66.73 10.5 7.55 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 111.852 0.315 . . . . 0.0 111.852 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 157.49 58.75 0.01 OUTLIER Glycine 0 CA--C 1.519 0.284 0 C-N-CA 120.592 -0.813 . . . . 0.0 112.939 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.4 m -177.36 74.19 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.781 0.324 . . . . 0.0 110.994 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.5 mp -69.54 -43.85 80.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.557 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -104.24 21.1 38.45 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.067 -179.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 55.45 40.88 31.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.96 0.41 . . . . 0.0 110.851 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 29.9 mtm-85 54.89 94.26 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.228 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo . . . . . 0 C--O 1.249 1.04 0 C-N-CA 122.524 2.15 . . . . 0.0 112.269 179.892 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 1.042 HG12 ' H ' ' A' ' 2' ' ' ASN . 86.5 t . . . . . 0 N--CA 1.448 -0.529 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 1.042 ' H ' HG12 ' A' ' 1' ' ' VAL . 5.2 t-20 78.44 -58.3 0.44 Allowed 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.056 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.406 ' HB2' ' O ' ' A' ' 2' ' ' ASN . 1.6 m-85 69.65 -75.0 0.07 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.091 -178.533 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 92.51 -37.26 3.43 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.343 178.827 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -162.76 32.97 0.1 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.798 0.299 . . . . 0.0 111.137 -179.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -105.88 -43.09 1.58 Allowed Glycine 0 CA--C 1.52 0.345 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.596 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.636 HG23 ' O ' ' A' ' 7' ' ' VAL . 17.0 m -88.13 104.57 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.6 t -143.65 -146.88 0.2 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 179.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.8 p -63.11 -37.63 87.97 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.565 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 13' ' ' LYS . 2.2 m -137.16 151.54 48.92 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.337 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.602 ' O ' ' HG3' ' A' ' 11' ' ' LYS . 13.6 tppt? -77.43 -5.12 48.65 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.3 m -150.78 69.02 0.96 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.308 0.575 . . . . 0.0 110.112 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.446 ' O ' ' HB2' ' A' ' 10' ' ' SER . 4.6 tttt 74.61 170.15 0.29 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.168 -0.923 . . . . 0.0 108.651 -177.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -120.6 56.31 1.0 Allowed 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.12 26.87 1.49 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.851 -1.068 . . . . 0.0 112.338 -178.656 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.7 p -164.55 130.04 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.092 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 39.2 p-10 -63.83 -162.77 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.873 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 75.8 21.27 1.66 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.764 0.316 . . . . 0.0 110.828 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -91.87 -46.24 3.71 Favored Glycine 0 C--N 1.332 0.322 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.4 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -65.11 -27.85 69.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.696 0.284 . . . . 0.0 110.843 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.76 -67.2 0.36 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.866 179.289 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.691 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 44.4 t80 -54.58 -27.14 36.86 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -179.492 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.525 ' HA ' ' CD1' ' A' ' 26' ' ' TYR . 29.9 mm-40 -75.17 -38.8 60.73 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.849 -178.274 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -78.16 -44.47 25.85 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.2 0.524 . . . . 0.0 109.926 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -56.22 23.92 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.61 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.691 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -63.44 -37.39 87.12 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.891 -1.049 . . . . 0.0 113.639 -177.094 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.652 HG23 ' CE1' ' A' ' 26' ' ' TYR . 4.3 p -65.68 -45.1 84.16 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.448 -0.501 . . . . 0.0 109.706 177.656 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -43.34 64.79 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.847 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.37 -43.95 11.98 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.497 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.404 ' O ' HG23 ' A' ' 34' ' ' VAL . 35.7 mm -72.84 -54.0 17.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 121.007 0.432 . . . . 0.0 111.176 -179.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 27' ' ' THR . 3.3 t-20 -56.36 -50.19 72.25 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.771 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.6 m -54.23 -40.3 67.58 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.688 0.28 . . . . 0.0 111.089 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.653 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -56.11 -35.7 67.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 -179.781 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.557 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.3 t -74.8 -60.36 2.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.342 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.93 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.9 m -57.05 -38.09 72.73 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.081 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.54 -43.06 97.9 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.674 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 33' ' ' PHE . 20.3 m -80.79 -29.51 11.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.044 0.45 . . . . 0.0 110.318 179.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.35 -22.47 47.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.227 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.5 m -69.56 -37.0 76.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.381 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.96 -0.08 8.31 Favored Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.761 -0.733 . . . . 0.0 113.11 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 57.24 22.06 7.27 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.911 0.355 . . . . 0.0 111.594 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -75.14 -81.52 0.49 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.65 -179.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 2.8 m 178.26 62.86 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.866 0.365 . . . . 0.0 110.894 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 35.3 mt -119.54 -41.65 2.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.703 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.94 -27.23 59.27 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.774 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 tpt180 61.6 69.05 0.67 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.9 0.381 . . . . 0.0 110.52 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.435 ' N ' ' HD2' ' A' ' 48' ' ' PRO . 15.0 mtt85 -81.83 -51.55 0.81 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.295 -179.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.435 ' HD2' ' N ' ' A' ' 47' ' ' ARG . 81.5 Cg_endo . . . . . 0 C--O 1.25 1.085 0 C-N-CA 122.203 1.935 . . . . 0.0 112.297 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.821 HG23 ' N ' ' A' ' 2' ' ' ASN . 20.0 m . . . . . 0 N--CA 1.449 -0.519 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.821 ' N ' HG23 ' A' ' 1' ' ' VAL . 3.4 t-20 76.16 -60.06 0.49 Allowed 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.555 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 64.59 109.34 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.009 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -110.45 76.02 0.22 Allowed Glycine 0 C--O 1.229 -0.157 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -163.26 -54.79 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.204 0.526 . . . . 0.0 110.667 -179.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 133.17 102.65 0.81 Allowed Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 110.537 -1.025 . . . . 0.0 110.537 -178.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.421 ' O ' ' O ' ' A' ' 8' ' ' SER . 15.6 m -86.24 -33.02 7.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.494 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.421 ' O ' ' O ' ' A' ' 7' ' ' VAL . 52.3 p 51.3 109.68 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.058 178.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 9.0 m -94.29 170.09 9.75 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.353 179.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.5 t -98.47 -49.54 4.61 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.661 179.07 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 12' ' ' THR . 10.3 tttp -77.54 -8.33 57.65 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 113.885 1.069 . . . . 0.0 113.885 -179.29 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.578 HG22 ' O ' ' A' ' 11' ' ' LYS . 10.5 t 52.44 48.06 23.41 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.783 0.325 . . . . 0.0 111.515 -178.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.13 39.41 0.21 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.251 0.548 . . . . 0.0 109.99 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.8 m -89.16 -66.27 0.94 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.031 -179.428 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 9.7 t -110.0 175.06 5.58 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.767 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.62 ' O ' HG22 ' A' ' 16' ' ' VAL . 12.6 p -164.27 33.73 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.161 0.505 . . . . 0.0 110.71 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 67.37 -71.74 0.1 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.485 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -52.61 -22.57 5.19 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.601 -179.162 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.47 -62.9 5.81 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.726 -0.749 . . . . 0.0 113.05 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 15.4 mm-40 -62.92 -30.78 71.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.963 0.411 . . . . 0.0 110.517 -179.534 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.86 -65.38 0.69 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.543 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -53.31 -42.35 66.59 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 -178.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.674 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.8 tt0 -68.38 -36.86 79.77 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.991 -177.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -72.93 -28.88 62.71 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -80.45 -53.94 6.14 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.506 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.674 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -73.58 -54.25 8.62 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.273 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.505 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.8 m -57.66 -25.39 60.14 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.731 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.36 -33.36 49.07 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.438 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.94 -42.72 7.99 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.682 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.505 HG22 ' HA ' ' A' ' 27' ' ' THR . 9.0 tp -67.37 -41.32 86.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.641 0.734 . . . . 0.0 111.339 -179.228 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.437 ' N ' HG23 ' A' ' 30' ' ' ILE . 2.0 t-20 -72.48 -41.72 65.71 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 58.4 m -65.24 -31.1 72.09 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.684 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.49 -40.58 87.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.984 0.421 . . . . 0.0 110.006 179.834 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.547 ' O ' HG22 ' A' ' 37' ' ' VAL . 2.9 t -66.81 -63.38 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.221 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.1 m -56.44 -34.79 67.16 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.355 179.568 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.15 -43.3 98.87 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.322 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.684 HG13 ' O ' ' A' ' 33' ' ' PHE . 19.9 m -80.23 -27.38 11.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.972 0.415 . . . . 0.0 110.268 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -76.8 -22.69 53.3 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.844 -179.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 74.4 m -76.43 -42.39 44.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.792 0.329 . . . . 0.0 111.1 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -83.35 -48.49 5.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.642 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -70.79 -60.63 2.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.799 0.333 . . . . 0.0 111.136 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 94.4 44.99 3.34 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.478 -179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.65 -55.56 32.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.669 0.271 . . . . 0.0 110.461 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.726 HG23 ' H ' ' A' ' 46' ' ' ARG . 0.4 OUTLIER -168.52 -40.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.4 179.626 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 53.03 13.83 2.49 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 115.125 0.81 . . . . 0.0 115.125 178.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.726 ' H ' HG23 ' A' ' 44' ' ' ILE . 19.9 mmt180 -121.07 -69.17 0.86 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 118.182 0.991 . . . . 0.0 111.192 179.422 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 15.8 ptm180 -108.53 148.75 38.32 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.081 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo . . . . . 0 C--O 1.249 1.071 0 C-N-CA 122.471 2.114 . . . . 0.0 112.286 179.986 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.611 ' O ' HG12 ' A' ' 1' ' ' VAL . 87.4 t . . . . . 0 N--CA 1.449 -0.501 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.474 ' O ' ' CD1' ' A' ' 3' ' ' TYR . 9.4 p30 -158.94 151.32 21.49 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.474 ' CD1' ' O ' ' A' ' 2' ' ' ASN . 28.4 m-85 -158.19 -175.21 5.21 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.64 -178.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -154.76 36.49 0.67 Allowed Glycine 0 CA--C 1.518 0.239 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.436 -179.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -162.67 -67.97 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.711 0.291 . . . . 0.0 110.753 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 130.98 76.19 0.14 Allowed Glycine 0 C--N 1.332 0.343 0 C-N-CA 121.02 -0.61 . . . . 0.0 112.686 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.579 ' O ' HG13 ' A' ' 7' ' ' VAL . 15.0 p -89.03 58.44 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 121.017 0.437 . . . . 0.0 111.091 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.6 p 61.31 126.76 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.464 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -147.52 -88.19 0.09 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.297 179.155 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 32.6 t 37.24 67.2 0.38 Allowed 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.327 0.584 . . . . 0.0 110.621 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.9 pttp -162.06 -21.11 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.201 -0.909 . . . . 0.0 111.236 -179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.9 t -150.86 -21.07 0.22 Allowed 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 120.675 0.274 . . . . 0.0 111.477 178.502 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.422 ' O ' ' CB ' ' A' ' 14' ' ' CYS . 3.3 tptt -158.35 -166.22 1.88 Allowed 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 -178.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.422 ' CB ' ' O ' ' A' ' 13' ' ' LYS . 11.3 m 74.22 137.06 0.06 Allowed 'General case' 0 C--N 1.329 -0.316 0 O-C-N 122.298 -0.251 . . . . 0.0 110.45 -178.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 10.7 p -172.06 175.51 3.76 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.384 0.611 . . . . 0.0 112.2 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 16' ' ' VAL . 7.1 p -75.84 81.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.719 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -56.24 -24.85 45.03 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 115.518 -0.764 . . . . 0.0 112.313 -178.315 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 9.9 p90 -92.88 18.35 9.16 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 120.718 0.294 . . . . 0.0 111.064 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.15 -34.58 58.08 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 121.278 -0.487 . . . . 0.0 112.895 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -71.71 -31.77 67.09 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.684 0.278 . . . . 0.0 111.239 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.02 -70.02 0.17 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.547 179.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.536 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 21.4 t80 -57.22 -33.35 67.44 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -179.143 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.712 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 32.1 tt0 -75.37 -37.24 60.72 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 121.121 -0.232 . . . . 0.0 111.035 -178.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -70.64 -30.8 67.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.526 0.679 . . . . 0.0 109.627 179.776 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -79.82 -58.31 3.24 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.144 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.712 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -68.48 -58.53 4.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.132 -0.94 . . . . 0.0 113.3 -177.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.55 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.4 m -54.38 -37.45 65.02 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.893 -0.323 . . . . 0.0 110.912 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -55.99 -48.9 75.02 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.176 179.267 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.42 -53.66 8.52 Favored Glycine 0 CA--C 1.52 0.369 0 C-N-CA 120.595 -0.812 . . . . 0.0 113.097 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.638 ' O ' HG23 ' A' ' 34' ' ' VAL . 2.5 tt -61.41 -29.45 45.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.138 0.494 . . . . 0.0 111.915 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -69.51 -48.92 59.0 Favored 'General case' 0 C--N 1.326 -0.429 0 O-C-N 122.035 -0.415 . . . . 0.0 110.169 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 16.6 m -54.04 -38.85 65.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.241 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.425 ' O ' HG12 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -59.11 -37.73 77.89 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.195 0.522 . . . . 0.0 110.49 179.59 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.646 ' HA ' HG12 ' A' ' 37' ' ' VAL . 4.2 t -67.49 -59.87 3.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.892 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 73.1 m -45.32 -55.65 5.74 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.471 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -63.93 -47.49 85.39 Favored Glycine 0 N--CA 1.453 -0.21 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.349 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.646 HG12 ' HA ' ' A' ' 34' ' ' VAL . 5.0 p -65.95 -24.98 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.849 0.357 . . . . 0.0 110.439 -179.887 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.446 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -78.92 -24.03 44.34 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.549 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 t -56.5 -28.46 59.91 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.393 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 112.93 39.59 1.15 Allowed Glycine 0 C--N 1.33 0.214 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.453 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -61.26 -41.29 96.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.829 0.347 . . . . 0.0 111.134 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 115.08 89.18 1.61 Allowed Glycine 0 C--N 1.33 0.218 0 C-N-CA 120.978 -0.629 . . . . 0.0 112.512 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 51.7 p -171.29 -51.52 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.818 0.342 . . . . 0.0 110.75 179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -150.56 -79.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.812 179.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 59.08 27.79 62.98 Favored Glycine 0 C--N 1.33 0.219 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.557 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 70.8 mtt180 -128.57 32.46 4.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.794 0.33 . . . . 0.0 110.648 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -101.87 141.51 22.7 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.695 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo . . . . . 0 C--O 1.25 1.075 0 C-N-CA 122.397 2.065 . . . . 0.0 112.212 -179.497 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.64 ' CG1' ' N ' ' A' ' 2' ' ' ASN . 11.5 t . . . . . 0 N--CA 1.449 -0.491 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.64 ' N ' ' CG1' ' A' ' 1' ' ' VAL . 3.2 m-20 -162.13 -160.13 0.65 Allowed 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.578 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.448 ' HB3' HG11 ' A' ' 7' ' ' VAL . 3.2 m-85 61.25 163.66 0.08 Allowed 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 120.751 0.31 . . . . 0.0 110.772 -179.204 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.504 ' O ' ' HB2' ' A' ' 5' ' ' ASN . . . 159.95 96.99 0.12 Allowed Glycine 0 C--N 1.337 0.604 0 C-N-CA 120.307 -0.949 . . . . 0.0 113.543 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.504 ' HB2' ' O ' ' A' ' 4' ' ' GLY . 21.1 m-20 73.38 60.51 0.1 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.945 0.402 . . . . 0.0 110.386 178.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 158.81 46.36 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.034 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.448 HG11 ' HB3' ' A' ' 3' ' ' TYR . 8.3 m -150.94 -177.18 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.588 -0.306 . . . . 0.0 110.534 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 40.2 t -81.22 -148.93 0.07 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 62.7 m -49.43 125.07 10.41 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.148 0.499 . . . . 0.0 110.326 179.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.401 ' O ' ' HG3' ' A' ' 11' ' ' LYS . 9.3 m -119.75 -40.89 2.71 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.43 -0.804 . . . . 0.0 111.223 -178.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.401 ' HG3' ' O ' ' A' ' 10' ' ' SER . 31.7 mttt -161.45 -77.74 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.589 179.56 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 16.5 p -90.42 -32.66 16.33 Favored 'General case' 0 C--N 1.333 -0.152 0 N-CA-C 112.883 0.698 . . . . 0.0 112.883 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.7 tmtt? -79.92 84.41 5.69 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 -177.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 5.6 t -161.41 -74.5 0.06 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.789 179.12 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.402 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.7 OUTLIER -153.79 122.64 6.38 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.835 178.888 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 15' ' ' SER . 16.9 t 77.45 131.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 N-CA-C 110.504 -0.184 . . . . 0.0 110.504 179.259 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -70.33 126.46 29.7 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.947 0.403 . . . . 0.0 111.032 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 1.7 t-105 -92.23 -39.63 11.43 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.67 179.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -43.57 -49.33 7.15 Favored Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.258 -0.496 . . . . 0.0 113.265 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -65.56 -35.01 79.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.843 0.354 . . . . 0.0 111.004 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.0 -67.21 0.46 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.198 179.567 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.866 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 28.4 t80 -55.33 -17.92 5.6 Favored 'General case' 0 CA--C 1.508 -0.644 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.26 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.693 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 49.0 tt0 -84.38 -45.26 12.93 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.334 -178.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -69.28 -33.68 73.58 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -67.89 -55.46 12.78 Favored 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.125 179.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.866 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.3 OUTLIER -68.21 -36.93 80.29 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.543 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.615 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.1 p -59.79 -46.19 89.96 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 120.198 -0.601 . . . . 0.0 109.575 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -52.43 -41.38 63.21 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.229 179.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.06 -52.01 7.18 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.54 179.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.615 HG22 ' HA ' ' A' ' 27' ' ' THR . 1.2 tt -70.91 -50.33 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 120.78 0.324 . . . . 0.0 111.836 -179.165 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.549 ' N ' HG23 ' A' ' 30' ' ' ILE . 2.1 t-20 -55.34 -50.97 68.27 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 120.805 0.336 . . . . 0.0 110.417 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 44.0 m -49.66 -44.33 47.68 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.631 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -53.38 -34.73 58.77 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.089 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.534 ' O ' HG22 ' A' ' 37' ' ' VAL . 3.2 t -72.2 -61.65 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.345 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.3 m -51.49 -39.17 57.06 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.763 179.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.15 98.73 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.818 179.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.569 ' O ' ' HB2' ' A' ' 41' ' ' ALA . 32.9 m -80.95 -29.52 11.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.073 0.463 . . . . 0.0 110.432 179.237 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -70.54 -30.03 66.66 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.626 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.8 p -81.02 -45.27 16.81 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.397 179.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -127.11 45.17 1.17 Allowed Glycine 0 C--N 1.334 0.428 0 C-N-CA 120.877 -0.677 . . . . 0.0 113.083 -179.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.569 ' HB2' ' O ' ' A' ' 37' ' ' VAL . . . -50.25 -28.32 7.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.677 0.275 . . . . 0.0 111.697 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.98 -67.94 1.91 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.795 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 1.8 t 58.49 69.4 0.73 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.152 0.501 . . . . 0.0 111.068 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.543 ' O ' ' HG2' ' A' ' 47' ' ' ARG . 24.6 pt 44.09 39.09 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.043 179.372 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.76 -54.78 31.16 Favored Glycine 0 CA--C 1.523 0.572 0 C-N-CA 120.547 -0.835 . . . . 0.0 113.411 179.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 17.0 mmt180 -62.67 -33.74 75.68 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.543 ' HG2' ' O ' ' A' ' 44' ' ' ILE . 10.9 mtt180 56.07 89.63 0.1 Allowed Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 120.646 0.26 . . . . 0.0 111.318 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--O 1.25 1.113 0 C-N-CA 122.366 2.044 . . . . 0.0 112.119 -179.964 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 1.693 HG21 ' CD2' ' A' ' 3' ' ' TYR . 14.4 p . . . . . 0 N--CA 1.449 -0.494 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.955 ' N ' HG22 ' A' ' 1' ' ' VAL . 23.1 m120 -160.87 21.42 0.13 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.812 -179.419 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 1.693 ' CD2' HG21 ' A' ' 1' ' ' VAL . 7.8 m-85 -80.69 -153.28 0.09 Allowed 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.608 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 178.19 73.71 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 80.83 86.05 0.04 OUTLIER 'General case' 0 CA--C 1.521 -0.168 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -178.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 138.73 89.25 0.2 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.931 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t 60.58 118.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.704 0.288 . . . . 0.0 110.848 179.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 78.6 p -169.52 132.15 1.2 Allowed 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.997 0.427 . . . . 0.0 111.046 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.502 ' HA ' ' HB3' ' A' ' 13' ' ' LYS . 11.5 m 66.92 -54.92 0.44 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.611 -0.722 . . . . 0.0 112.381 179.088 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 85.9 p 60.36 37.03 20.35 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -179.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 8.3 tttm 78.26 -59.67 0.42 Allowed 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 112.096 0.406 . . . . 0.0 112.096 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.3 t -88.12 66.62 8.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.977 -178.312 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.502 ' HB3' ' HA ' ' A' ' 9' ' ' CYS . 0.0 OUTLIER -159.17 -55.09 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.252 179.18 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 26.5 p -125.53 40.82 3.66 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.137 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.68 178.65 7.49 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.107 0.479 . . . . 0.0 110.987 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.605 HG13 ' O ' ' A' ' 16' ' ' VAL . 7.2 p -163.59 100.42 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.27 0.557 . . . . 0.0 111.063 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -109.56 152.87 24.93 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.186 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -45.82 -33.45 3.14 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.106 0.479 . . . . 0.0 110.534 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.39 -53.67 43.59 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.786 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 10.0 mt-30 -56.65 -22.47 34.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.638 0.256 . . . . 0.0 111.689 -179.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.33 -71.48 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.752 0.311 . . . . 0.0 111.113 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.579 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 56.9 t80 -51.53 -31.31 23.66 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.575 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 2.2 mt-30 -80.15 -47.49 14.64 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.999 0.428 . . . . 0.0 111.27 -177.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.487 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 45.8 tt0 -60.61 -27.06 67.46 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.461 0.648 . . . . 0.0 109.403 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 2.1 ttm-85 -81.09 -57.01 3.71 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 115.058 -0.974 . . . . 0.0 111.084 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.579 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.1 OUTLIER -76.44 -45.1 32.86 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.679 -178.624 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.526 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.4 m -63.35 -39.09 93.59 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.307 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -58.48 -49.62 76.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.751 0.31 . . . . 0.0 111.356 179.047 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.18 -43.04 82.05 Favored Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.533 -0.842 . . . . 0.0 113.019 -179.366 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.575 HG22 ' O ' ' A' ' 26' ' ' TYR . 1.0 OUTLIER -72.17 -47.36 54.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.782 0.325 . . . . 0.0 111.152 -179.348 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.539 ' N ' HG23 ' A' ' 30' ' ' ILE . 21.9 t-20 -59.28 -41.22 88.42 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.757 179.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 24.0 p -57.33 -47.97 80.18 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.981 0.42 . . . . 0.0 109.918 179.661 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.56 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -46.83 -39.2 11.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.268 179.031 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.475 ' N ' ' CD1' ' A' ' 33' ' ' PHE . 2.7 t -70.71 -66.01 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.423 -178.574 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 50.6 m -46.71 -53.75 11.09 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.866 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.79 -45.62 90.96 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.035 179.213 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 33' ' ' PHE . 47.3 t -71.96 -23.27 21.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.821 0.343 . . . . 0.0 110.509 179.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.457 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -81.18 -22.57 38.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.527 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.8 t -67.12 -31.96 72.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.379 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.39 5.1 11.61 Favored Glycine 0 CA--C 1.518 0.249 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.933 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . 63.9 14.97 8.79 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 111.963 0.357 . . . . 0.0 111.963 179.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -179.22 72.36 0.07 OUTLIER Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.787 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -107.27 -17.17 14.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.444 0.164 . . . . 0.0 111.381 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 48.2 pt 42.18 42.73 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-O 120.944 0.402 . . . . 0.0 111.514 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -146.8 59.9 0.48 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.3 179.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.459 ' O ' ' O ' ' A' ' 47' ' ' ARG . 0.1 OUTLIER -86.81 -39.12 16.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.385 0.136 . . . . 0.0 111.059 179.757 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.459 ' O ' ' O ' ' A' ' 46' ' ' ARG . 0.8 OUTLIER 35.36 105.13 0.01 OUTLIER Pre-proline 0 N--CA 1.472 0.641 0 N-CA-C 112.743 0.646 . . . . 0.0 112.743 179.67 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo . . . . . 0 C--O 1.249 1.04 0 C-N-CA 122.299 1.999 . . . . 0.0 112.246 179.569 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.969 HG22 ' O ' ' A' ' 1' ' ' VAL . 0.3 OUTLIER . . . . . 0 N--CA 1.449 -0.477 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 44.2 m-20 -161.36 91.8 0.87 Allowed 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 -79.45 145.87 33.06 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.633 -0.427 . . . . 0.0 110.123 -178.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 101.22 -83.12 0.5 Allowed Glycine 0 N--CA 1.452 -0.241 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -177.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -78.17 -48.34 16.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.798 0.333 . . . . 0.0 111.828 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -55.23 -67.82 2.01 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 121.079 -0.582 . . . . 0.0 113.337 -179.057 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.8 p -88.42 126.88 41.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 120.771 0.32 . . . . 0.0 110.795 -179.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.4 t -77.97 82.8 4.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.56 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -64.82 -45.42 86.28 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.847 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.4 ' O ' ' HG2' ' A' ' 11' ' ' LYS . 1.6 p 54.23 -84.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.881 -0.599 . . . . 0.0 112.565 179.495 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.4 ' HG2' ' O ' ' A' ' 10' ' ' SER . 3.6 mmmt -161.66 -24.11 0.05 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -178.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.404 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -88.02 86.36 7.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.981 0.419 . . . . 0.0 110.403 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.404 ' HG2' ' O ' ' A' ' 12' ' ' THR . 0.0 OUTLIER 47.51 -173.78 0.01 OUTLIER 'General case' 0 C--O 1.231 0.125 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.881 -179.246 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -133.97 -158.48 0.89 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.911 -0.315 . . . . 0.0 111.333 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -75.03 152.15 38.69 Favored 'General case' 0 CA--C 1.519 -0.227 0 CA-C-O 121.162 0.505 . . . . 0.0 110.614 -179.027 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.631 HG13 ' HA3' ' A' ' 19' ' ' GLY . 8.6 p -165.22 131.6 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.729 -179.728 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -61.82 140.91 58.21 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.584 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 57.14 33.89 24.02 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.172 0.511 . . . . 0.0 109.818 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.631 ' HA3' HG13 ' A' ' 16' ' ' VAL . . . -105.18 -43.0 1.68 Allowed Glycine 0 C--N 1.332 0.309 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.726 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -64.66 -41.55 96.01 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.847 0.356 . . . . 0.0 110.269 179.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.98 -64.18 0.94 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.978 179.053 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.686 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 22.2 t80 -55.12 -31.28 61.13 Favored 'General case' 0 CA--C 1.509 -0.606 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 -179.366 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.705 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 9.2 tt0 -78.74 -34.58 45.66 Favored 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.419 -177.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.444 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 53.1 tp10 -73.56 -29.46 62.45 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.024 0.828 . . . . 0.0 109.515 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.27 -57.07 3.78 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.477 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.705 ' CD2' ' HA ' ' A' ' 23' ' ' GLN . 0.1 OUTLIER -69.7 -57.72 4.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -177.884 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.555 ' HA ' HG22 ' A' ' 30' ' ' ILE . 0.6 OUTLIER -54.88 -41.29 70.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.744 0.307 . . . . 0.0 111.03 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.444 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -57.11 -45.78 83.14 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.347 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.87 -42.88 19.3 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.825 -0.702 . . . . 0.0 113.419 -179.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.586 ' O ' HG23 ' A' ' 34' ' ' VAL . 10.7 tp -71.05 -31.35 44.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.963 0.411 . . . . 0.0 111.839 -178.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.407 ' HB2' ' O ' ' A' ' 27' ' ' THR . 56.3 t30 -72.24 -45.03 61.91 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.785 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 65.9 p -62.76 -36.18 82.21 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.072 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -58.71 -35.72 73.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.934 0.397 . . . . 0.0 110.889 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.586 HG23 ' O ' ' A' ' 30' ' ' ILE . 2.7 t -70.93 -63.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.519 -179.417 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -50.68 -38.17 45.28 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.737 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -60.37 -44.51 97.51 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.513 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.574 HG22 ' O ' ' A' ' 34' ' ' VAL . 33.7 m -80.38 -26.62 11.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.957 0.408 . . . . 0.0 110.934 179.679 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -80.42 -20.76 43.19 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.821 -179.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.5 t -60.78 -32.49 71.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.824 0.345 . . . . 0.0 111.115 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.59 51.03 0.05 OUTLIER Glycine 0 N--CA 1.453 -0.213 0 C-N-CA 120.688 -0.767 . . . . 0.0 112.262 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -69.67 -36.9 76.43 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.824 0.345 . . . . 0.0 110.86 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -101.72 -22.13 10.56 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.927 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.2 t -61.34 -54.58 41.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.661 0.267 . . . . 0.0 111.045 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.513 HG23 ' N ' ' A' ' 45' ' ' GLY . 2.2 tt -126.65 -48.84 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.191 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.513 ' N ' HG23 ' A' ' 44' ' ' ILE . . . 54.04 24.11 26.59 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.829 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.45 -45.05 11.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.765 0.317 . . . . 0.0 111.1 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . 0.474 ' N ' ' HD2' ' A' ' 48' ' ' PRO . 40.3 mmm-85 -75.15 -50.08 3.9 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.704 -179.646 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.474 ' HD2' ' N ' ' A' ' 47' ' ' ARG . 96.0 Cg_endo . . . . . 0 C--O 1.248 1.003 0 C-N-CA 122.036 1.824 . . . . 0.0 112.135 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 1.469 ' CG1' ' HB2' ' A' ' 5' ' ' ASN . 4.6 p . . . . . 0 N--CA 1.449 -0.517 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 1.022 ' H ' HG22 ' A' ' 1' ' ' VAL . 4.5 t-20 -163.1 -46.43 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.511 0.672 . . . . 0.0 109.315 -179.633 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -80.52 17.13 1.15 Allowed 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.661 -179.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.437 ' O ' ' HB3' ' A' ' 5' ' ' ASN . . . 124.28 -28.93 5.2 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.962 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 1.469 ' HB2' ' CG1' ' A' ' 1' ' ' VAL . 54.4 t30 74.89 63.19 0.07 Allowed 'General case' 0 CA--C 1.517 -0.291 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -178.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 100.89 91.5 2.11 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.646 -0.787 . . . . 0.0 111.171 -178.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.453 HG13 ' N ' ' A' ' 8' ' ' SER . 12.0 p -149.68 -42.76 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.474 0.178 . . . . 0.0 111.062 -179.135 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.453 ' N ' HG13 ' A' ' 7' ' ' VAL . 2.2 t 178.2 130.51 0.06 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.726 0.298 . . . . 0.0 111.15 178.505 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 11.0 p -102.93 -44.08 5.35 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.211 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.0 t 61.88 8.72 2.6 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.658 -0.701 . . . . 0.0 112.593 179.27 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 31.4 mttp -78.25 12.82 1.72 Allowed 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 58.36 16.41 4.06 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 179.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.0 tttp -160.13 -39.35 0.05 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.121 0.486 . . . . 0.0 110.216 -179.64 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 68.93 31.23 4.31 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.845 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 22.4 p -173.68 137.91 0.63 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.429 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 16' ' ' VAL . 7.1 p -164.8 116.95 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.041 -179.727 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -72.44 -33.27 66.95 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.979 0.419 . . . . 0.0 110.677 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -51.49 -31.27 23.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.267 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.53 -43.71 97.35 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.566 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -64.01 -42.2 97.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.96 0.409 . . . . 0.0 110.601 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.56 -51.65 64.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.95 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.698 ' O ' ' HB3' ' A' ' 26' ' ' TYR . 40.0 t80 -57.3 -27.74 62.42 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -179.037 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.5 ' O ' ' HD1' ' A' ' 26' ' ' TYR . 18.1 tt0 -71.46 -46.25 60.47 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.025 -178.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -71.81 -48.04 49.1 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.014 0.435 . . . . 0.0 110.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -56.13 -58.58 7.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.574 0.702 . . . . 0.0 111.457 179.576 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.698 ' HB3' ' O ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.18 -32.82 73.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.867 -1.061 . . . . 0.0 113.182 -177.442 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.593 ' HA ' HG22 ' A' ' 30' ' ' ILE . 1.2 p -66.7 -45.27 79.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 177.121 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -49.42 -46.3 47.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.47 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.85 -53.85 9.07 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.823 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.593 HG22 ' HA ' ' A' ' 27' ' ' THR . 7.2 tp -66.8 -49.65 72.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.779 0.29 . . . . 0.0 111.63 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.53 ' N ' HG23 ' A' ' 30' ' ' ILE . 8.3 t-20 -52.46 -40.11 61.9 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-O 120.826 0.346 . . . . 0.0 110.583 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 73.4 m -60.75 -43.92 97.36 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 110.522 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.553 ' O ' HG23 ' A' ' 37' ' ' VAL . 0.0 OUTLIER -56.59 -33.59 66.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.136 0.493 . . . . 0.0 110.981 179.779 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.445 HG23 ' O ' ' A' ' 30' ' ' ILE . 3.4 t -69.06 -60.94 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.373 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 m -48.04 -58.0 5.04 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.021 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -56.73 -50.01 66.38 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.273 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.553 HG23 ' O ' ' A' ' 33' ' ' PHE . 75.2 t -68.53 -16.35 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.546 0.213 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.419 ' N ' ' O ' ' A' ' 34' ' ' VAL . . . -80.0 -26.17 39.98 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 120.831 0.348 . . . . 0.0 111.371 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.8 t -64.47 -30.25 71.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.007 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -103.15 -39.24 2.68 Favored Glycine 0 C--N 1.329 0.168 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.638 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -141.8 -77.37 0.27 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.773 0.321 . . . . 0.0 111.168 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.86 44.35 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.738 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.5 t -155.47 38.75 0.39 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.698 0.285 . . . . 0.0 110.803 179.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.7 pt -117.79 30.06 2.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.187 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -112.68 39.04 2.99 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.672 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -118.27 -40.44 2.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.695 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 7.6 ptt85 -152.94 105.38 2.65 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.808 179.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo . . . . . 0 C--O 1.248 0.993 0 C-N-CA 122.422 2.081 . . . . 0.0 112.305 179.817 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.862 HG12 ' N ' ' A' ' 2' ' ' ASN . 40.7 t . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.862 ' N ' HG12 ' A' ' 1' ' ' VAL . 47.3 t30 -161.76 -5.01 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 120.542 0.21 . . . . 0.0 111.055 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.412 ' H ' ' H ' ' A' ' 2' ' ' ASN . 1.6 p90 -159.34 -179.96 8.43 Favored 'General case' 0 C--O 1.231 0.096 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.95 -55.09 0.03 OUTLIER Glycine 0 C--N 1.334 0.417 0 C-N-CA 120.185 -1.007 . . . . 0.0 113.302 -179.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.6 m120 -162.28 63.05 0.22 Allowed 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.123 0.487 . . . . 0.0 110.544 -179.432 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -153.8 -37.39 0.03 OUTLIER Glycine 0 N--CA 1.454 -0.151 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.94 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.4 p -88.5 140.01 16.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.556 0.217 . . . . 0.0 110.468 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -81.43 68.72 7.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.872 0.368 . . . . 0.0 111.174 -179.091 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -171.77 101.03 0.18 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.2 p -78.52 -102.23 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 1.6 ptpt -162.7 37.71 0.11 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.64 0.257 . . . . 0.0 111.319 178.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.09 -77.66 0.13 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.1 mtmm -80.95 -57.49 3.51 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.3 m 57.89 170.71 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.794 0.33 . . . . 0.0 110.743 -179.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t -81.62 -27.93 33.95 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.046 0.451 . . . . 0.0 110.533 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.415 ' O ' HG23 ' A' ' 16' ' ' VAL . 8.0 m -76.45 105.84 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.408 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 32.1 m120 -42.34 -33.86 0.71 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.71 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -89.17 36.49 0.82 Allowed 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.553 179.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -89.95 -42.4 5.35 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.323 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -63.3 -43.27 98.34 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.019 0.437 . . . . 0.0 110.486 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -68.66 -57.66 5.37 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.88 179.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.845 ' O ' ' HD2' ' A' ' 26' ' ' TYR . 38.1 t80 -57.78 -21.0 39.41 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.209 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.707 ' HA ' ' CD2' ' A' ' 26' ' ' TYR . 7.5 tm0? -81.49 -48.01 12.41 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.689 -178.205 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 28' ' ' ALA . 1.9 tt0 -64.73 -30.74 71.76 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.558 179.15 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.04 -51.61 11.93 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.563 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.845 ' HD2' ' O ' ' A' ' 22' ' ' PHE . 0.2 OUTLIER -77.44 -55.55 5.29 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -177.811 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.469 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 1.2 m -55.94 -21.97 23.65 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.932 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.412 ' HB2' ' O ' ' A' ' 24' ' ' GLU . . . -75.84 -58.11 3.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.066 0.46 . . . . 0.0 110.495 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.88 -43.55 65.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.173 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.601 ' O ' HG23 ' A' ' 34' ' ' VAL . 42.0 mm -56.57 -51.04 70.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.923 0.392 . . . . 0.0 110.957 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 42.9 t-20 -50.09 -53.16 29.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.904 0.383 . . . . 0.0 110.408 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.7 p -63.17 -36.15 82.67 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.763 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -55.99 -38.55 70.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.029 0.442 . . . . 0.0 110.703 179.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 30' ' ' ILE . 4.1 t -63.97 -58.98 5.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.42 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.368 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 70.7 m -53.92 -42.81 69.19 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.677 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -59.14 -47.06 92.65 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.0 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 34' ' ' VAL . 32.7 m -76.6 -26.62 16.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.886 0.374 . . . . 0.0 110.703 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -71.85 -24.52 61.71 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.718 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 66.3 m -64.64 -34.21 77.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.864 0.364 . . . . 0.0 111.04 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 160.28 54.53 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.454 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -60.32 -32.06 70.87 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 111.401 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -70.15 -15.58 72.29 Favored Glycine 0 CA--C 1.52 0.381 0 C-N-CA 120.821 -0.704 . . . . 0.0 113.242 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 54.0 m -58.36 -57.37 13.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.831 0.315 . . . . 0.0 111.341 -179.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.698 HG23 ' H ' ' A' ' 45' ' ' GLY . 1.2 tp -133.78 -69.38 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.014 -179.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.698 ' H ' HG23 ' A' ' 44' ' ' ILE . . . 92.72 -37.09 3.47 Favored Glycine 0 C--N 1.332 0.318 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.148 179.112 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 10.2 tpp180 68.83 -65.01 0.3 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.752 0.31 . . . . 0.0 111.414 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 3.8 mmt85 57.36 73.22 0.8 Allowed Pre-proline 0 CA--C 1.532 0.262 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.066 -179.482 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo . . . . . 0 C--O 1.248 0.987 0 C-N-CA 122.24 1.96 . . . . 0.0 112.247 179.845 . . . . . . . . 0 0 . 1 stop_ save_